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Chronic glucocorticoid (GC) excess (Cushing’s syndrome, pharmacotherapy) causes 
metabolic and cardiovascular disease. This might be predicted from the known 
metabolic (dyslipidaemia, insulin resistance/hyperglycaemia) and hypertensive effects 
of chronically elevated GC levels. Intracellular GC levels within target tissues are 
controlled by 11β-hydroxysteroid dehydrogenases. 11β-Hydroxysteroid 
dehydrogenase type 1 (11β-HSD1, encoded by Hsd11b1) is an enzyme that, in intact 
cells and in vivo, converts inert GCs (cortisone in humans, and 11-
dehydrocorticosterone in mice and rats) into their active forms (cortisol and 
corticosterone, respectively). Consequently, 11β-HSD1 amplifies intracellular GC 
levels. Additionally, 11β-HSD1 is also involved in the metabolism of 7-oxysterols; it 
catalyses the reduction of 7-ketocholesterol (7-KC) to 7β-hydroxycholesterol (7β-
HC). 7-KC may inhibit cholesterol biosynthesis through its ability to inhibit 
cleavage/processing of sterol regulatory element binding protein-2 (SREBP-2), the 
key regulator of cholesterol synthesis. Alteration of cholesterol homeostasis is a major 
risk factor for cardiovascular disease. Improvement of metabolic syndrome and 
attenuation of atherosclerosis are observed in susceptible rodent models with 11β-
HSD1 deficiency or inhibition. Conversely, pilot data showed decreased levels of 7-
KC as well as increased levels of cleaved SREBP-2 protein (the transcriptionally 
active form) in liver of mice with hepatic 11β-HSD1 overexpression (LOE mice), 
suggesting increased cholesterol biosynthesis. It was hypothesised that hepatic 11β-
HSD1 promotes cholesterol biosynthesis through hepatic induction of SREBP-2 target 
genes in the cholesterol biosynthetic pathway. 
 
The hypothesis was tested in adult, male LOE and wild-type C57BL/6 mice. In mice 
fed a standard chow diet, hepatic levels of mRNA encoding hydroxymethylglutaryl-
coenzyme A (HMG-CoA) reductase and HMG-CoA synthase, SREBP-2 targets in the 
cholesterol biosynthetic pathway, did not differ between genotypes. Compared to 
chow, a cholesterol-rich ‘Western’ diet (WD) decreased hepatic levels of mRNA 
encoding SREBP-2, HMG-CoA reductase and HMG-CoA synthase in wild-type as 
well as in LOE mice. These data imply that LOE mice show a normal physiological 
response with respect to cholesterol synthesis when challenged with cholesterol-rich 




diet, and, contrary to the hypothesis, liver 11β-HSD1 does not increase cholesterol 
biosynthesis via elevated expression of mRNAs encoding hepatic cholesterol 
biosynthetic enzymes.  
 
The liver X receptors (LXR) are well-known as sensors of oxysterols and regulators 
of genes involved in processes that decrease total body cholesterol levels i.e. reverse 
cholesterol transport and cholesterol excretion into bile. Cholesterol is the precursor 
to oxysterol LXR ligands. It was predicted that liver overexpression of 11β-HSD1 
leads to activation of LXRα (the isoform with dominant roles in reverse cholesterol 
transport and whole-body cholesterol homeostasis) and its downstream targets 
involved in cholesterol efflux and excretion, in response to increased intracellular 
cholesterol levels. Indeed, levels of Lxrα mRNA were increased in livers of WD-fed 
LOE mice compared to wild-type mice on the same diet. There was no evidence for 
increased cholesterol clearance through bile acid synthesis in LOE mice as indicated 
by unchanged levels of hepatic Cyp7a1 mRNA between LOE and wild-type mice. 
However, consistent with being direct targets of LXRα, increased Abcg5 and Abcg8 
mRNA levels were observed in livers of WD-fed LOE mice compared to WD-fed 
wild-type mice. These results corroborate findings in chow-fed LOE mice. Moreover, 
these data suggest that LOE mice ‘sense’ intracellular cholesterol excess and respond 
to it by increasing cholesterol efflux into the biliary lumen for excretion, thereby 
supporting a role for hepatic 11β-HSD1 in promoting biliary cholesterol secretion.  
 
To assess the effect(s) of hepatic 11β-HSD1 deficiency on cholesterol homeostasis as 
well as evaluate the importance of liver 11β-HSD1 in metabolic syndrome, liver-
specific 11β-HSD1 knockout (LKO) mice were generated by crossing “floxed” 
Hsd11b1 mice with Alb-Cre transgenic mice in which Cre expression is restricted to 
hepatocytes. In liver of LKO mice, 11β-HSD1 mRNA, protein and enzyme activity 
were reduced by >80%, with no differences in 11β-HSD1 protein levels in kidney, 
adipose tissue or muscle between LKO and floxed Hsd11b1 littermate controls. These 
results indicate liver-specificity of Hsd11b1 knockdown in these mice. Body weight 
and weights of liver, adipose tissue, adrenal, muscle, kidney and brain were unaltered 
by liver-specific 11β-HSD1 deficiency on a standard chow diet. These mice were 
subject to a 14-week high fat (HF) diet, which typically causes metabolic syndrome in 




control but not globally 11β-HSD1 deficient mice. In HF-fed LKO mice, weights of 
the subcutaneous and epididymal fat depots were decreased compared to HF-fed 
control mice, resulting in an overall decrease in total white adipose tissue weight. 
Although no differences were observed in subcutaneous adipocyte hypertrophy 
between HF-fed LKO and control mice in a small number of samples tested, the 
above finding suggests that liver 11β-HSD1 influences adiposity and that liver-
specific deficiency of 11β-HSD1 may reduce diet-induced adiposity.  
 
In terms of cholesterol homeostasis, no differences were observed in hepatic levels of 
mRNAs encoding cholesterol biosynthetic enzymes as well as those encoding 
enzymes/transporters for cholesterol catabolism/excretion between LKO and control 
mice, on either chow or HF diet. 
 
In summary, these data do not support a role for hepatic 11β-HSD1 in cholesterol 
synthesis. However, my evidence suggests that increased hepatic 11β-HSD1 
promotes hepatobiliary cholesterol secretion. Finally, knockdown of liver 11β-HSD1, 
combined with HF feeding, reduces adiposity, suggesting that hepatic 11β-HSD1 may 
play a key role in adipose tissue lipogenesis/lipolysis and/or lipid storage, and that 
liver-specific 11β-HSD1 inhibition (or deficiency) may be advantageous in diet-
induced obesity. Data presented in this thesis contribute to the understanding of the 

















Prolonged glucocorticoid excess causes metabolic syndrome and cardiovascular 
disease. This might be predicted from the known metabolic (dyslipidaemia, insulin 
resistance) and hypertensive effects of chronically elevated glucocorticoid levels. In 
cells of target tissues, active glucocorticoid levels are controlled by an enzyme known 
as 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1).  
  
It has been long known that 11β-HSD1, in intact cells, coverts inactive 
glucocorticoids into their active forms, thereby amplifying intracellular glucocorticoid 
levels. Improvement of metabolic syndrome and attenuation of atherosclerotic heart 
disease are observed in susceptible rodent models with 11β-HSD1 deficiency or 
inhibition. Recent studies have revealed that 11β-HSD1 is also involved in the 
metabolism of 7-oxysterols, which are oxygenated cholesterol derivatives. Alteration 
of cholesterol homeostasis is a major risk factor for cardiovascular disease. It was 
hypothesised that hepatic 11β-HSD1 plays a role in cholesterol homeostasis. I 
investigated this hypothesis using mouse models of liver 11β-HSD1 over-expression 
and liver-specific 11β-HSD1 deficiency. My data suggest that increased liver 11β-
HSD1 promotes hepatobiliary cholesterol secretion, both on control and cholesterol-
rich diets. Deficiency of liver 11β-HSD1, combined with high fat feeding, resulted in 
reduced white fat weight, suggesting that hepatic 11β-HSD1 deficiency or inhibition 
may be advantageous in diet-induced adiposity/obesity.   
 
The implications of this work are broad due to the current obesity and heart disease 
epidemics in humans. Diet-induced obesity studies in rodents are fundamental to 
unravel the complex mechanisms underlying this multifaceted disease, ultimately 
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Chapter	  1.	  	  Introduction






Dyslipidaemia, as the name suggests, is an abnormality in the amount of lipids and 
lipoproteins in the blood; it is characterised by increased plasma levels of 
triglycerides, total cholesterol, and low-density lipoproteins, and decreased levels of 
high-density lipoprotein (Van Gaal et al., 2006). Dyslipidaemia is a component of the 
metabolic syndrome and is strongly associated with an increased risk of 
atherosclerosis, type 2 diabetes, obesity and fatty liver disease, all major causes of 
death and disability in many parts of the world (Paterson et al., 2004; Beaven and 
Tontonoz, 2006). In the above-mentioned conditions, excess cholesterol and/or 
altered plasma lipid profile influence whole-body cholesterol storage and removal. 
Steroid hormones such as glucocorticoids (GCs) can also contribute to the 
development of these diseases; chronic GC excess promotes dyslipidaemia and 
insulin resistance/hyperglycaemia, and is strongly associated with increased 
cardiovascular events (Walker, 2007; Hadoke et al., 2009). 11β-hydroxysteroid 
dehydrogenase (HSD) enzymes regulate intracellular GC levels by catalysing inter-
conversion of active GCs and their inert forms.  While 11β-HSD2 inactivates GCs, 
11β-HSD1 typically regenerates active GCs in tissues where it is expressed, therefore 
amplifying intracellular GC levels (Seckl and Walker, 2001; Chapman and Seckl, 
2008). Knockout of 11β-HSD1 in mice improves key cardiovascular risk factors 
associated with liver and adipose tissue function (Kotelevtsev et al., 1997; Morton et 
al., 2004), and pharmacological inhibition of 11β-HSD1 reduces atherosclerosis 
(Hermanowski-Vosatka et al., 2005). 11β-HSD1 also catalyses the reduction of 
oxysterols (Schweizer et al., 2004; Hult et al., 2004), which are believed to play a role 
in the regulation of cholesterol homeostasis. This thesis will explore the role of 
hepatic 11β-HSD1 in cholesterol homeostasis.  
 
1.1.	  Glucocorticoids	  and	  Risk	  Factors	  for	  Cardiovascular	  Disease	  	  
 
Glucocorticoids are endogenous steroid hormones. The active forms are found as 
cortisol in humans and corticosterone in rats and mice.  GCs have profound effects on 
physiological systems as they play a role in regulating the stress response (Sapolsky et 




al., 2000), intermediary metabolism (McEwen et al., 1997) as well as cognition 
(Setiawan et al., 2007). GCs provide a “brake” on innate inflammatory mechanisms, 
and generally display anti-inflammatory and immunosuppressive actions (McEwen et 
al., 1997; Sapolsky et al., 2000). Hence, they are widely prescribed to treat a number 
of chronic inflammatory conditions (including rheumatoid arthritis, asthma, and 
inflammatory bowel disease), as well as for immune suppression in organ 
transplantation patients.  
 
At the cellular level, a great number of GC effects are mediated by the action of GCs 
on two types of intracellular receptor: glucocorticoid receptor (GR) and 
mineralocorticoid receptor (MR). MRs have a high affinity for physiological GCs 
whereas GRs have a lower affinity for them, so are only occupied at higher 
concentrations of GCs (Funder, 1997; Reul et al., 2000). MR is expressed in a 
restricted range of tissues notably the distal nephron of the kidney, the colon and 
salivary glands, whereas GR is widely expressed and at higher levels than MR at most 
sites (reviewed by Chapman et al., 2013).  
 
Under conditions of stress (such as starvation or exercise), GCs stimulate pathways to 
maintain blood glucose levels, including hepatic gluconeogenesis, protein breakdown 
(from muscle) and lipolysis (from adipose tissue) (Friedman et al., 1993; Slavin et al., 
1994; Hanson and Reshef 1997; Buckingham, 2006; Vegiopoulous and Herzig, 2007). 
GCs also inhibit glucose uptake by muscle and fat during conditions of stress (Horner 
et al., 1987).  
 
Although beneficial in adapting to short-term stress, chronic exposure to elevated GC 
levels has detrimental effects (Sapolsky et al., 1986; Dallman et al., 2004). The 
metabolic and cardiovascular consequences are evident in Cushing’s syndrome 
(caused by pituitary adenomas, ectopic adrenocorticotropic hormone-producing 
tumours or long term administration of synthetic GCs) that is characterised by central 
obesity, insulin resistance, hyperglycaemia, dyslipidaemia and hypertension, all major 
risk factors for cardiovascular disease (Bjorntorp and Rosmond, 1999; Walker et al., 
2000). Apart from the density of glucocorticoid receptors, GC action on target tissues 




is determined by intracellular metabolism by 11β-hydroxysteroid dehydrogenases, 
and therefore these enzymes are key to understanding here. 
1.2.	  11β-­‐Hydroxysteroid	  Dehydrogenases	  
 
Short-chain alcohol dehydrogenases/reductases (SDRs) comprise a large family of 
enzymes that are evolutionarily conserved (Oppermann et al., 2003). This family 
includes mammalian enzymes such as 15-hydroxyprostaglandin dehydrogenase and 
17β-hydroxysteroid dehydrogenase, as well as 11β-hydroxysteroid dehydrogenase. 
Even though only about 10-30% homology exists between the molecular sequences of 
the different dehydrogenases, the three-dimensional structures are highly similar 
(Filling et al., 2002). Most recognised SDR enzymes are the NADH or NADPH-
dependent oxidoreductases that display distinct tissue expression patterns. 
 
1.2.1.	  11β-­‐Hydroxysteroid	  Dehydrogenase	  Type	  1	  and	  Type	  2	  
	  
11β-Hydroxysteroid dehydrogenases (11β-HSD) are microsomal enzymes that come 
under the SDR class of enzymes (Edwards et al., 1988), and regulate intracellular GC 
levels by catalysing the inter-conversion of active GCs (cortisol in humans, 
corticosterone in rodents) and their inert 11-keto forms (cortisone in humans, 11-
dehydrocorticosterone in rodents) (Monder and Shackleton, 1984; Seckl and 
Chapman, 1997). There are two isozymes of this enzyme; 11β-HSD type 1 
(11βHSD1) and 11β-HSD type 2 (11β-HSD2), the products of distinct genes (Stewart 
and Krozowski, 1999). While 11β-HSD2 inactivates GCs, 11β-HSD1 is a reductase 
in vivo, regenerating active GCs from inactive forms (Figure 1.1), therefore locally 
amplifying GC levels available for activation of GRs within target cells (Seckl and 
Walker, 2001; Chapman and Seckl, 2008).  
 
11β-HSD1 is expressed predominantly in GC target tissues including liver, adipose 
tissue, lung, and brain (Krozowski et al., 1990; Seckl and Chapman, 1997). On the 
other hand, 11β-HSD2 is more restricted, with expression in aldosterone target tissues 
such as kidney as well as in tissues of the developing embryo and placenta (Agarwal 
et al., 1990; Edwards, 1991; Walker and Edwards, 1991; Muneyyirci-Delale et al., 




1996; Seckl and Chapman, 1997; Gitau et al., 1998; Moore et al., 2000; Draper and 









Figure	   1.1:	   11β-­‐Hydroxysteroid	   dehydrogenases	   (11β-­‐HSDs)	   catalyse	   the	  
intracellular	   interconversion	   of	   11-­‐keto	   forms	   (cortisone,	   11-­‐
dehydrocorticosterone)	   and	   11-­‐hydroxyl	   forms	   (cortisol,	   corticosterone)	   of	  
glucocorticoids.	  
Arrows indicate the reaction direction in vivo, but 11β-HSD1 can act as a 
dehydrogenase in cell-free conditions (see text for details). The specific 
glucocorticoids depicted in this figure are cortisone and cortisol, which are found in 










1.3.	  11β-­‐HSD1:	  Gene	  structure	  and	  Enzymology	  
 
The encoding gene, HSD11B1, is found near the end of the long arm of chromosome 
1 in mice and humans, and chromosome 13 in rats (reviewed by Chapman et al., 
2013). It comprises seven exons, with exons 2-7 encoding the full-length protein 
(reviewed by Chapman et al., 2013). There are three promoters, P1, P2 and P3, in the 
HSD11B1 gene (Moisan et al., 1992; Bruley et al., 2006), with P2-initiated transcripts 
found in most tissues including liver, adipose and brain (Bruley et al., 2006; Staab et 
al., 2011) and P1-initiated transcripts predominating in mouse lung but hardly found 
in human lung (Staab et al., 2011). Transcription from the P3 promoter encodes a 
protein without 11β-HSD1 activity (Mercer et al., 1993) and its biological relevance 
is unclear (reviewed by Chapman et al., 2013). 
 
The P2 promoter of Hsd11b1 contains several binding sites for the CCAAT/enhancer 
binding protein (C/EBP) transcription factors, and in liver, transcription from P2 
promoter is dependent on C/EBPα  (Williams et al., 2000). In a variety of cell types 
such as adipocytes, fibroblasts and lung epithelial cells, C/EBPβ mediates 11β-HSD1 
regulation in response to proinflammatory cytokines, GCs, diet and other regulators 
(Gout et al., 2006; Arai et al., 2007; Sai et al., 2008; Ignatova et al., 2009; Yang et 
al., 2009).  
 
11β-HSD1 is a 34kDa transmembrane glycosylated protein located inside the inner 
leaflet of the endoplasmic reticulum (ER), in close association with hexose-6-
phosphate dehydrogenase (H6PDH), which supplies the co-factor NADPH that in turn 
allows 11β-reduction (Atanasov et al., 2004; Banhegyi et al., 2004; Bujalska et al., 
2005; Atanasov et al., 2008). In tissue homogenates, 11β-HSD1 is bidirectional, 
catalysing both reductase and dehydrogenase reactions, depending on co-factor (and 
substrate) availability (reviewed by Chapman et al., 2013).  
 
11β-HSD1 has broad substrate specificity. Apart from catalysing GC interconversion, 
11β-HSD1 also interconverts 7-ketocholesterol and 7β-hydroxycholesterol (Hult et 
al., 2004; Schweizer et al., 2004; also see 1.7 and 1.8). The 7-keto-sterol substrates 
competitively inhibit GC metabolism, and vice versa, with GC substrates also 




inhibiting the 7-keto-sterol reduction (Nashev et al., 2007; Wamil et al., 2008; Balazs 
et al., 2009). The 11β-HSD1 reaction direction is affected by these 7-sterols when 
H6PDH is limiting; while 7-ketocholesterol represses, 7β-hydroxycholesterol 
enhances cellular GC action at GR, and by increasing supply of NADPH to 11β-
HSD1 (through overexpression of H6PDH) this effect is reduced (Wamil et al., 2008). 
It has also been shown that human 11β-HSD1 converts the secondary bile acid 7-oxo-
lithocholic acid to chenodeoxycholic acid (Odermatt et al. 2011), and that 11β-HSD1 
plays a role in detoxification of xenobiotics (Maser and Oppermann, 1997).  
 
1.4.	  11β-­‐HSD1:	  Insights	  from	  mouse	  models	  
1.4.1.	  Knockout	  and	  Inhibition	  of	  11β-­‐HSD1	  	  
	  
In order to study the importance of 11β-HSD1 in vivo as well as determine 
therapeutic potential, 11β-HSD1 knockout (Hsd11b1-/-) mice were generated 
(Kotelevtsev et al., 1997). Deficiency/knockout of 11β-HSD1 improves multiple 
metabolic syndrome parameters (see below) as well as protecting against age-related 
cognitive loss and skin thinning (Sandeep et al., 2004; Yau et al., 2011; Tiganescu et 
al., 2013). Amongst the above-mentioned effects of 11β-HSD1 deficiency, this thesis 
will mostly focus on the metabolic disease parameters. 
 
11β-HSD1 deficient mice have reduced levels of plasma triglyceride (TG) and non-
esterified fatty acids (NEFA) (Morton et al., 2001). These mice also have raised high-
density lipoprotein (HDL) cholesterol, with elevated liver mRNA and serum levels of 
apolipoprotein AI (ApoAI) (Morton et al., 2001; for further detail on HDL and other 
lipoproteins, refer to 1.5.3). Furthermore, 11β-HSD1 knockout mice resist 
hyperglycaemia on high fat (HF) diet (Kotelevtsev et al., 1997; Morton et al., 2004), 
exhibit enhanced insulin sensitivity in liver and adipose tissue (Morton et al., 2001; 
Morton et al., 2003; Morton et al., 2004), and have reduced “disadvantageous” 
visceral fat depot upon HF feeding (Morton et al., 2004). On a high cholesterol diet, 
11β-HSD1 knockout mice have lower plasma cholesterol and a higher HDL to total 
cholesterol ratio (compared to wild-type mice on the same diet), factors which are all 
associated with a cardioprotective phenotype (Morton et al., 2004). Indeed, 11β-




HSD1 deficiency is also observed to be atheroprotective. In C57BL/6 mice with a 
targeted deletion of the Apoe gene (which encodes apolipoprotein E), hepatic uptake 
of circulating cholesterol is diminished and development of aortic atherosclerotic 
plaques is observed when these mice are fed an atherogenic “Western” diet (Zhang et 
al., 1992; Plump et al., 1992). Crossing Hsd11b1-/- mice with Apoe knockout mice 
(Apoe-/-) showed that deficiency of 11β-HSD1 results in a substantial reduction of 
atherosclerosis in the dyslipidaemic Apoe-/- mice (Kipari et al., 2013; Garcia et al., 
2013). Over and above improved metabolic risk factors, recent evidence suggests 
direct atheroprotective effects of 11β-HSD1 deficiency/inhibition. 11β-HSD1 
inhibition in Apoe-/- mice reduces inflammatory gene expression in the vasculature as 
a protective mechanism against atherosclerosis (Luo et al., 2013). Also, Kipari et al. 
(2013) showed that transplantation of 11β-HSD1-deficient bone marrow cells into 
irradiated Apoe-/- mice confers atheroprotection, and the mechanism may involve 
cholesterol accumulation in macrophages as 11β-HSD1-deficient macrophages 
showed enhanced cholesterol export (Kipari et al., 2013).  
 
The above evidence, along with studies on the role of GCs in the pathogenesis of 
metabolic and cardiovascular disease, point to the suggestion that 11β-HSD1 would 
be a valuable therapeutic target for type 2 diabetes, obesity, dyslipidaemia and 
atherosclerosis (Walker, 2007; Wamil and Seckl, 2007; Chapman et al., 2013). 
Consistent with this, pharmacological inhibition of 11β-HSD1 improves insulin 
resistance, glucose, insulin and glucagon levels in mouse models of obesity and type 2 
diabetes (Hermanowski-Vosatka et al., 2005; Lloyd et al., 2009). Also, selective 
inhibition of 11β-HSD1 dramatically decreases circulating and intra-aortic cholesterol 
levels in atherosclerosis-prone Apoe-/- mice (Hermanowski-Vosatka et al., 2005), and 
carbenoxolone (a non-selective 11β-HSD1 inhibitor) reduces atherosclerosis in 
susceptible Ldlr-/- mice (Nuotio-Antar et al., 2007). As in mice, inhibition of 11β-
HSD1 in humans improves several metabolic disease risk factors. Phase II clinical 
trials using selective 11β-HSD1 inhibitor ICNB13739 in type 2 diabetes patients have 
shown reduction in levels of plasma glucose and glycated haemoglobin A1c, possibly 
via increased insulin sensitivity (Rosenstock et al., 2010). In hyperlipidaemic 
subjects, the inhibitor reduces plasma cholesterol and TG levels (Rosenstock et al., 
2010). Another clinical trial showed that selective inhibition of 11β-HSD1 results in 




modestly reduced haemoglobin A1c, low-density lipoprotein (LDL) cholesterol, 
blood pressure as well as body weight in patients with type 2 diabetes and metabolic 
syndrome (Feig et al., 2011).  
 
1.4.2.	  Tissue-­‐specific	  Overexpression	  of	  11β-­‐HSD1	  
 
11β-HSD1 activity is consistently found to be increased (two- to three-fold) in 
subcutaneous adipose tissue of obese men and women (Rask et al., 2001; Rask et al., 
2002; Paulmyer-Lacroix et al., 2002; Sandeep et al., 2005; Goedecke et al., 2006; 
Paulsen et al., 2007). This effect is accompanied by a reduction in hepatic 11β-HSD1 
activity in simple obesity in the absence of type 2 diabetes (Rask et al., 2001), but 
liver 11β-HSD1 activity is unaltered if obesity is complicated by type 2 diabetes 
(Stimson et al., 2011). To investigate the pathogenic implications of increased 
adipose 11β-HSD1, aP2-HSD1 mice were generated, using the adipocyte fatty acid 
binding protein (aP2) promoter (Masuzaki et al., 2001). These mice overexpress 11β-
HSD1 by two-to-three-fold selectively in adipose tissue, modelling obese humans and 
rodents. Contrary to Hsd11b1-/- mice, the aP2-HSD1 mice fully replicate metabolic 
syndrome with insulin resistance/diabetes (which is exacerbated by HF feeding), 
dyslipidaemia, hypertension, hyperphagia and visceral obesity (Masuzaki et al., 
2001).  
 
Overexpression of 11β-HSD1 in adipose tissue increases intra-adipose corticosterone 
levels but circulating GC levels are unaltered (Masuzaki et al., 2001). Also, in aP2-
HSD1 mice, corticosterone delivery to the liver is increased (approximately three-
fold) through spillover of adipose corticosterone into the portal vein (Masuzaki et al., 
2001). The enzyme 11β-HSD1 is most highly expressed in liver (Agarwal et al., 
1989; Jamieson et al., 1995), and it has been suggested that heterogeneity of hepatic 
11β-HSD1 may be relevant to the development of fatty liver and insulin-resistant 
phenotype (without obesity) in humans such as that observed in myotonic dystrophy 
where dyslipidaemia and insulin resistance occur with increased hepatic 11β-
reduction of cortisone to cortisol (Johansson et al., 2001; Masuzaki et al., 2001). To 
dissect the role of elevated hepatic GCs, transgenic mice overexpressing 11β-HSD1 
selectively in liver (under the hepatic transcriptional control of the human APOE gene 




promoter) were generated (Paterson et al., 2004). These liver overexpressor (LOE) 
mice show two- to five-fold increase (depending on the line) in 11β-HSD1 activity 
selectively in the liver, and display mild insulin resistance, fatty liver and 
dyslipidaemia, without impairment of glucose tolerance, obesity or changes in 
adipose mass distribution (Paterson et al., 2004). A similar phenotype of insulin 
resistance and fatty liver, irrespective of obesity, has been observed in patients with 
non-alcoholic fatty liver disease (Marchesini et al., 2003) and is a possible early 
indicator of more widespread insulin resistance and the full metabolic syndrome 
(McGarry, 1992). Interestingly, in response to HF diet, the LOE mice reveal altered 
cholesterol lipoprotein profile and attenuated hepatic induction of regulators of 
cholesterol homeostasis including LXRα (Paterson et al., 2004).  
 
Along with the above indirect evidence, there is increasing direct indication that 11β-
HSD1 may play a role in cholesterol homeostasis as it is involved in the metabolism 
of 7-oxysterols. Before further discussing the potential role of 11β-HSD1 in 
cholesterol homeostasis through the metabolism of its alternative substrates, a 
background on cholesterol homeostasis is important. 
	  
1.5.	  Cholesterol	  Homeostasis	  
	  
Initially, cholesterol was discovered in bile and gallstones by Poulletier de la Salle in 
1769, and then Chevrul rediscovered it in 1815, naming it “cholesterine”. Cholesterol 
was later found in blood (Dam, 1958). Cholesterol is the primary sterol synthesised by 
animals. Apart from being an essential structural component of animal cell 
membranes establishing proper membrane fluidity and permeability, cholesterol is a 
vital precursor for the biosynthesis of steroid hormones, bile acids and Vitamin D 
(Simons and Ikonen, 2000; Hsu et al., 2006; Norlin and Wikvall, 2007). Despite its 
importance, animal cells cannot tolerate excess cholesterol. Raised levels of blood 
cholesterol and intracellular cholesterol accumulation can result in pathological 
consequences such as atherosclerotic cardiovascular disease and may also contribute 
to early onset of Alzheimer’s disease and renal dysfunction (Kees-Folts and Diamond, 
1993; Guyton and Klemp, 1996; Abrass, 2004; Wellington, 2004). It is, therefore, not 




surprising that mammals have developed complex mechanisms to tightly control 
whole-body cholesterol levels and maintain cholesterol homeostasis (Goldstein and 
Brown, 1990; Brown and Goldstein, 1999; Jessup and Kritharides, 2008; Goldstein 
and Brown, 2009).  
 
1.5.1.	  Cholesterol	  Biosynthesis	  
	  
The liver is the major site of cholesterol synthesis; in mammals, approximately 70% 
of cholesterol is synthesised in the liver (Spady and Dietschy, 1983). The other major 
organ of cholesterol synthesis is the intestine, which accounts for nearly 20% of 
cholesterol production (Berg et al., 2002).  
 
The complex cholesterol molecule, which contains 27 carbons, is synthesised from 
acetyl CoA, a two-carbon substrate, in a series of approximately 30 enzymatic 
reactions (Goldstein and Brown, 1990; Kelley and Herman, 2001; Kovacs et al., 
2002). The first stage in the cholesterol biosynthetic pathway is formation of 
isopentenyl pyrophosphate from acetyl CoA. This set of reactions occurs in the 
cytosol, starting with the formation of 3-hydroxy-3methylglutaryl CoA (HMG CoA), 
which is then reduced to mevalonate. Synthesis of mevalonate is the committed step 
in cholesterol formation and the enzyme catalysing this irreversible step, 3-hydroxy-
3-methylglutaryl CoA reductase (HMGCR), is an important control site in cholesterol 
synthesis. Mevalonate is converted into 3-isopentenyl pyrophosphate. Six molecules 
of isopentenyl pyrophosphate are condensed to form squalene, which cyclises into a 
tetracyclic product (lanosterol) that is eventually converted into cholesterol in a 
multistep process (Berg et al., 2002) (Figure 1.2).  
 
With the exception of HMGCR, the first enzymes of cholesterol biosynthetic pathway 
are soluble proteins found in the ER membrane (Goldstein and Brown, 1990; Gaylor, 
2002; Kovacs et al., 2002). Reactions generating mevalonate can also occur within 
the peroxisome, and the succeeding reactions that result in the formation of farnesyl-
pyrophosphate are exclusively peroxisomal (Olivier and Krisans, 2000). The 
remaining biosynthetic reactions take place in the ER (Figure 1.2). Hence, cholesterol  
 






Figure	  1.2:	  Cholesterol	  biosynthetic	  pathway.	  
A schematic representation of the cholesterol biosynthetic pathway, showing a 
number of cholesterol by-products and enzymes. Enzymes in the pathway are found 
in the cytosol, endoplasmic reticulum (ER) and peroxisomes. HMG, 3-hydroxy-3-
methylglutaryl; DHC, dehydrocholesterol. Figure adapted from Liscum, 2002. 
 
 




biosynthetic enzymes are compartmentalised in the cytosol, ER and/or peroxisome. 
The reason behind this is unclear but it has been suggested that this adds another level  
of complexity to the regulation of this important metabolic pathway (Olivier and 
Krisans, 2000; Liscum, 2002; Berg et al., 2002). 
	  
1.5.1.1.	  Regulation	  of	  Cholesterol	  Synthesis	  
	  
Cholesterol can be obtained via the diet or it can be synthesised de novo. A 
remarkable example illustrating the regulatory power of cholesterol homeostasis is the 
case study of the 88-year old patient who ate around 25 eggs a day for approximately 
15 years but still maintained normal serum cholesterol levels between 3.88 and 
5.1mM (normal values in adults being <5.17mM) (Kern, 1991). 
 
The rate of cholesterol biosynthesis depends on the availability of cholesterol in the 
diet. The cholesterol biosynthetic pathway is regulated by the sterol end product as 
well as non-sterol intermediates and other physiological factors, acting on several 
enzymes in the cholesterol biosynthetic pathway, though the focus has mostly been on 
HMGCR, the rate-limiting enzyme. Combined together, these regulatory factors can 
modify the amount of HMGCR over a 200-fold range. Whereas sterols regulate 
HMGCR gene transcription, non-sterols regulate its mRNA translation, and both 
sterols and non-sterols play a role in the stringent regulation of HMGCR protein 
degradation (Goldstein and Brown, 1990). Other physiological factors that influence 
cholesterol synthesis include diurnal rhythm, insulin and glucagon, GCs, oestrogen 
and bile acids, and these factors regulate HMGCR at transcriptional, translational as 
well as post-translational levels (Chambers and Ness, 1997; Ness and Chambers, 
2000). Other enzymes in the cholesterol synthesis pathway that have been well 
studied include HMG-CoA synthase (HMGCS), farnesyl-PP synthase and squalene 
synthase (Brown and Goldstein, 1997; Edwards et al., 2000; Hampton 2000).  
 
Each of the genes encoding the above-mentioned enzymes contains a sterol regulatory 
element (SRE) within their promoter regions that is recognised by a membrane-bound 
transcription factor, the sterol regulatory element binding protein (SREBP) (Brown 
and Goldstein, 1997). Cloning of SREBP cDNA (Yokoyama, 1993; Hua 1993) 




revealed that there are two SREBP genes that produce three distinct proteins. SREBP-
1a and -1c derive from one gene but from different promoters, whereas SREBP-2 is 
derived from a second gene (Brown and Goldstein, 1997). SREBPs not only regulate 
cholesterol synthesis but also the synthesis of fatty acids (Horton and Shimomura, 
1999; Osborne, 2000). The functional roles were first deduced from studying 
transgenic mice overexpressing SREBP-1a, -1c, or -2 in liver (Shimano et al., 1996; 
Shimano et al., 1997; Horton et al., 1998). SREBP-1a is a strong activator of 
cholesterol and fatty acid synthesis and is likely to be important in cells that are 
rapidly dividing and need lipid for membrane production (Horton and Shimomura, 
1999; Osborne, 2000). SREBP-1c is mainly in the liver, where it primarily activates 
genes of fatty acid synthesis, and it is important for maintaining basal transcription 
levels of fatty acid and cholesterol biosynthetic enzymes during fasting (Osborne, 
2000; Horton et al., 2002). SREBP-2 selectively activates cholesterol biosynthetic 
genes and mainly responds when the liver’s demand for cholesterol increases (Horton 
et al., 1998; Pai et al., 1998). 
 
Sterol regulatory element binding proteins are cytosolic 68kDa proteins and belong to 
the basic helix-loop-helix leucine zipper (bHLH-Zip) family of transcription factors. 
However, unlike other bHLH-Zip transcription factors, SREBPs are 125kDa trans-
membrane proteins located in the ER that undergo a two-step cleavage process to 
generate an N-terminal 68kDa fragment including the bHLH-Zip motif, which travels 
to the nucleus to activate transcription of genes involved in cholesterol and fatty acid 
synthesis. The C-terminal domain serves a regulatory function (Brown and Goldstein, 
1997; Horton and Shimomura, 1999; Osborne, 2000). The sequential two-step 
cleavage of the full-length precursor SREBP is dependent on the cellular cholesterol 
content.  
 
Three proteins required for the regulation of SREBP cleavage have been identified 
using somatic cell genetic approaches (Chang et al., 1997); SREBP cleavage-
activating protein (SCAP), an escort protein, and two proteases, Site-1 protease (S1P) 
and Site-2 protease (S2P) (Chang et al., 1997; Goldstein et al., 2002). After synthesis 
in the ER, SREBPs complex with SCAP (Sakai and Rawson, 2001). SCAP is both a 
chaperone for SREBPs as well as a sensor of sterols (Brown et al., 2002). When 
cellular cholesterol levels are low, SCAP escorts SREBP from the ER to the golgi, 




where the two proteases are located. In the golgi, S1P cleaves SREBP between its two 
membrane-spanning segments, therefore dividing the SREBP molecule in half. The 
NH2-terminal bHLH-Zip domain is freed from the membrane via a second cleavage 
mediated by S2P. The NH2-terminal domain (nuclear SREBP or nSREBP) 
translocates to the nucleus, where it activates transcription of target genes (e.g. 
HMGCR) by binding to their SREs in the promoter/enhancer regions (Figure 1.3). 
When the cholesterol content of cells rises, the SCAP/SREBP complex is retained in 
the ER so the SREBP precursor does not reach the golgi to be cleaved (Figure1.3). As 
a result, the transcription of target genes reduces (Brown and Goldstein, 1997; 
Goldstein et al., 2002).  
 
An interesting question is whether cholesterol (end product) inhibits processing of all 
SREBPs. Studies in cultured human embryonic kidney (HEK-293) cells show that 
SREBPs are differentially regulated in that cholesterol blocks the processing of 
SREBP-2 but not SREBP-1 (Hannah et al., 2001). Inhibition of SREBP-1 cleavage 
requires an unsaturated fatty acid, such as oleate, in addition to sterols (Hannah et al., 
2001). It was suggested that in the presence of sterols but absence of fatty acids, 
SCAP may be able to escort SREBP-1 proteins (but not SREBP-2) to the golgi, but 
further studies are required to confirm the mechanism of this differential regulation. 
 
1.5.2.	  Absorption	  of	  Dietary	  Cholesterol	  
 
While cholesterol can be synthesised in the body from acetyl CoA, it is a process that 
requires considerable energy input. Thus, dietary cholesterol, obtained from foods 
derived from animal sources that are rich in fat/lipid content (such as eggs, cheese, 
butter and meat) is absorbed for use by the body, reducing the need for de novo 
cholesterol biosynthesis. The daily intake of cholesterol in humans on a typical 
Western-style diet is between 300-500 mg (Wang, 2007).  
 
The major sites of dietary cholesterol absorption are the duodenum and proximal 
jejunum. Most dietary cholesterol is in the form of free sterol, though about 10-15% is 
esterified as cholesteryl ester (CE; cholesterol esterified to long-chain fatty acids).  
 








Figure	  1.3:	  SREBP	  processing	  and	  activation	  
The sterol regulatory element-binding protein (SREBP) precursor is inserted into the 
endoplasmic reticulum (ER) membrane. The SREBP regulatory domain (Reg) 
interacts with the SREBP cleavage-activating protein (SCAP), most likely through 
SCAP’s WD repeats. When cholesterol levels are low, SCAP escorts SREBP to the 
Golgi where the bHLH-Zip domain is released by sequential cleavage, first by S1P, 
then by S2P. The mature SREBP translocates into the nucleus and activates gene 
transcription. In cholesterol replete cells, the SREBP precursor and SCAP remain in 
the ER and the SREBP precursor is not proteolysed to release its bHLH-Zip 
transcription factor (see text for details). SRE, sterol regulatory element. Figure 








Only non-esterified cholesterol can be absorbed, therefore CEs have to be hydrolysed 
to release free cholesterol, which can then be absorbed. Cholesterol is almost 
insoluble in an aqueous environment (Swell et al., 1958; Holt et al., 1986) so is 
partitioned into bile salt micelles to be absorbed. Cholesterol usually enters bile salt 
micelles with triglycerides (TGs), monoacylglycerides, fatty acids, and phospholipids, 
to form mixed micelles, which are then transported to the brush border of the 
enterocyte (Westergaard and Dietschy, 1976; Hernell et al., 1990; Yao et al., 2002).  
 
Cholesterol absorption used to be considered a simple, passive diffusion process. 
However, it is now recognised that it is transporter-facilitated and cholesterol is 
selectively taken up by enterocytes with relatively high efficiency compared to 
structurally similar plant sterols (Monreau et al., 2002). There are inter-individual 
(human) and inter-strain (mouse) variations in the efficiency of cholesterol absorption 
(Yang et al., 1995; Yao et al., 2002), and multiple genes participate in cholesterol 
absorption (Altmann et al., 2004; Berge et al., 2000; Lee et al., 2001; Lu et al., 2001).  
 
Genetically modified animal models have provided insights into the transporter-
facilitated mechanism of cholesterol absorption. Niemann-Pick C1 like 1 (NPC1L1) is 
a glycosylated protein localised at the brush border membrane of the enterocyte that 
acts as a cholesterol uptake transporter (Iyer et al., 2005). NPC1L1 has about 50% 
amino acid homology to NPC1, which is mutated in the cholesterol storage disease, 
Niemann-Pick disease (Carstea et al., 1997). In rodents, NPC1L1 is present only in 
the small intestine. However, in humans, in addition to the small intestine, NPC1L1 is 
also located in other tissues such as liver and stomach. Deletion of Npc1l1 in mice 
results in reduced intestinal cholesterol absorption (Altmann et al., 2004). A SRE in 
the promoter and a sterol-sensing domain of NPC1L1 appear to regulate cholesterol 
absorption in response to cholesterol intake; Npc1l1 expression is suppressed in mice 
that are fed a cholesterol-rich diet and increased in the cholesterol-depleted porcine 
intestine (Huff et al., 2006).  
 
The scavenger receptor class B type 1 (SR-B1) may also play a role in the control of 
cholesterol absorption. SR-B1 is localised at both the apical and basolateral 
membranes of enterocytes (Cai et al., 2004). The intestine-specific overexpression of 
SR-B1 in mice leads to an increase in cholesterol as well as TG absorption in short-




term experiments (Bietrix et al., 2006). However, targeted deletion of Sr-b1 in mice 
has little effect on cholesterol absorption in vivo (Altmann et al., 2002; Mardones et 
al., 2001; Wang and Carey, 2002) suggesting that SR-B1 is not essential for intestinal 
cholesterol absorption.  
 
Once cholesterol is transported into intestinal enterocytes, it can either be pumped 
back into the lumen via the cholesterol efflux transporters ABCG5/G8 (Berge et al., 
2000; Lee et al., 2001; Lu et al., 2001), or it can be esterified for transport within 
chylomicrons (see below and 1.5.3).  
 
It is worth pointing out that although this section’s focus is on absorption of dietary 
cholesterol, this process of lipid absorption does not occur in isolation in the intestine. 
Dietary TGs are emulsified by bile acids and hydrolysed by the enzyme lipase, 
resulting in a mixture of fatty acids and monoglycerides. These then pass from the 
intestinal lumen into enterocytes, where they are repackaged to form TGs, which 
further combine with phospholipids, cholesterol ester and apolipoprotein B-48 (see 
1.5.3) to form chylomicrons (Carey et al., 1983). These chylomicrons pass into 
lacteals (lymphatic capillaries, found in the villi of the intestine) and are carried to the 
thoracic duct, where they enter the general circulation. In this way, nearly all dietary 
lipid is transported in chylomicrons from the gut to the blood through the lymphatic 
system (Dixon, 2010).  
 
1.5.3.	  Cholesterol	  Transport	  
	  
The cholesterol (with fats) absorbed from the diet is transported in the blood in the 
form of lipoproteins, with different lipoproteins involved at different stages of 
cholesterol delivery. 
 
Lipoproteins consist of a hydrophobic cholesteryl ester and TG core surrounded by an 
outer polar layer of cholesterol, phospholipids and specific apolipoproteins. 
Apolipoproteins (e.g. apoA, apoB, apoC, apoD or apoE), as well as aiding lipid 
transport, also facilitate recognition by enzymes, allowing removal of lipids from the 
particle (Kingsbury and Bondy, 2007).  




There are five classes of lipoproteins based on size and density; chylomicrons, very 
low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL). The composition, density and 
source of each class of lipoprotein is summarised in Table 1.1.  
 
As mentioned previously, dietary cholesterol is absorbed by intestinal enterocytes, 
which package it into the TG-rich chylomicrons (Chappell and Medh, 1998; 
Ginsberg, 1998). Chylomicrons are the largest of the lipoprotein particles and 
predominantly transport TGs to adipose tissue, but also deliver dietary cholesterol to 
the liver (Smith et al., 1978). The TGs in the chylomicrons are hydrolysed by 
lipoprotein lipase (LPL), found on the surface of endothelial cells, leaving 
chylomicron remnants containing mostly cholesterol. The liver rapidly clears these 
cholesterol remnants (Chappell and Medh, 1998).  
 
The liver repackages cholesterol derived from chylomicron remnants, as well as 
endogenously synthesised cholesterol with TGs, into VLDL particles for transport to 
tissues. Like chylomicrons, VLDL is a substrate for LPL. As TGs and cholesterol are 
delivered to tissues, VLDL particles become less dense to form IDL particles, which 
are either internalised by the liver or converted to cholesterol-rich LDL (Chappell and 
Medh, 1998; Ginsberg, 1998). 
 
LDL transports approximately two-thirds of the cholesterol in human plasma. Cells 
can internalise LDL through cell surface LDL receptors (LDLR). Receptor-mediated 
endocytosis of LDL and the subsequent liberation of its packaged cholesterol releases 
cholesterol for use in steroidogenesis or in cell membrane renewal (Brown and 
Goldstein, 1986). Clearance of circulating LDL requires the hepatic LDLR.  
 
HDL particles, the smallest and densest of the lipoproteins, are produced as protein-
rich particles in the liver and small intestine (Millar et al., 1995; Asztalos and 
Schaefer, 2003) and return excess cholesterol from tissues to the liver. HDL collects 
cholesterol from cells by interaction with the ATP-binding cassette transporter A1 
(ABCA1). Lecithin-cholesterol acyltransferase (LCAT) converts free cholesterol into 
cholesteryl ester, which is then taken up into the core of HDL particles, thereby 
 






Table	  1.1:	  The	  source	  and	  composition	  of	  lipoproteins	  
 Chylomicrons VLDL IDL LDL HDL 
Density (g/ml) <0.95	   <0.95-­‐
1.006	  
1.006-­‐1.019	   1.019-­‐1.063	   1.063-­‐
1.210	  
Diameter (nm) 75-­‐1200	   30-­‐80	   25-­‐35	   18-­‐25	   5-­‐12	  
Components (% dry 
weight) protein 
1-­‐2	  %	   10%	   18%	   25%	   33%	  
Triglyceride (%) 83	   50	   31	   10	   8	  
Cholesterol and CEs 
(%) 
8	   22	   29	   46	   30	  




A-­‐I,	  A-­‐II,	  B-­‐48,	  
C-­‐I,	  C-­‐II,	  C-­‐III	  
B-­‐100,	  C-­‐I,	  
C-­‐II,	  C-­‐III,	  E	  
B-­‐100,	  C-­‐I,	  












There are five different classes of lipoproteins based on their size and density; 
chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein 
(IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). This table 
summarises the composition and source of the different lipoproteins. Source of 




















increasing the size of HDL particles as they circulate through the bloodstream. In 
humans, esterified cholesterol can be transferred from HDL to VLDL and LDL 
particles, via cholesteryl ester transfer protein (CETP), for delivery to steroidogenic 
tissues such as the adrenal glands and gonads, or returned to the liver for excretion of 
cholesterol in bile (Assmann and Gotto, 2004). The transfer of cholesterol from extra-
hepatic tissues to the liver is termed reverse cholesterol transport. 
	  
1.5.4.	  Cholesterol	  Efflux	  
	  
Sterol removal is vital for the maintenance of cellular cholesterol balance. Peripheral 
cells do not break down cholesterol so their only mechanism for removal is via 
cholesterol efflux and reverse cholesterol transport (RCT) (Glomset and Wright, 
1964; Glomset, 1968).  
 
The specific process of cholesterol efflux from cholesterol-enriched macrophages in 
atherosclerotic lesions has been termed macrophage reverse cholesterol transport 
(Cuchel and Rader, 2006). The adenosine triphosphate (ATP) binding cassette 
transporters A1 (ABCA1) and G1 (ABCG1) are the key molecules involved in 
cholesterol efflux from macrophage foam cells. ABCA1 promotes cholesterol as well 
as phospholipid efflux onto lipid-poor apolipoproteins, apoA-1 or apoE (Rust et al., 
1999; Bodzioch et al., 1999; Brooks-Wilson et al., 1999; Wang et al., 2000). Some 
studies show that, in addition to its role in cholesterol efflux from arterial wall cells, 
ABCA1 is also responsible for the initiation of HDL particle formation in the liver 
and small intestine (Timmins et al., 2005; Brunham et al., 2006). ABCG1 promotes 
efflux of free cholesterol onto HDL particles (Wang et al., 2004; Kennedy et al., 
2005). Within HDL particles, the enzyme LCAT esterifies some of the free 
cholesterol. In humans, CETP transfers esterified cholesterol to TG-rich lipoproteins, 
which are subsequently removed from the circulation when LDL receptors or heparin 
sulphate proteoglycans mediate the hepatic uptake of remnant lipoproteins 
(MacArthur et al., 2007). In rodents, and possibly humans, free and esterified 
cholesterol in HDL particles is directly taken up into the liver by SR-B1, in a process 
of selective uptake (Acton et al., 1996; Rinninger et al., 1994). The above-mentioned 
process of cholesterol efflux not only operates to remove cholesterol from 




macrophage-derived foam cells, but also from other peripheral cells.  
 
The relative contributions of the different cholesterol efflux mechanisms have been 
determined in mouse macrophages; aqueous diffusion, 35%; ABCA1, 35%; ABCG1, 
21%; and SR-B1, 9% (Adorni et al., 2007). On the other hand, in human 
macrophages, the SR-B1 pathway is relatively more important, and ABCG1 does not 
contribute to efflux (Larrede et al., 2009). 
 
The complicated process of RCT allows the removal of cholesterol from peripheral 
cells for delivery to the liver for faecal excretion. 
 
1.5.5.	  Cholesterol	  Excretion	  
 
Cholesterol is excreted via a number of pathways: minimal amounts are excreted 
through skin and intestinal cell shedding (Bhattacharyya et al., 1972; Ferezou et al., 
1981; Bhattacharyya et al., 1983), with the majority excreted via biliary (or 
hepatobiliary) cholesterol secretion (Bloch et al., 1943; Dikkers and Tietge, 2010), 
which is considered to be the final step in the RCT pathway. Once excess cholesterol 
from the periphery is brought into the liver, the liver secretes cholesterol into bile 
either directly as free cholesterol or after conversion into bile acids, therefore 
resulting in irreversible elimination of cholesterol from the body via the faeces 
(Angelin et al., 2002; Lewis, 2006).  
 
Direct secretion of cholesterol into bile takes place in a process involving the ATP-
binding cassette transporters, ABCG5 and ABCG8 (Berge et al., 2000; Graf et al., 
2003). This heterodimer transporter pair is expressed in the liver and intestine (Klett 
et al., 2004b). In humans, mutations in both have been identified, leading to 
sitosterolaemia, an autosomal recessive disorder characterised by the accumulation of 
plant sterols in blood and tissues as well as decreased biliary sterol secretion (Hazard 
and Patel, 2007; Scriver et al., 1995). In the intestine, ABCG5 and ABCG8 
efflux/secrete absorbed plant sterols back into the intestinal lumen (see 1.5.2), 
whereas in the liver, ABCG5/G8 promote sterol efflux into the bile canaliculus, for 
secretion in bile (Yu et al., 2002a; Yu et al., 2002b) (Figure 1.4). Supporting this,  










Figure	  1.4:	  A	  schematic	  overview	  of	  the	  major	  cholesterol	  excretion	  pathways.	  
Refer to above text for detailed description on cholesterol efflux and excretion. 
ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette 
transporter G1; ABCG5, ATP-binding cassette transporter G5; ABCG8, ATP-binding 
cassette transporter G8; apoA-I, apolipoprotein A-I; CH, cholesterol; HDL, high 
density lipoprotein; Sr-B1, scavenger receptor class B type 1; TICE, transintestinal 












biliary cholesterol secretion is reduced by approximately 75% in ABCG5 and/or 
ABCG8 knockout mice (Yu et al., 2002b; Klett et al, 2004a; Plösch et al., 2004). On 
the other hand, biliary cholesterol secretion is significantly increased in mice with 
transgenic overexpression of ABCG5/G8 (Yu et al., 2002a; Yu et al., 2005).  
 
The liver can also eliminate cholesterol from the body via hepatic conversion of 
cholesterol into bile acids (Russell and Setchell, 1992; Chiang and Vlahcevic, 1996; 
Chiang, 2002). Bile acids are amphipathic molecules, containing hydrophobic and 
hydrophilic properties, and a negative charge at one end (Hofmann et al., 2008). 
Therefore, unlike water-insoluble cholesterol, bile acids are water-soluble and readily 
excreted. In humans, the major primary bile acids include cholic acid (CA) and 
chenodeoxycholic acid (CDCA). In mice, CA and β-muricholic acid (MCA) are the 
main primary bile acids (Ziboh et al., 1961).  
 
Bile acid synthesis takes place in hepatocytes via two pathways, the classic (or 
neutral) pathway and the alternative (or acidic) pathway (Russell, 2003). In humans, 
the classic pathway produces CA and CDCA in equal amounts. Cholesterol 7α-
hydroxylase, encoded by CYP7A1, catalyses the first, rate-limiting, step of the classic 
pathway (Myant and Mitropoulos, 1977). The alternative pathway mainly produces 
CDCA (Javitt et al., 1989; Javitt, 1994), and in this pathway, sterol 27-hydroxylase, 
encoded by CYP27A1, catalyses the first reaction (Pikuleva et al., 1998). Studies in 
genetically modified mice and in rats reveal that the percentage of total daily bile acid 
production via the alternate pathway is significantly greater in these animal models 
than that found in humans (Vlahcevic et al., 1997; Rosen et al., 1998; Schwarz et al., 
1998; Duane and Javitt, 1999; Li-Hawkins et al., 2000; Repa et al., 2000a). 
 
Although the liver is the major organ involved in cholesterol metabolism and 
excretion, evidence supports a role for the small intestine in active cholesterol 
excretion, in a process called transintestinal cholesterol efflux (TICE) (Temel and 
Brown, 2010; van der Velde et al., 2010; Vrins, 2010; Brufau et al., 2011). 
Interestingly, despite their significantly reduced biliary cholesterol secretion, 
ABCG5/G8 double knockout mice do not show the expected low faecal neutral sterol 
output (Yu et al., 2002b), suggesting that biliary cholesterol secretion might not be 




the only cholesterol excretion route. Faecal sterols of non-dietary origin have been 
observed in rats with long-term bile diversion (Bandsma et al., 2000) as well as in 
patients with biliary obstruction (Cheng and Stanley, 1959). Performing intestine 
perfusions in mice that were injected with radiolabelled cholesterol confirmed the 
presence of the TICE pathway as the direct secretion of cholesterol from blood 
through the intestinal wall into the intestinal lumen was established (van der Velde et 
al., 2007; van der Veen et al., 2009). The complete length of the small intestine can 
secrete considerable amounts of cholesterol, but this secretion is most significant at 
the proximal end. It has also been revealed that, in mice, the TICE pathway accounts 
for nearly 33% of total neutral sterol loss (van der Veen et al., 2009). In humans, 
although there are studies showing the role of the gut in cholesterol excretion (Cheng 
and Stanley, 1959; Simmonds et al., 1967), the relative contribution of this non-
biliary pathway to total sterol output remains to be established (Temel and Brown, 
2012).  
 
The liver X receptors (LXRα and LXRβ) regulate cholesterol homeostasis, 
specifically with respect to the RCT pathway. The liver X receptors are members of 
the nuclear hormone receptor superfamily of ligand-activated transcription factors, 
and their activation promotes cholesterol efflux from peripheral cells as well as 
cholesterol excretion from liver, and inhibition of intestinal cholesterol absorption 
(Calkin and Tontonoz, 2010). LXR activation increases transcription of ABCA1 and 
ABCG1, increasing cholesterol efflux, and hepatic ABCG5, ABCG8, CYP7A1 aiding 
cholesterol excretion (Lehmann et al., 1997; Peet et al., 1998; Repa et al., 2002; Yu et 
al., 2003; Calkin and Tontonoz, 2010). LXR activation also inhibits cholesterol 
absorption because activation of ABCG5/8 in the small intestine limits intestinal 
cholesterol absorption. Animal studies have also shown LXRα to be predominant in 









1.6.	  Cholesterol	  Homeostasis	  and	  Cardiovascular	  Disease	  
 
When intracellular cholesterol levels exceed cellular demand and removal processes, 
the excessive build-up of cholesterol can disrupt cell membranes and promote 
apoptosis (Feng et al., 2003). Moreover, cholesterol accumulation in cells of the 
artery wall can lead to atherosclerotic cardiovascular disease, which is a leading cause 
of morbidity and mortality worldwide (Yuan et al., 2006; Cullen et al., 2005).  
 
The term ‘atherosclerosis’ is derived from the Greek words “athero” referring to paste 
or gruel, and “sclerosis” referring to hardness. Atherosclerosis results from the 
accumulation of fatty material along the inner artery wall lining, and is the primary 
cause of heart disease. The fatty deposits may increase in size, developing into plaque 
or lesions, which are mainly composed of cholesterol-enriched macrophages (foam 
cells) (Cullen et al., 2005; Maxfield and Tabas, 2005; Pennings et al., 2006). This 
eventually leads to hardening and narrowing of the blood vessel, and when unstable 
plaques rupture, it can result in a life-threatening myocardial infarction or stroke 
(Cullen et al., 2005; Maxfield and Tabas, 2005).  
 
Patients with familial hypercholesterolaemia, a rare inherited disorder, accumulate 
extremely high levels of blood cholesterol from early childhood and develop coronary 
heart disease in youth, despite absence of other risk factors such as high blood 
pressure or smoking (Yuan et al., 2006). Elevated levels of plasma LDL cholesterol 
and decreased levels of HDL cholesterol are associated with the development (and 
progression) of atherosclerosis (Libby, 2002; Brewer and Santamarina-Fojo, 2003; 
Hersberger and von Eckardstein, 2003; Cullen et al., 2005; Pennings et al., 2006). 
The Framingham Heart Study is an ongoing study on the residents of the town of 
Framingham in Massachusetts, USA, which started with approximately 5200 adult 
subjects (Mahmood et al., 2013). This study was one of the first studies developed to  
identify and assess risk factors for cardiovascular disease. Amongst other risk factors, 
this study showed that as total cholesterol levels rise above 200 mg/dl, heart disease 
risk increases accordingly. Another major finding of this study is that high levels of 
HDL cholesterol reduce risk of heart disease (Mahmood et al., 2013). In the Seven 
Countries Study, the dietary intake and heart disease rates of seven countries (USA, 




Finland, Netherlands, Italy, Greece, Former Yugoslavia, Japan) and 16 population 
subgroups were examined, showing a positive correlation between the intake of 
dietary cholesterol and blood cholesterol levels (and, ultimately, heart disease rates) 
(Kromhout, 1999). Plasma cholesterol levels and its distribution among lipoproteins 
are predictive tools to assess risk of a cardiac event, and are routinely used in the 
clinics. Cholesterol homeostasis (or its deregulation) plays a crucial role in the 
initiation of atherosclerosis (Yuan et al., 2012).  
 
Reduction of hepatic cholesterol synthesis is an attractive therapeutic approach. 
Statins are competitive inhibitors of HMGCR, the rate-limiting enzyme in the 
cholesterol biosynthetic pathway, and are used in therapies against 
hypercholesterolaemia and atherosclerosis (Shepherd et al., 2002; De Bacquer et al., 
2003; Baigent et al., 2005). However, the use of statins can have severe side-effects, 
the most frequent being myopathy, ranging from myalgia to fatal rhabdomyolysis 
(Hamilton-Craig, 2001; Rozman and Monostory, 2010).  
 
Preventing the absorption of dietary cholesterol can also help control plasma 
cholesterol levels in hypercholesterolaemic conditions. Ezetimibe is a drug that does 
exactly this, in both humans and mice, through NPC1L1 inhibition (Davis et al., 
2002). Although cholesterol absorption inhibition by ezetimibe has shown to 
stimulate a compensatory increase in endogenous cholesterol biosynthesis (Davis et 
al., 2002; Davis and Veltri, 2007), ezetimibe monotherapy lowers plasma LDL 
cholesterol concentrations by approximately 15-20% (Sudhop et al., 2002; Dujovne et 
al., 2002). Trials have also shown additional cholesterol-lowering benefit by 
combining ezetimibe with statin therapy (Mikhailidis et al., 2011). Additionally, 
ezetimibe has also shown to stimulate RCT from macrophages in mice (Sehayek and 
Hazen, 2008; Briand et al., 2009).  
 
As one of the major killers in the Western and increasingly the developing world, it is 
important to understand the (patho)physiology of atherosclerosis for continued 
identification of therapeutic targets. Oxysterols have been identified as modulators of 
cholesterol metabolism and also been linked with atherosclerosis.  




1.7.	  Oxysterols	  in	  Cholesterol	  Metabolism	  and	  Atherosclerosis	  
 
Oxysterols are oxygenated cholesterol derivatives that are formed either by enzymatic 
or non-enzymatic reactions. In mammals, oxysterols are always present at very low 
concentrations compared to cholesterol (Brown and Jessup, 1999). Oxysterols fall 
into two main categories, 1) those that are oxygenated on the sterol ring, including 
7α/β-hydroperoxycholesterol, 7-ketocholesterol (7-KC) and 7α/β-hydroxycholesterol 
(7α-HC; 7β-HC), and 2) those that are oxygenated on the side chain, e.g. 24S-
hydroxycholesterol, 25-hydroxycholesterol and 27-hydroxycholesterol (Schroepfer 
Jr., 2000).  
 
As natural ligands for LXRs, oxysterols have been shown to stimulate downstream 
cholesterol efflux and excretion pathways, as well as limit lipoprotein uptake 
(Janowski et al., 1996; Zelcer et al., 2009). Oxysterols also directly inhibit processing 
of SREBPs, thereby inhibiting the cholesterol biosynthesis pathway (Schmidt et al., 
2006; Radhakrishnan et al., 2007).   
 
Despite making up less than 0.1% of the total cholesterol in the body, oxysterols are 
major components of oxidised LDL (nearly 60%) and, therefore, are highly abundant 
in the plasma and vessel wall (Dzeletovic et al., 1995; Brown and Jessup, 1999). Both 
7-KC and 7β-HC are prominent in atherosclerotic plaques (Hughes et al., 1994; 
Brown and Jessup, 1999; Jessup and Brown, 2005; Larsson et al., 2006). Unlike 
normal physiological levels, the oxysterol:cholesterol ratio in atherosclerotic plaques 
is much higher (Bjorkhem et al., 1994; Zieden et al., 1999). There is also evidence 
that 7β-HC is possibly more toxic than 7-KC (Steffen et al., 2006).  
 
1.8.	  A	  Role	  for	  11β-­‐HSD1	  in	  7-­‐Oxysterol	  Metabolism	  
 
As well as catalysing the intracellular conversion of inactive GCs to active GCs, the 
enzyme 11β-HSD1 also interconverts 7-oxysterols in some animal models, catalysing 
the reduction of 7-KC to 7β-HC (Schweizer et al., 2004; Hult et al., 2004; see 1.3). 
As these 7-oxysterol substrates competitively inhibit GC metabolism, they could be 




important regulators of intracellular GC levels in tissues where they accumulate to 
substantial levels such as liver, adipose tissue and brain (Wamil et al., 2008; 
Chapman et al., 2013).  
 
Interestingly, 7-KC inhibits cleavage of SREBP-2, whereas 7β-HC does not (Brown 
et al., 2002). In liver microsomes of mice transgenically overexpressing hepatic 11β-
HSD1 (LOE mice), there are significantly reduced levels of 7-KC compared to those 
found in control mice (Dr. T. Mitic, unpublished data, shown in Chapter 3 of this 
thesis). Moreover, preliminary data point out to LOE liver microsomes having 
increased levels of cleaved SREBP-2 protein compared to control mice, suggesting 
increased de novo cholesterol synthesis (Dr. T. Mitic and K. Manwani, unpublished 
data; see 3.1). These findings, along with the evidence for altered cholesterol handling 
in HF-fed LOE mice (Paterson et al., 2004), form the basis for the following 
hypothesis. 
	  
1.9.	  Hypothesis	  and	  Aims	  
 
Hypothesis: Hepatic 11β-HSD1 converts 7-KC to 7β-HC, removing an endogenous 
brake on cholesterol synthesis. Thus, hepatic 11β-HSD1 promotes de novo cholesterol 
biosynthesis. This hypothesis predicts that hepatic 11β-HSD1 plays a role in 
cholesterol homeostasis: elevated 11β-HSD1 levels in liver are predicted to increase 
cholesterol synthesis whereas liver-specific 11β-HSD1 deficiency is predicted to 
decrease cholesterol biosynthesis.  
 
In order to test this hypothesis, the following aims were set: 
 
1. To examine the in vivo effects of liver 11β-HSD1 overexpression on cholesterol 
biosynthetic and excretion pathways. 
 
2. To study the in vivo effects of 11β-HSD1 on cholesterol synthesis and clearance 
pathways when substrate for lipid/cholesterol is increased.  
 




3. To examine the in vivo effects of liver-specific 11β-HSD1 deficiency on 
















































Unless stated otherwise, all chemicals were purchased from Sigma-Aldrich, U.K. 
2.1.1.	  General	  Chemicals	  
Table	  2.	  1	  General	  chemicals	  
Anti-SREBP2 Antibody, rabbit polyclonal 
(ab112046) 
Abcam 
Agilent 600 RNA Nano Kit Agilent Technologies 
3H-corticosterone Amersham Pharmacia Biotech 
Dc Protein Assay 
Blotting-grade Blocker Non-fat Dry Milk 
Bio-Rad Laboratories Ltd. 
GelRed Nucleic Acid Gel Stain Biotium, Inc. 
Rainbow™ Full-Range Molecular Weight Marker GE Healthcare 
SuperScript® III Reverse Transcriptase  
1kB DNA Ladder 
TRIzol® Reagent 
Alexa Fluor® 700 Goat Anti-rabbit IgG 
Alexa Fluor® 800 Donkey Anti-sheep IgG 
NuPAGE® LDS Sample Buffer 
NuPAGE® Sample Reducing Agent 
NuPAGE® Transfer Buffer 
NuPAGE® MES SDS Running Buffer 
NuPAGE® Antioxidant 
Novex® 4-12% Bis-Tris Gels 
Invitrogen 
IRDye® Goat Anti-rabbit 800CW IgG 
IRDye® Goat Anti-mouse 800CW IgG 
IRDye® Goat Anti-mouse 680 IgG 
LI-COR Biosciences 
SeaKem™ LE Agarose Lonza 
Anti-β-tubulin Antibody, mouse monoclonal Millipore 




GoTaq® DNA Polymerase 
1kb DNA Ladder 
Promega 
RNeasy® Mini Kit 
DNeasy® Blood&Tissue Kit 
Qiagen 
LightCycler® 480 Probes Master 
Universal ProbeLibrary Probes 
cOmplete Protease Inhibitor Cocktail 
Roche Applied Science 
Cryo-M-Bed Embedding Medium TAAB Laboratories 
Equipment 
PermaFluor™ Aqueous Mounting Medium Thermo Scientific 




2.1.2.	  Miscellaneous	  Equipment	  
 
Table	  2.	  2	  Miscellaneous	  equipment	  
Agilent 2100 Bioanalyzer  Agilent Technologies 
Ultracentrifuge J2-MC Beckman Coulter 
Power Pack 200 Agarose Gel System  Bio-Rad 
pH Meter BASIC 
AA-160 Balance 
Denver Instrument 
Eppendorf 5415 R Centrifuge 
Eppendorf 5810 R Centrifuge 
Eppendorf 
Surgical instruments Fine Science Tools Inc. 
Rotamixer Vortex Hook&Tucker Instruments 
T10 Ultra-Turrax® Basic Homogeniser IKA 
XCell SureLock™ Mini-Cell Electrophoresis 
System 
Invitrogen 
3510 pH Meter Jenway 
Leica CM1900 Cryostat Leica 
Odyssey® Infrared Imaging System LI-COR Biosciences 
Rainin EDP3-Plus Electronic Multichannel Pipettes  Mettler Toledo 
Milli-Q® Integral Water Purification System 
Synringe 0.2µm filters 
Millipore 
OPTImax Tunable Microplate Reader Molecular Devices 
NanoDrop ND-1000 Spectrophotometer NanoDrop Technologies 
LightCycler® 480 384-well qPCR Plates and 
Plastic Covers 
Roche Applied Science 
0.2ml Strip-tubes with lids StarLab 
Stuart® Heat-stir CB 162 Platform 
Stuart® Gyro-rocker SSL3 Platform 
Stuart® SB2 Rotator 
Stuart Equipment 
Disposable scalpels Swann-Morton 
Ori-Block DB-3 Heating Block 
HB-1D Oven Hybridiser 
Thermal Cycler TC-412 
Thermal Cycler TC-512 
Techne 
Savant DNA110 SpeedVac® Concentrator 
HistoStar Embedding Workstation 
Nunclon™ Surface 96-well Plates 
Tissue Flotation Bath 
Sterilin® 90mm Petri Dishes 
Thermo Scientific 
UviPro System UviTec 
Vacuum Gas Pump 
SuperFrost® Plus Microscopic Slides 
Cover Glass Rectangular 22x50mm Thickness 
No.1  
VWR International Ltd. 
Whatman® paper No.1 Whatman 
Zeiss Axioscop microscope Zeiss 
	  






Table	  2.	  3	  Analysis	  software	  
Means of acquisition Software 
Agilent 2100 Bioanalyzer 2100 Expert Software (Agilent 
Technologies) 
LightCycler® 480  LightCycler® 480 release 1.5 O SP3 (Roche) 
NanoDrop ND-1000 spectrometer ND-1000 v3.3.0 (NanoDrop Technologies) 
Odyssey® Infrared Imager Odyssey v3.0 (LI-COR Biosciences) 
OPTImax Tunable Microplate Reader SoftMax Pro 4.8 (Molecular Devices) 
Statistical analysis and Image 
processing 
GraphPad Prism 5 (GraphPad) 
UviPro System UviPro 12.4 (UviTec) 
Zeiss Axioscop microscope KSM 300 3.0 (Zeiss) 
2.1.4.	  Solutions	  and	  Buffers	  
	  
All solutions were prepared with Milli-Q® water unless stated otherwise. All buffers 
were stored at 4°C. 
 
Blocking buffer: 5% w/v Blotting-grade non-fat dry milk in TBST 
 
‘C’ buffer: Dissolve 63g glycerol, 8.77g NaCl, 186mg ethylenediaminetetraacetic 
acid (EDTA) and 3.03g Tris in 500ml water; pH 7.7 
 
Coomassie stain: 45% v/v methanol, 10% v/v acetic acid, 0.25% w/v Coomassie blue 
dye 
 
Coomassie destain solution: 45% v/v methanol, 10% v/v acetic acid 
 
DEPC-water: 0.1ml of diethylpyrocarbonate (DEPC) per 100ml, mix well, leave for 
1-25h, autoclave 
 
DNA ladder: 25% v/v 1kb DNA ladder (Promega), 25% v/v TE buffer, 50% v/v 
Orange G loading dye 
 
DNA/RNA loading buffer: 0.3% w/v Orange G, 40% v/v glycerol 




Homogenisation buffer: Dissolve 100g glycerol, 300mg Tris and 186mg EDTA in 
500ml water; pH 7.5  
 
Lysis buffer: 25mM HEPES, 68.5mM NaCl, 0.5mM MgCl2, 0.5mM CaCl2, 5mM 
NaF, 1mM EDTA, 5mM sodium pyrophosphate, 1% NP-40, 10% glycerol, 1X 
protease inhibitor cocktail (PIC; see below) 
 
MOPS (10X): 0.4M 3-(N-morpholino)propanesulfonic acid (MOPS), 0.1M sodium 
acetate, 10mM EDTA; pH 7.0 
 
NADP: 1.1mg nicotinamide adenine dinucleotide sodium salt in 1684µl ‘C’ buffer 
(final concentration of 2mM) 
 
Paraformaldehyde (4%): Bring water/PBS to 80°C, add 4% w/v paraformaldehyde 
and stir at 80°C until dissolved 
 
PIC (Protease Inhibitor Cocktail, 25X): Dissolve a table of complete protease 
inhibitor cocktail (Roche Applied Science) in 2ml respective solution 
 
Running buffer (SDS-PAGE): 1X NuPAGE® MES SDS Running buffer 
(Invitrogen), 0.05% v/v NuPAGE® Antioxidant (Invitrogen) 
 
TBE (10X): 1.1M Tris, 0.9M boric acid, 12.5mM EDTA 
 
TBS (10X): 0.2M Tris, 1.37M NaCl; pH 7.6 
 
TBST: 0.1% v/v Tween-20 in 1X TBS 
 
TE: 10mM Tris pH 8.0, 1mM EDTA 
 
Transfer buffer: 1X NuPAGE® Transfer buffer (Invitrogen), 20% v/v methanol, 
0.1% NuPAGE® Antioxidant (Invitrogen) 






All animal experiments were carried out according to the accepted standards of 
humane animal care under the auspices of the United Kingdom Animals (Scientific 
Procedures) Act 1986, after prior approval by the University of Edinburgh Animal 
Ethical Review Committee. All experimental procedures were performed under a UK 
Home Office Project Licence (Seckl, 60/3962) and personal licence (Manwani, 
60/12840). 
 
All mice were bred and maintained in the Biomedical Research Facility, Little France, 
Edinburgh, U.K., unless stated otherwise. Mice were kept in groups of 1-8 per cage 
under controlled conditions (12h light/dark cycle; 21°C), with ad libitum access to 
water and standard rodent chow diet (Special Diet Services, U.K.), except in the case 
of diet experiments (section 2.2.3).  
 
For the experiments conducted during preparation of this thesis the following strains 
of mice were used:  
 
v C57BL/6 mice (in-house stock) 
v “Floxed” Hsd11b1 mice: Hsd11b1flox/flox mice (generated by a commercial 
supplier, TaconicArtemis; see Appendix for further details; in-house stock) 
v Mice transgenically overexpressing 11β-HSD1 in the liver: LOE mice 
(Paterson et al., 2004; in-house) 
v 11β-HSD1 deficient mice (“old knockout”): HSD1 KO (Kotelevtsev et al., 
1997; Morton et al., 2004; in-house) 
v Newer global 11β-HSD1 knockout mice: Del (generated in-house by crossing 
Hsd11b1flox/flox mice with Hprt-Cre mice; unpublished) 
v C57BL/6-Tg(Alb-cre) transgenic mice, stock number: 003574 (Postic et al., 
1999; ordered from The Jackson Laboratory, U.S.A.) 
v Liver-specific 11β-HSD1 knockout mice: LKO (generated as part of this 
study; see 2.2.1, and Chapter 5) 
 
	  





2.2.1.	  Generation	  of	  LKO	  mice	  	  
	  
In order to generate liver-specific 11β-HSD1 knockout (LKO) mice, the Cre-lox 
system was used. C57BL/6-Tg(Alb-cre) transgenic mice (one male, and one female) 
were ordered from The Jackson Laboratory, U.S.A. (JAX Mice Database- 003574 
B6.Cg-Tg(Alb-cre)21Mgn/J; http://jaxmice.jax.org/strain/003574.html). These Alb-
cre mice were made by injecting a transgene containing a 2.34 kb mouse albumin 
enhancer/promoter, nuclear localisation sequence-modified Cre recombinase, and a 
2.1 kb fragment from the human growth hormone, into the pronuclei of B6D2(F2) 
mice, with subsequent backcrossing to C57BL/6 mice (Postic et al., 1999).  
 
Alb-cre mice were bred to Hsd11b1flox/flox mice. The Hsd11b1flox/flox mice have exon 3 
of the Hsd11b1 gene flanked by loxP sites, allowing Cre-driven recombination 
(Figure 2.1A). The resulting F1 progeny were bred to Hsd11b1flox/flox to generate a line 
of liver-specific 11β-HSD1 knockout mice, LKO (Figure 2.1B). Offspring were 
genotyped by polymerase chain reaction (PCR) analysis of ear notch or tail DNA (see 
2.2.2 for genotyping protocol and reactions); Cre genotyping identified presence (or 
absence) of the Cre transgene (Figure 2.2A) and “Flox” genotyping was carried out to 



















































Figure	   2.1:	   A	   schematic	   representation	   of	   Cre-­‐mediated	   recombination	   at	   the	  
Hsd11b1	   allele,	   and	   a	   scheme	   showing	   the	   generation	  of	  mice	  with	   liver-­‐specific	  
knockout	  of	  Hsd11b1	  (LKO	  mice).	  
(A) Cre-mediated recombination leads to deletion of the “floxed” exon 3 of the 
Hsd11b1 allele. (B) Two rounds of breeding were required to produce mice with 
liver-specific knockout of Hsd11b1 (~3 months/breeding round). All mice were bred 
and maintained in the Biomedical Research Facility, Little France, Edinburgh, U.K. 
A 
B 





































Figure	   2.2:	   Representative	   gel	   images	   showing	   genotyping	   of	   offspring	   from	   the	  
cross	  between	  Alb-­‐Cre	  and	  Hsd11b1flox/flox	  mice.	  
(A) Genotyping for Cre transgene (465bp) showed that mice 2, 5, 6 and 7 are positive 
for Cre. ‘+’ indicates a positive control, ‘WT’ wild-type control (negative for Cre) and 
‘-’ indicates H2O control. ‘L’ indicates 1kb DNA ladder. (B) Genotyping for the 
‘floxed’ allele of Hsd11b1 (385 bp for floxed Hsd11b1, 255 bp for wild-type allele) 
showed that mice 1, 2 and 3 were homozygous (flox/flox) for the ‘floxed’ allele. ‘+’ 
indicates samples from heterozygous mice (flox/+), ‘WT’: wild-type control. Taken 
together, data from (A) and (B) show that mouse 2 (Hsd11b1flox/flox:Cre) is a liver-











2.2.2.	  Genotyping	  	  
	  
Animals were genotyped by PCR using DNA obtained from their frozen tissues.	  
 
2.2.2.1.	  Tissue	  DNA	  Extraction	  using	  Spin-­‐Column	  Protocol	  
 
DNA was extracted from a frozen piece of tissue (tail or ear clips from weaned 
animals) using a DNeasy® Tissue&Blood kit (Qiagen, UK). Tissue was incubated 
with 180µl of AL buffer (Qiagen, supplied with the kit) supplemented with 20µl of 
proteinase K solution (supplied with the kit) at 56°C, with rotation, until completely 
lysed (usually ~4 h). Tubes were then vortexed and a further 200µl of AL buffer was 
added, followed by 200µl of 96% ethanol. Contents were thoroughly mixed and 
transferred to a spin column placed in a 2ml collection tube. Tubes were centrifuged 
at 8000g, room temperature for 1 min. The column was then placed into a new 2ml 
collection tube, and 500µl of AW1 buffer (Qiagen, supplied with the kit) was added, 
followed by centrifugation as above. The column was again placed into a new 2ml 
collection tube and 500µl of AW2 buffer (Qiagen, supplied with the kit) was added, 
followed by centrifugation at 12,000g, room temperature for 3 min. The column was 
then placed into a 1.5ml tube and 100µl of AE buffer (Qiagen, supplied with the kit) 
was added. Samples were incubated at room temperature for 1 min, and then 
centrifuged at 8000g for 1 min to elute the DNA. DNA was processed immediately or 
stored at -20°C.  
 
2.2.2.2.	  PCR	  analysis	  of	  Transgene	  Expression	  
 
PCR reactions for each DNA sample were carried out using a Qiagen Taq kit. 1.5µl 
DNA was added to 2.5µl MgCl2-free buffer (supplied with the kit), 2.25µl MgCl2 
(supplied with the kit), 1µl dNTP mix (10mM), 1µl forward primer (10pmol/µl), 1µl 
reverse primer (10pmol/µl), 0.2µl Taq DNA polymerase (Qiagen, UK), and 15.55µl 
nuclease-free water. Specific primer sequences, PCR conditions, and expected 
product lengths are listed in Table 2.4. In each case, the final step comprised a final 
extension at 72°C for 10 min followed by 4°C hold. PCR products were detected by 
agarose gel electrophoresis as described in (2.2.9). 


























 Cre Flox 
Primers	   	   	  
Forward	  (5’-­‐3’)	   gaccgtacaccaaaatttgcctg	   cttgcatgtgtttggtgttgg	  
Reverse	  (5’-­‐3’)	   ttacgtatatcctggcagcgatc	   cccacaatgcatttggaaacatt	  
PCR	   	   	  
Denature	   94°C,	  10	  minutes	   96°C,	  10	  minutes	  
No.	  of	  cycles	   32	   35	  
Step1	   94°C,	  1	  minute	   95°C,	  30	  seconds	  
Step2	   64°C,	  1	  minute	  	   60°C,	  30	  seconds	  
Step3	   72°C,	  1	  minute	   72°C,	  1	  minute	  
Product	   	   	  
Size	   465bp	   WT:	  255bp	  
	   	   Flox:	  385bp	  




2.2.3.	  Dietary	  Experiments	  	  
 
Young adult (5-6 week old) male mice (n = 6-8/group) were fed one of the following 
diets; chow diet (Special Diet Services, U.K.), 58% high fat (D12331; Research Diets 
Inc., U.S.A.) or western diet (0.21% cholesterol and 41% fat; D12079B; Research 
Diets Inc., U.S.A.), for 12 weeks. Diet constituents are shown in Tables 2.5 (chow), 
2.6 (high fat) and 2.7 (western). Body weight was measured weekly, and, at the end of 
the experiment, mice were killed by cervical dislocation. Blood was collected in 
EDTA tubes for plasma collection. The following tissues were harvested at sacrifice, 
snap frozen on dry ice and weighed. Whole livers were dissected out from the 
animals, collected in pre-labelled small plastic bags and placed on dry ice. Left sided 
subcutaneous (SC) and epididymal (Epi) adipose pads, as well as entire mesenteric 
(Mes) fat depots, were removed from the animals and wrapped in pre-labelled 
aluminium foil, then snap frozen on dry ice. Left adrenals were removed from the 
mice and immediately placed into 10% formalin. Twenty-four hours post fixation, 
adrenals were cleaned of any attached fat by manual dissection, and then weighed on 
a microbalance. RNA was extracted from liver as described in (2.2.7). Due to an 
ongoing pinworm infection treatment in the Little France Biomedical Research 
Facility, Edinburgh, this experiment was carried out in the Hugh Robson Building 
Animal Unit, Edinburgh, U.K. This dietary experiment is described in Chapter 4 of 
this thesis. 
 
A second dietary experiment is described in chapter 6 of this thesis. Male, adult (8 
week old) LKO, littermate Hsd11b1flox/flox control, Del, and HSD1 KO mice (n = 7-
10/group) were fed high fat diet (D12331; Research Diets Inc., U.S.A.) for 14 weeks. 
Body weight was measured weekly and glucose tolerance test (GTT) carried out at 
week 13 of the diet (see 2.2.4). Mice were culled by cervical dislocation and blood 
was collected in EDTA tubes for plasma collection. Liver, white adipose tissue depots 
(left SC, left Epi, whole Mes), left quadriceps muscle, and left adrenal glands were 
harvested as described above. Liver, white adipose tissue depots and muscle were 
quickly weighed before being snap frozen on dry ice, whereas adrenals were fixed in 
10% formalin for 24 h before being weighed as described above. Right sided SC fat 
depots were also collected in 10% formalin for picrosirius red staining (see 2.2.15). 
RNA was extracted from liver as described in (2.2.7).  




Table	  2.	  5	  Chow	  diet	  constituents	  	  
Chow	  Diet	  (Product	  code	  801722,	  Special	  Diets	  Services)	   kcal%	  
Protein	   22.0	  
Carbohydrate	   68.9	  
Fat	   9.1	  
Ingredients	   (%)	  
Crude	  Oil	   3.05	  
Crude	  Protein	   16.44	  
Total	  Dietary	  Fibre	   15.06	  
Pectin	   1.40	  
Hemicellulose	   8.85	  
Cellulose	   3.89	  
Lignin	   1.40	  
Starch	   42.37	  
Sugar	   3.90	  
Saturated	  Fatty	  Acids	   (%)	  
C12:0	  Lauric	   0.03	  
C14:0	  Myristic	   0.14	  
C16:0	  Palmitic	  	   0.33	  
C18:0	  Stearic	  	   0.06	  
Monounsaturated	  Fatty	  Acids	   (%)	  
C14:1	  Myristoleic	  	   0.02	  
C16:1	  Palmitoleic	  	   0.10	  
C18:1	  Oleic	  	   0.87	  
Polyunsaturated	  Fatty	  Acids	   (%)	  
C18:2(ω6)	  Linoleic	  	   0.96	  
C18:3(ω3)	  Linolenic	  	   0.11	  
C20:4(ω6)	  Arachidonic	  	   0.11	  
Amino	  Acids	   (%)	  
Arginine	  	   1.19	  
Lysine	  	   1.04	  
Methionine	  	   0.28	  
Cystine	   0.29	  
Tryptophan	   0.22	  
Histidine	   0.46	  
Threonine	   0.69	  
Isoleucine	   0.77	  
Leucine	  	   1.46	  
Phenylalanine	  	   0.96	  
Valine	   0.91	  
Tyrosine	   0.69	  
Glycine	   1.55	  




Aspartic	  Acid	  	   1.00	  
Glutamic	  Acid	   3.72	  
Proline	   1.34	  
Serine	   0.78	  
Alanine	   0.21	  
Macro	  Minerals	   (%)	  
Calcium	   0.83	  
Total	  Phosphorus	  	   0.64	  
Phytate	  Phosphorus	  	   0.23	  
Available	  Phosphorus	   0.41	  
Sodium	   0.27	  
Chloride	  	   0.40	  
Potassium	   0.69	  
Magnesium	   0.22	  
Micro	  Minerals	  	   	  
Iron	   130.65	  mg/kg	  
Copper	   16.42	  mg/kg	  
Manganese	   91.05	  mg/kg	  
Zinc	   86.59	  mg/kg	  
Cobalt	   494.92	  µg/kg	  
Iodine	   390.43	  µg/kg	  
Selenium	   265.49	  µg/kg	  
Fluorine	  	   9.63	  mg/kg	  
Vitamins	  	   	  
β-­‐Carotene	   1.28	  mg/kg	  
Retinol	   5218.35	  µg/kg	  
Vitamin	  A	   17376.38	  iu/kg	  
Cholecalciferol	  	   76.94	  µg/kg	  
Vitamin	  D	   3077.42	  iu/kg	  
α-­‐Tocopherol	   93.03	  mg/kg	  
Vitamin	  E	   102.81	  iu/kg	  
Vitamin	  B1	  (Thiamine)	  	   15.84	  mg/kg	  
Vitamin	  B2	  (Riboflavin)	   13.28	  mg/kg	  
Vitamin	  B6	  (Pyridoxine)	   17.65	  mg/kg	  
Vitamin	  B12	  (Cyanocobalamine)	  	   78.17	  µg/kg	  
Vitamin	  C	  (Ascorbic	  Acid)	   1.80	  mg/kg	  
Vitamin	  K	   185.05	  mg/kg	  
Folic	  Acid	  (Vitamin	  B9)	   4.30	  mg/kg	  
Nicotinic	  Acid	  (Vitamin	  PP)	   78.92	  mg/kg	  
Pantothenic	  Acid	  (Vitamin	  B3/5)	   25.24	  mg/kg	  
Choline	  (Vitamin	  B4/7)	   899.51	  mg/kg	  
Inositol	   2253.88	  mg/kg	  
Biotin	  (Vitamin	  H)	   488.74	  µg/kg	  
[Table adapted from manufacturer’s diet sheet] 




Table	  2.	  6	  High	  fat	  diet	  constituents	  	  
High	  Fat	  Diet	  (Product	  #D12331,	  Research	  Diets	  Inc.)	   gm%	   kcal%	  
Protein	   23.0	   16.4	  
Carbohydrate	   35.5	   25.5	  
Fat	   35.8	   58	  
Ingredients	   gm	   kcal	  
Caesin,	  30	  Mesh	   228	   912	  
DL-­‐Methionine	   2	   0	  
Maltodextrin	  10	   170	   680	  
Corn	  Starch	   0	   0	  
Sucrose	   175	   700	  
Soybean	  Oil	   25	   225	  
Coconut	  Oil,	  Hydrogenated	   333.5	   3001.5	  
Mineral	  Mix	  S10001	   40	   0	  
Sodium	  Bicarbonate	   10.5	   0	  
Potassium	  Citrate,	  1	  H2O	   4	   0	  
Vitamin	  Mix	  V10001	   10	   40	  
Choline	  Bitartrate	   2	   0	  
FD&C	  Red	  Dye	  #4	   0.1	   0	  
Total	   1000.1	   5558.5	  



















Table	  2.	  7	  Western	  diet	  constituents	  	  
Western	  Diet	  (Product	  #D12079B,	  Research	  Diets	  Inc.)	   gm%	   kcal%	  
Protein	   20	   17	  
Carbohydrate	   50	   43	  
Fat	   21	   41	  
Ingredients	   gm	   kcal	  
Caesin,	  80	  Mesh	   195	   780	  
DL-­‐Methionine	   3	   12	  
Corn	  Starch	   50	   200	  
Maltodextrin	  10	   100	   400	  
Sucrose	   341	   1364	  
Cellulose	   50	   0	  
Milk	  Fat,	  Anhydrous*	   200	   1800	  
Corn	  Oil	   10	   90	  
Mineral	  Mix	  S10001	   35	   0	  
Calcium	  Carbonate	   4	   0	  
Vitamin	  Mix	  V10001	   10	   40	  
Choline	  Bitartrate	   2	   0	  
Cholesterol,	  USP*	   1.5	   0	  
Ethoxyquin	   0.04	   0	  
Total	   1001.54	   4686	  
 
* Anhydrous milk fat typically contains approximately 0.3% cholesterol. On this 
basis, D12079B contains approximately 0.21% cholesterol.  
 
















2.2.4.	  Glucose	  Tolerance	  Test	  (GTT)	  
	  
Mice were housed individually for several days before carrying out GTT, so that they 
could acclimatise to single-housing. Mice were fasted for 6 h, and then blood was 
taken for plasma glucose assay. Initially, 10µl blood was taken from a tail nick, into 
EDTA-coated microtubes (Sarstedt, U.K.). Mice were then injected intraperitoneally 
with 2mg glucose/g body weight. Further blood samples (10µl/sample) were taken at 
15 min, 30 min, 60 min, and 120 min after the injection. Blood was centrifuged at 
2500g, 4°C for 10 min, plasma extracted and stored at -80°C for later analysis.  
 
2.2.5.	  Plasma	  Glucose	  Measurement	  
	  
Plasma glucose levels were quantified using an Infinity Glucose Hexokinase Liquid 
Stable Reagent (Thermo Electron, U.S.A.). A series of glucose standards ranging 
from 0-400mg/dL was used to produce a standard curve. In a 96-well plate, 2µl of 
standard or sample plasma were mixed with 250µl of glucose hexokinase reagent and 
incubated at room temperature, in the dark, for 3 min. The reagent causes the glucose 
within the sample to be phosphorylated, generating NADH. The absorbance of 
NADH within the plate was then measured at 340nm using a plate-reader 
spectrophotometer (Molecular Devices, OPTImax). The glucose concentration within 
the plasma samples was determined with reference to the standard curve. 
 
For the dietary experiment described in Chapter 6, blood glucose levels were also 
measured using a handheld glucometer (OneTouch Ultra, LifeScan, U.S.A.) on a drop 
of tail-vein blood, according to the manufacturer’s protocol. 
 
2.2.6.	  Plasma	  Insulin	  Measurement	  
	  
Plasma insulin levels were measured using a Ultra Sensitive Mouse Insulin ELISA 
Kit (Crystal Chem, U.S.A.). An insulin standard curve (0, 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 
6.4, 12.8, 25.6 ng/ml) was made using the mouse insulin stock solution supplied with 
the kit. In a 96-well plate, 5µl of standards or sample plasma were mixed with 95µl of 
sample diluent buffer (supplied with the kit) and incubated at 4°C for 2 h. The 




solution was aspirated and the wells washed 5 times with washing buffer (supplied 
with the kit; 300µl per well). Into each well, 100µl of anti-insulin enzyme conjugate 
solution (supplied with the kit) was then added. After incubation for 30 min at room 
temperature, the wells were washed 7 times as described above. Then, 100µl enzyme 
substrate solution (supplied with the kit) was added into each well, and after 40 min 
incubation at room temperature, without exposure to light, the reaction was stopped 
by adding 100µl of stop solution (supplied with the kit) to each well. The plate was 
read within 30 min, using a plate-reader spectrophotometer (Molecular Devices, 
OPTImax), at two wavelengths- 450nm and 630nm. The reading subtraction results 
(A450-A630) were compared to the standard curve to calculate the sample 
concentrations. 
 
2.2.7.	  RNA	  Extraction	  from	  Tissue	  
 
Total RNA was extracted from liver tissue using TRIzol® reagent (Invitrogen, U.K.). 
Prior to RNA extraction, in order to protect RNA samples from RNase contamination, 
all the apparatus used was autoclaved and all solutions prepared with DEPC-
treated/RNase-free water.  
 
Snap-frozen liver samples were weighed and ∼50mg homogenized in 1000µl of 
TRIzol® reagent. The homogenate was either used immediately or frozen at -80°C 
for later extraction. To extract RNA, 200µl of chloroform was added to each sample, 
which was then vigorously shaken for 15-30 s. The samples were then incubated at 
room temperature for 2-3 min, after which they were centrifuged at 12,000g, 4°C for 
15 min. The upper (aqueous) phase was transferred to a fresh tube, mixed with 500µl 
isopropanol, and allowed to sit at room temperature for 10 min. Samples were then 
centrifuged at 12,000g, 4°C for 10 min. After this centrifugation step, the supernatant 
was discarded, and the pellet washed with cold 50-75% ethanol, vortexed for 15 s and 
centrifuged at 7500g, 4°C for 10 min. Once again, the supernatant was discarded. The 
RNA pellet was allowed to air dry before finally resuspending in 30-50µl RNase-free 
water. RNA was processed immediately or stored at -80°C. 




2.2.8.	  RNA	  Quantification	  and	  Quality	  Control	  	  
 
RNA concentration was measured using a NanoDrop spectrophotometer at a 
wavelength of 260nm. RNA eluate (1.2µl) was placed on the NanoDrop platform, and 
the values for RNA concentration, 260/280nm and 230/260nm ratios were recorded.  
RNA integrity was routinely analysed by gel electrophoresis in 1% agarose either in 
0.5x TBE or under denaturing conditions (see 2.2.9). The quality of RNA was 
assessed by the presence of two distinct bands, corresponding to 28S and 18S rRNA 
at the approximate intensity ratio of 2:1, with no additional smears or high-molecular 
weight genomic DNA contamination (Figure 2.3).  
 
Additionally, some RNA samples were analysed using an Agilent 2100 Bioanalyzer. 
Gel-dye solution was prepared by mixing 65µl of gel matrix (supplied with the kit) 
with 1µl of dye (supplied with the kit) and centrifuged at 13,000g, room temperature, 
for 10 min. The chip was placed into the priming station and 9µl of the gel-dye mix 
was placed in the well marked “G”. The chip priming station was closed, plunger 
positioned at 0.7ml and pressed. After 5 min, the plunger was pulled back and 5µl of 
the sample marker was placed in each well of the chip. Ladder and RNA samples 
(1µl) were then loaded onto the chip, vortexed and placed in the analyser. Good 
quality total RNA was characterised by two distinct 18S and 28S peaks, and an RNA 
Integrity Number (RIN; incorporating the entire electrophoretic trace analysis) higher 








Figure	  2.3:	  Representative	  RNA	  agarose	  gel	  image.	  











2.2.9.	  Agarose	  Gel	  Electrophoresis	  
	  
Agarose gels were prepared with, and electrophoresed in, 0.5x TBE buffer. For 
genotyping PCR products, a 1.5% agarose gel was used, and for primer specificity 
testing, a 3.5% agarose gel was used.  
 
Agarose was melted in the TBE buffer using a microwave. GelRed Nucleic Acid 
Stain (0.005% final concentration) was added to molten agarose before pouring into a 
gel tray. Samples (excluding PCR samples already containing loading concentrate) 
were mixed with Orange G loading dye (2:10) and loaded onto the gel. A DNA ladder 
was loaded into one lane. 
 
Denaturing gels (1.2% agarose) were prepared in MOPS buffer with 0.8% 
formaldehyde. RNA samples were mixed with 400U/ml RNasin® Plus RNase 
inhibitor, 10mM DTT and DEPC-treated water in a final volume of 10µl. 2.5µl of 
37% formaldehyde, 2.5µl of 10x MOPS and 10µl of deionised formamide were 
added. Samples were then heated at 65°C for 15 min, quickly chilled and mixed with 
Orange G loading buffer before electrophoresis on a denaturing gel in 1x MOPS 
buffer. 
 
Gels were electrophoresed at ~80-130V and visualised under UV light (λ=260nm) on 
a transilluminator.  
 
2.2.10.	  Quantitative	  PCR	  
2.2.10.1.	  cDNA	  Synthesis	  
	  
Reverse transcription of RNA was carried out using the SuperScript® III reverse 
transcriptase system (Invitrogen, UK). Each 20µl reaction used 1µg of total RNA. In 
order to remove all traces of genomic DNA contamination prior to first-strand cDNA 
synthesis, 1µg of all RNA samples were initially treated with DNase I (Invitrogen, 
UK) according to the manufacturer’s protocol. RNA was then denatured for 5 min at 
65°C with 25ng random primers and dNTPs at 0.5mM final concentration. Tubes 
were immediately placed on ice for 1 min, then briefly centrifuged to collect the 




contents. To each sample, 4µl of 5x First Strand buffer, 1µl 0.1mM DTT, 1µl 
SuperScript® reverse transcriptase and 1µl RNasin® Plus RNase inhibitor were 
added. Reactions were incubated at 25°C for 5 min, followed by 50°C for 60 min and 
70°C for 15 min. Control reactions with no enzyme or no RNA were included to 
detect contamination of reagents. cDNA was stored at -20°C for further analysis. 
	  
2.2.10.2.	  Quantitative	  (q,	  real-­‐time)	  PCR 
 
Quantitative PCR (qPCR) was used to measure mRNA levels in tissues. Reactions 
were carried out in a LightCycler® 480 thermocycler (Roche Diagnostics Ltd., UK) 
using 480 Probes Master Mix and fluorescent probes from the Universal Probe 
Library (UPL; Roche Diagnostics Ltd., UK). Primer sets were designed with 
ProbeFinder software within the UPL system, so as to span exon-exon junctions in the 
target mRNA to prevent amplification of the target from any contaminating genomic 
DNA. Each custom primer set was tested for the presence of one product of expected 
size by gel electrophoresis (see 2.2.9). Details of each assay can be found in Table 
2.8. 
 
A standard curve was prepared by serially diluting a mix of equal volumes of all 
cDNA samples (standard curve range was from 1 to 1:256 for all gene expression 
assays). cDNA samples were diluted in sterile water prior to assay (1:20 for liver and 
1:10 for adipose tissue). The reaction mix was prepared as follows: 5µl LightCycler 
480 Probes Master Mix, 0.1µl probe (final concentration 1pmol), 0.1µl of each primer 
(final concentration 0.2pmol), 2.7µl sterile water per sample. Reaction mix was added 
to a 384-well plate, followed by 2µl of cDNA sample/standards. Each sample was 
analysed in triplicate. Plates were sealed and centrifuged (2000g, room temperature, 2 
min) to ensure all solutions were in the wells. The relative amplification levels for 
each sample were measured. Reaction conditions were as follows: 95oC for 5 min; 50 
cycles of 95oC for 10 s, 60oC for 30 s, 72oC for 1 s; cooling 40oC for 30 s.  
 
Data were analysed using the 2nd derivative maximum method, where a fractional 
cycle (Cp) is determined from the amplification curve’s second derivative max 
indicating the cycle at which exponential amplification can no longer be sustained and  




Table	  2.	  8	  List	  of	  qPCR	  primer	  sequences	  and	  probe	  numbers	  
Gene	  of	  

































































































































starts to decline towards linear growth. The efficiency of each assay was ~2. The 
standard curve was used as a reference for extrapolating quantitative information for 
mRNA targets of unknown concentrations. 
	  
2.2.10.2.1.	  Validation	  of	  internal	  controls	  
 
Gene expression levels were determined by normalising mRNA levels of the gene of 
interest to the levels of an internal standard mRNA. In preliminary experiments, based 
on the availability within the lab, Actb, Hprt and Tbp were tested to confirm their 
relevance as internal standards (housekeeping genes). These candidate internal 
controls had similar Cp values and cycle-amplification profile between experimental 
groups; their mRNA levels did not change with genotype or dietary manipulation 
(Figure 2.4) thereby validating their use as internal controls. The specific internal 
control(s) used in each experiment can be found in Chapters 3-6.  
	  
2.2.11.	  Protein	  Extraction	  and	  Analysis	  
2.2.11.1.	  Protein	  Extraction	  from	  tissues	  
	  
Total protein was extracted from frozen tissue; 50-100mg of frozen tissue samples 
were homogenised in 500µl lysis buffer and incubated for 1 h, 4°C with rotation 
before centrifugation at 12,000g, 4°C for 5 min. The supernatant was then transferred 
into a fresh tube and processed immediately or stored at -20°C.  
 
2.2.11.2.	  Protein	  Quantification	  
 
Protein concentration of lysates was determined using the Bio-Rad DC protein assay 
(Bio-Rad). This is a colourimetric assay for protein determination. Sample 
concentrations were determined from a standard curve created from a series of 
dilutions of bovine serum albumin (BSA), ranging from 0-1.2mg/ml. To ensure all 
samples lay within the standard curve, a test assay was carried out using the most 
diluted sample within the set. This sample was compared with the highest protein 
standard (1.2mg/ml) using the Bio-Rad protein assay. Dilution was required if the  






























Figure	  2.4:	  Validation	  of	  internal	  controls	  
Representative experiments demonstrating lack of differences in hepatic Tbp mRNA 














































































sample shared a similar or greater colour to the highest standard. All samples were 
diluted according to the test assay and measured in duplicate in a 96-well plate. To 
each well, 5µl of diluted sample or standard was added followed by 25µl of reagent 
A’ (5% v/v reagent S in reagent A), and 200µl of reagent B. The plate was then 
incubated at room temperature for 15 min before reading in a plate-reader 
spectrophotometer at 750nm (Molecular Device, OPTImax). A standard curve was 
created by measurement of absorbance of the series of concentrations of BSA. 
Absorbance values of unknown samples were interpolated onto the standard curve to 
determine their concentrations. 
 
2.2.11.3.	  Separation	  of	  Proteins	  by	  Electrophoresis	  (SDS-­‐PAGE)	  
 
Protein samples (25µg-40µg) were adjusted to 6.5µl with water and added to a pre-
prepared mix of 2.5µl NuPAGE® SDS sample buffer (Invitrogen, UK) and 1µl of 
NuPAGE® reducing agent (Invitrogen). Samples were incubated at 70oC for 10 min 
to denature the protein. Samples and 5µl of Full-Range Rainbow marker (Invitrogen, 
UK) were loaded onto a 4-12% Bris-Tris Novex® pre-cast gel (Invitrogen, UK). The 
inner chamber of the electrophoresis tank was filled with 200ml of 1x NuPAGE® 
MES running buffer (Invitrogen, UK) and 500µl of NuPAGE® antioxidant 
(Invitrogen, UK), and the outer chamber with 600ml of 1x NuPAGE® MES running 
buffer. Samples were electrophoresed at 200V on ice until the dye front reached the 
bottom of the gel. 
 
2.2.11.4.	  Coomassie	  Gel	  Staining	  
	  
Following electrophoresis, the gel tank was disassembled and the gel transferred into 
a dish containing Coomassie staining solution and agitated gently overnight until 
uniformly blue. The gel was then placed in destain solution (45% v/v methanol, 10% 
v/v acetic acid) and agitated as above. The solution was changed, when appropriate, 
until the gel became translucent with visible protein bands and no further blue dye 
transferred into the destain solution.  
 




2.2.11.5.	  Western	  blot	  	  
 
Following electrophoresis, the gel tank was disassembled, and the gel transferred into 
a transfer sandwich (from the bottom: sponge-paper-gel-membrane-paper-sponge). 
Sponges were pre-soaked for 1 h in cold (4°C) transfer buffer. The sandwich cassette 
was then placed in the tank and all chambers filled with transfer buffer. Proteins were 
transferred at 30V on ice for 60 min. Following the transfer, the membrane was 
placed into the Ponceau Red solution (see 2.2.11.6) or directly into blocking buffer 
and incubated under agitation for 1 h at room temperature. The blocking solution was 
then removed and the membrane incubated with primary antibody diluted into 
blocking buffer. Antibody dilutions were as follows: rabbit polyclonal anti-SREBP-2 
1:500, sheep polyclonal anti-11β-HSD1 (raised in sheep, kind gift from Scott 
Webster; De Sousa Peixoto et al., 2008; Turban et al., 2012; Coutinho et al., 2013) 
1:1000, mouse polyclonal β-tubulin 1:10,000. The membrane was incubated 
overnight at 4°C under agitation, and then washed three times (10 min/wash) in TBST 
buffer, at room temperature under agitation. The membrane was then incubated for 1 
h at room temperature under agitation in the dark with the appropriate IRdye® 
secondary antibodies diluted 1:10,000 in blocking solution. Finally, the membrane 
was rinsed with TBST three times as described above and imaged using a LI-COR® 
Odyssey infrared scanner (2.2.12.7).  
	  
2.2.11.6.	  Ponceau	  Red	  Staining	  
	  
To assess transfer efficiency, the membrane was placed into a dish containing 
Ponceau Red solution, swirled for 2 min, then the membrane was washed with water 
until no more red dye eluted and the protein bands were clearly visible by eye. The 
membrane was then blocked and processed as above. 
 
2.2.11.7.	  Analysis	  and	  quantification	  
	  
Protein levels were measured using an infrared LI-COR® Odyssey scanner. 
Membranes were scanned at two wavelengths, 700nm (red channel) and 800nm 
(green channel). The protein of interest and internal control were detected and 




analysed within the same membrane by drawing equal sized rectangles around each 
band, with the scanner calculating optical density.  
 
2.2.12.	  Hepatic	  Subcellular	  Fractionation	  (Hepatic	  Microsomal	  Extraction)	  
 
Livers were stored at –80°C until use when they were slowly defrosted on wet ice. 
Each sample was cut into small pieces (100mg) and disrupted repeatedly (15 sec) in 
glass tubes (10x1cm) containing sucrose buffer (1ml). Tubes were stored on wet ice. 
Homogenates were then transferred into clean glass tubes (13x1cm), and sucrose 
buffer was added to 90% tube height. Samples were subjected to centrifugation 
(1000g, 4°C, 15 min) for separation of cell debris and the nuclear fraction (pellet). 
The supernatant was transferred into Beckman ultracentrifuge tubes (5x1cm). A 
further centrifugal separation (13,000g, 4°C, 30 min) was performed. The subsequent 
supernatant was collected in clean Beckman ultracentrifuge tubes and another 
centrifugal separation was performed (23,913g, 4°C, 1 h) to obtain light microsomes 
(pellet) and cytosolic fractions (supernatant). The supernatant was stored at –80°C. 
The remaining pellet of microsomes was reconstituted in sucrose buffer (500µl). 
Aliquots (40µl) were removed for immediate quantitation of protein (as in section 
2.2.11.2) and the remaining sample stored at –80°C until further use. 
 
2.2.13.	  Hepatic	  Nuclei	  Purification	  
 
Livers were stored at –80°C until processing. Each liver sample (~100mg) was 
homogenised in homogenisation buffer containing 10mM EGTA, 10mM EDTA, 
0.25M sucrose, 2mM MgCl2, 20mM Tris-HCL (pH 7.4), and subsequently 
centrifuged at 2500g for 5 min. Pellets were dissolved in homogenisation buffer and 
centrifuged at 1000g for 5 min. The supernatant was aspirated and pellets were 
dissolved in buffer containing 1mM EGTA, 1mM EDTA, 1.5mM MgCl2, 2.5% v/v 
glycerol and 20mM HEPES KOH (pH 7.6) for 60 min at 4°C. The nuclear extract was 
obtained after centrifugation at 100,000g, 4°C for 30 min. The protein concentration 
of each liver nuclear sample was measured as in section 2.2.11.2, and the samples 
were stored at –80°C until use. 




2.2.14.	  11β-­‐HSD1	  Activity	  Assay	  
	  
Liver homogenates (0.1mg/ml) were incubated in duplicate at 37oC with 25nM 3H-
corticosterone (Amersham Pharmacia Biotech, U.K.) and an excess (400µM) of the 
11β-HSD1-specific cofactor NADP. Under in vitro conditions, in homogenates, 11β-
HSD1 is bidirectional and the dehydrogenase assay is more reliable. This assay was in 
the linear range of protein concentration and product formation. Briefly, after a 25-
min incubation, steroids were extracted with ethyl acetate, separated by thin-layer 
chromatography (TLC), identified by migration in comparison to unlabelled 
standards, exposed to phosphorimager film (FLA2000; Fujifilm, U.K.) for 1-3 days, 
and analysed by quantitative phosphorimager software (Aida; Raytek Scientific, 
Sheffield, U.K.). 
 
In another assay, liver homogenates (25µg/ml) were incubated in duplicate at 37oC in 
Krebs-Ringer buffer containing 0.2% glucose, 2mM NADP, 50nM 3H-corticosterone, 
and unlabelled corticosterone (0.3-10µM). After 45 min, steroids were extracted with 
ethyl acetate, the organic phase was evaporated under nitrogen, and extracts were 
resuspended in mobile phase (60% water, 15% acetonitrile, and 25% methanol). 
Steroids were separated by high-performance liquid chromatography (HPLC) using a 
reverse phase µ-Bondapak C18 column (Phenomenex, UK) and were quantified by 
liquid scintillation counting. Each sample was measured for at least 25 min to ensure 
that peaks for both corticosterone and 11-dehydrocorticosterone were completely 
quantified.  
 
2.2.15.	  Adipose	  Picrosirius	  Red	  Staining	  
	  
Right sided subcutaneous fat depots excised from high fat diet-fed LKO, control, Del 
and HSD1 KO mice (Chapter 6; see 2.2.3) were fixed in 10% phosphate-buffered 
formalin solution for 24 h. Tissues were then transferred to 70% ethanol and 
embedded in paraffin blocks for subsequent sectioning. Using a microtome, sections 
of 5µm thickness were processed and collected onto electrostatic slides, which were 
then incubated at 37oC overnight. Total collagen content in subcutaneous fat was 
determined by staining the formalin-fixed paraffin sections of subcutaneous adipose 




tissue in picrosirius red (Sigma-Aldrich). Slides containing the tissue sections were 
immersed in picrosirius red solution for 2 h in the dark, after which they were rinsed 
in water, dehydrated and mounted. Adipose sections from each experimental group 
were processed simultaneously. The slides were viewed with a Zeiss light 
microscope. Pictures were acquired using a camera attached to the microscope and 
ImageJ software was used to quantify picrosirius red staining. 	  
 
2.2.16.	  Statistical	  Analyses	  
	  
For statistical analysis, GraphPad Prism 5 was used, except for Chapter 4 of this 
thesis, where data were analysed using GraphPad Prism 6 (allowing the use of 
Tukey’s and Fisher’s LSD post-hoc tests following two-way ANOVA). 
 
Comparisons between 2 groups (e.g. LOE versus WT) were made by Student’s t-test 
(unpaired). When variances between groups were not equal, an unpaired t-test with 
Welch’s correction was used. For the analysis of an effect of one factor (e.g. diet) in 
three or more groups, one-way ANOVA with Tukey’s post-hoc test was used. For the 
analysis of multiple levels of two factors (e.g. genotype and diet), two-way ANOVA 
with Tukey’s post-hoc test (unless specified otherwise) was used. 
 
Values are shown as means ± SEM. Significance was set as p<0.05. Full details of 




















Chapter	  3.	  	  Effect	  of	  Increased	  Hepatic	  11β-­‐

































In mice, deficiency (knockout) of 11β-HSD1 is protective against the adverse 
metabolic consequences of diet-induced obesity such as glucose intolerance and 
dyslipidaemia (Kotelevtsev et al., 1997; Morton et al., 2001; Morton et al., 2004). 
More recently, antidiabetic effects of pharmacological 11β-HSD1 inhibition have 
been observed in mice (Lloyd et al., 2009). Furthermore, in type 2 diabetes patients, 
inhibition of 11β-HSD1 reduces levels of plasma glucose, glycated haemoglobin A1c 
(HbA1c) and cholesterol (Rosenstock et al., 2010). Also, in mouse models, knockout 
or inhibition of 11β-HSD1 offers atheroprotection, despite only modest or no changes 
in plasma cholesterol levels (Hermanowski-Vosatka et al., 2005; Kipari et al., 2013; 
Luo et al., 2013). 
 
Transgenic mice expressing increased 11β-HSD1 activity selectively in the liver 
(LOE mice) exhibit insulin resistance, fatty liver (mainly as TG), and dyslipidaemia 
(Paterson et al., 2004). These mice also have elevated hepatic peroxisome 
proliferator-activated receptor alpha (PPARα) and mitochondrial carnitine 
palmitoyltransferase 1 (mCPT-1) expression, suggesting activation of lipid oxidation 
(Paterson et al., 2004). The acetyl-CoA produced from lipid oxidation may be utilised 
for cholesterol synthesis in LOE mice. Despite no differences in serum cholesterol 
levels or cholesterol distribution profile between LOE and control mice fed low-fat 
diet, high fat (HF) feeding altered the cholesterol lipoprotein profile in LOE mice, 
with decreased plasma HDL cholesterol but more cholesterol in low density 
lipoproteins (Paterson et al., 2004). The investigators also observed a trend for 
increased hepatic HMG-CoA reductase mRNA expression in LOE mice, though this 
did not achieve significance (Paterson et al., 2004). These liver-specific 11β-HSD1 
overexpressor mice were first created on a mixed background of 
C57BL/6xCBA/C3H, and F3 C57BL/6 backcross male mice were used for the initial 
study (Paterson et al., 2004). Since then, these mice have been backcrossed >10 
generations and, at the start of this PhD study, this model was already congenic on the 
C57BL/6 background.  
 




Apart from catalysing the intracellular conversion of GCs, 11β-HSD1 also catalyses 
reduction of 7-KC to 7-βHC (Schweizer et al., 2004; Hult et al., 2004). 7-KC has the 
potential to regulate cholesterol biosynthesis because it is an inhibitor of SREBP-2 
cleavage (Brown et al., 2002). In liver microsomes of LOE mice, levels of 7-KC are 
significantly reduced compared to levels in control mice (Dr. T. Mitic, unpublished 
data; Figure 3.1). Furthermore, pilot data obtained in collaboration with Dr. T. Mitic 
at the beginning of this study revealed that liver microsomes from LOE mice have 
increased levels of cleaved (mature) SREBP-2 protein compared to wild-type controls 
(Figure 3.2). Because mature SREBP-2 transcriptionally activates genes in the 
cholesterol biosynthetic pathway (Horton et al., 1998), this finding suggests increased 
cholesterol synthesis in LOE mice.  
 
Liver X receptors (LXR) are sterol sensors and their role in protecting cells from 
cholesterol overload by stimulating reverse cholesterol transport (RCT) and activating 
its conversion to bile acids in the liver is well established (Zhang and Mangelsdorf, 
2002; see 1.5.5). A common connection between SREBP-2 and LXR-mediated 
processes is their regulatory response to certain oxysterols. Whilst certain oxysterols 
inhibit SREBP-2 activation, they serve as ligands for LXR (Willy et al., 1995; Teboul 
et al., 1995; Peet et al., 1998; Venkateswaran et al., 2000; DeBose-Boyd et al., 2001; 
Janowski et al., 2001). As a transcription factor with a key role in regulating 
cholesterol biosynthesis, SREBP-2 may positively regulate LXR-target genes by 
enabling the generation of oxysterol ligands for LXR. This, indeed, has been implied 
as well as observed in multiple studies (Forman et al., 1997; Wong et al., 2004; Wong 
et al., 2006), suggesting that SREBP-2, which is well-known for its regulatory role in 
cholesterol synthesis, may also play an indirect role in regulation of LXR through 
generation of its endogenous ligands. In LOE mice, Paterson et al. (2004) observed 
increased hepatic expression of Lxrα (Paterson et al., 2004), the isoform that plays 
dominant roles in RCT and whole-body cholesterol homeostasis (Zhang et al., 2012; 


























Figure	  3.1:	  Liver	  microsomes	  of	  LOE	  mice	  have	  reduced	  levels	  of	  7-­‐KC	  compared	  to	  
wild-­‐type	  C57BL/6	  mice.	  
7-Ketocholesterol (7-KC) levels were measured in liver microsomes from chow-fed, 
6-8 week old, male wild-type control (C57BL/6) and liver 11β-HSD1 overexpressor 
(LOE) mice. Values are means ± SEM and were analysed by unpaired t-test (two-












































Figure	   3.2:	   Liver	   microsomes	   from	   LOE	   mice	   have	   increased	   levels	   of	   cleaved	  
SREBP-­‐2	  compared	  to	  wild-­‐type	  C57BL/6	  mice.	  
Western blot analysis was used to measure levels of uncleaved and cleaved SREBP-2 
protein in hepatic microsomes from chow-fed, 6-8 week old, male wild-type (WT) 
C57BL/6 and liver 11β-HSD1 overexpressor (LOE) mice. (A) A representative image of 
a SREBP-2 western blot, with protein bands for uncleaved as well as cleaved SREBP-2. 
Each lane contained 25µg of protein from one mouse. (B) SREBP-2 protein levels (red) 
were expressed relative to β-tubulin protein levels (green), the internal control. (C) The 
bands in Figure 3.2B were quantified. Data are means ± SEM and were analysed by 








The evidence presented above suggests that 11β-HSD1 may play an important role in 
cholesterol homeostasis. However, this area has been largely unexplored. Liver is the 
major controller of whole-body cholesterol homeostasis, with major roles in 
cholesterol biosynthesis, cholesterol uptake through LDLR, lipoprotein release into 
the blood, storage of cholesterol by esterification, cholesterol degradation (conversion 
to bile acids), and cholesterol export into bile (Trapani et al., 2012; see 1.5.5). 
Because liver is the principal organ involved in cholesterol homeostasis and the organ 
with highest expression of 11β-HSD1, the liver enzyme was chosen for study.  
 
To dissect the role of hepatic 11β-HSD1 in cholesterol homeostasis, mouse models 
with altered levels of 11β-HSD1 selectively in the liver were used to examine effects 
on hepatic cholesterol homeostasis. LOE mice, with hepatic overexpression of 11β-
HSD1 (Paterson et al., 2004), provided a valuable resource to study the role of 
increased hepatic 11β-HSD1 in cholesterol homeostasis. As mentioned above, these 
mice show an adverse metabolic phenotype of fatty liver and dyslipidaemia and, in 
response to HF diet, display altered cholesterol lipoprotein profile as well as 
attenuated hepatic induction of cholesterol homeostasis regulators including LXRα 
(Paterson et al., 2004). Furthermore, as mentioned earlier, preliminary data (Figures 
3.1 and 3.2) at the start of this study suggested increased cholesterol synthesis in LOE 
mice. Ideally, liver 11β-HSD1 overexpressors need to be compared to liver-specific 
11β-HSD1 knockout mice. Based on data from LOE mice, and according to the 
hypothesis of this chapter (see 3.2), increased 7-KC and reduced mature SREBP-2 
levels are predicted in liver of mice with knockout of hepatic 11β-HSD1, suggesting 
decreased hepatic cholesterol synthesis. Mice with knockout of liver 11β-HSD1 were 
generated during the course of this study (Chapter 5). However, the initial 











3.2.	  Hypothesis	  and	  Aims	  
 
As an inhibitor of SREBP-2 cleavage, 7-KC provides an endogenous brake on 
cholesterol biosynthesis. Therefore, reduced 7-KC levels in liver of LOE mice are 
predicted to increase hepatic cholesterol synthesis.   
 
Hypothesis: Increased liver 11β-HSD1 promotes de novo hepatic cholesterol 
biosynthesis via increased cleavage of hepatic SREBP-2 and induction of SREBP-2 




1) To test whether hepatic overexpression of 11β-HSD1 increases levels of mRNAs 
encoding hepatic cholesterol biosynthetic enzymes. 
 
2) To determine whether overexpression of liver 11β-HSD1 leads to activation of 
hepatic Lxrα and its downstream targets involved in cholesterol efflux and removal, 
in response to excess cholesterol due to increased cholesterol biosynthesis. 
 
3) To confirm that hepatic 11β-HSD1 overexpression leads to increased levels of 




















3.3.1.	  No	  differences	  in	  hepatic	  Hmgcr	  and	  Hmgcs	  mRNA	  levels	  between	  wild-­‐type	  
control	  and	  LOE	  mice 
	  
Increased cholesterol synthesis is accompanied by an increase in the mRNA levels 
and activity of key enzymes in the mevalonate pathway. HMG-CoA synthase 
(HMGCS) catalyses the initial step in this pathway to produce HMG-CoA 
(Clinkenbeard et al., 1975). The enzyme HMG-CoA reductase (HMGCR) then 
catalyses the conversion of HMG-CoA to mevalonate, the synthesis of which is the 
committed and rate-determining step in cholesterol formation (Brown and Goldstein, 
1980; Goldstein and Brown, 1990). Transcription of these enzymes is regulated by 
sterol levels, via SREBP-2 (Smith et al., 1988; Jiang et al., 1993; Vallett et al., 1996).  
 
Because preliminary data suggested increased cholesterol biosynthesis in LOE mice 
(Figures 3.1 and 3.2; see 3.1), SREBP-2 target genes in the cholesterol biosynthetic 
pathway were examined in livers from 6-8 week old wild-type (WT) C57BL/6 and 
liver-specific 11β-HSD1 overexpressor (LOE) mice, which were fed a standard chow 
diet. Messenger RNAs for HMG-CoA reductase as well as for HMG-CoA synthase 
were measured via qPCR.  
 
Contrary to predictions of the hypothesis, there were no differences in the hepatic 
levels of Hmgcr and Hmgcs mRNA between genotypes (Figure 3.3), suggesting no 
























































Figure	  3.3:	  Levels	  of	  hepatic	  Hmgcr	  and	  Hmgcs	  mRNA	  do	  not	  differ	  between	  wild-­‐
type	  control	  and	  LOE	  mice.	  
Total RNA was extracted from liver of chow-fed, 6-8 week old, male wild-type (WT) 
and liver 11β-HSD1 overexpressor (LOE) mice. Messenger RNA levels were 
measured by qPCR. (A) Hmgcr and (B) Hmgcs mRNA levels are expressed relative 
to Tbp mRNA. Values are means ± SEM and were analysed by unpaired t-test (two-









































































The LXR members of the nuclear receptor family are activated by oxysterols such as 
22(S)-hydroxycholesterol, 24(S), 25-epoxycholesterol, and 27-hydroxycholesterol, 
the levels of which are thought to be proportional to cellular cholesterol levels 
(Janowski et al., 1999; Fu et al., 2001). Extensive studies have established LXRα as a 
central regulator of cholesterol homeostasis which regulates a network of genes 
involved in cholesterol metabolism and excretion (Lehmann et al., 1997; Peet et al., 
1998; Venkateswaran et al., 2000; Kennedy et al., 2001; Repa et al., 2002; Joseph et 
al., 2002; Tangirala et al., 2002; Bełtowski, 2008; Hong et al., 2012; Zhang et al., 
2012; see 1.5.5). In addition to cholesterol metabolism and efflux, LXRα activation in 
animal models increases hepatic fatty acid synthesis (Peet et al., 1998; Repa et al., 
2000a; Schultz et al., 2000; Schuster et al., 2002; Kalaany et al., 2005; Lund et al., 
2006). Studies have indicated that SREBP-2, the key regulator of cholesterol 
biosynthesis, upregulates LXR activity through generation of its endogenous ligands 
(Forman et al., 1997; Wong et al., 2004; Wong et al., 2006).  
 
To investigate if overexpression of liver 11β-HSD1 leads to increased hepatic Lxrα 
expression (in response to excess cholesterol; see 3.2), Lxrα mRNA levels were 
measured in liver from chow-fed, 6-8 week old WT and LOE mice. An increase in 
hepatic Lxrα mRNA levels was observed in LOE mice compared to WT controls 













































Figure	   3.4:	   Levels	   of	   hepatic	  Lxrα 	  mRNA	  are	   increased	   in	   LOE	  mice	   compared	   to	  
their	  wild-­‐type	  littermates.	  
Total RNA was extracted from liver of chow-fed, 6-8 week old, male liver 11β-HSD1 
overexpressor (LOE) mice and their wild-type (WT) littermates. Lxrα mRNA levels 
were measured by qPCR and are expressed relative to Tbp mRNA levels, used as an 
internal control. Values are means ± SEM and were analysed by unpaired t-test (two-
















































3.3.3.	  No	  difference	  in	  hepatic	  Cyp7a1	  mRNA	  levels	  between	  wild-­‐type	  control	  and	  
LOE	  mice	  
	  
Cholesterol 7α-hydroxylase (encoded by Cyp7a1) catalyses the rate-limiting step in 
the classical pathway of bile acid synthesis and, in mice, is a direct target of LXRα 
(Zhu et al., 2012; see 1.5.5). LXRα deficient mice lose the ability to upregulate 
Cyp7a1 gene expression in response to increased intracellular cholesterol levels, and, 
therefore, accumulate cholesterol esters in the liver, eventually leading to impaired 
hepatic function (Peet et al., 1998). Despite the presence of LXRβ in LXRα deficient 
mice, it cannot substitute for LXRα in the regulation of Cyp7a1 expression (Lehmann 
et al., 1997; Peet et al., 1998). Consistent with this, LXRβ deficient mice retain 
normal hepatic cholesterol metabolism, highlighting the key role of LXRα in this 
process (Alberti et al., 2001).  
 
To determine whether hepatic induction of Lxrα in LOE mice leads to increased 
degradation of cholesterol via bile acid synthesis, Cyp7a1 mRNA levels were 
measured in liver samples from chow-fed, 6-8 week old LOE mice and their WT 
littermates. 
 
There was no difference in the hepatic levels of Cyp7a1 mRNA between genotypes 
(Figure 3.5), suggesting no difference in hepatic cholesterol catabolism through bile 











































Figure	  3.5:	  Similar	  hepatic	  Cyp7a1	  mRNA	  levels	  in	  WT	  control	  and	  LOE	  mice.	  
Total RNA was extracted from liver of chow-fed, 6-8 week old, male liver 11β-HSD1 
overexpressor (LOE) mice and their wild-type (WT) littermates. Cyp7a1 mRNA 
levels were measured by qPCR and are expressed relative to Tbp mRNA levels, used 
as an internal control. Values are means ± SEM and were analysed by unpaired t-test 




















































3.3.4.	  LOE	  mice	  have	  increased	  hepatic	  Abcg8	  mRNA	  levels	   
	  
In addition to stimulation of bile acid synthesis, activation of LXR also induces 
hepatic cholesterol excretion by increasing transcription of the (hepatic) ATP-binding 
cassette (ABC) transporters G5 and G8 (Repa et al., 2002; Yu et al., 2003; Graf et al., 
2003; Hong et al., 2012; see 1.5.5). These transporters are expressed at the canalicular 
membrane of hepatocytes where they drive cholesterol transport into bile for 
excretion (Yu et al., 2002).  
 
To determine whether LOE mice show activation of hepatic cholesterol secretion into 
bile, Abcg5 and Abcg8 mRNA levels were measured in liver from chow-fed, 6-8 week 
old LOE mice and their WT littermates. 
 
LOE mice had increased hepatic Abcg8 mRNA levels compared to WT control mice 
(Figure 3.6B). Although not reaching statistical significance, levels of Abcg5 mRNA 
were increased to a similar extent in livers of LOE mice (Figure 3.6A). Together, 












































Figure	  3.6:	  Levels	  of	  hepatic	  Abcg8	  mRNA	  are	  increased	  in	  LOE	  mice	  compared	  to	  
WT	  controls.	  
Total RNA was extracted liver of chow-fed, 6-8 week old, male liver 11β-HSD1 
overexpressor (LOE) mice and their wild-type (WT) littermates. Messenger RNA 
levels were measured by qPCR. (A) Abcg5, and (B) Abcg8 mRNA levels are 
expressed relative to Tbp mRNA. Values are means ± SEM and were analysed by 





































































3.3.5.	  No	  change	  in	  hepatic	  Abca1	  mRNA	  levels	  between	  wild-­‐type	  control	  and	  LOE	  
mice 
	  
ABC transporter A1 (ABCA1) mediates cholesterol efflux from peripheral cells to 
lipid-poor apolipoproteins (apo-A1 and apoE), which then form HDL. In doing so, 
ABCA1 controls the rate-limiting step in HDL particle assembly, and is considered 
essential for RCT (Vaisman et al., 2001; Basso et al., 2003; Kang et al., 2013; see 
1.5.4). Studies in mouse models have shown the crucial role of hepatic ABCA1 in the 
formation of nascent HDL particles; adenoviral and transgenic overexpression of 
hepatic ABCA1 raises plasma HDL concentrations (Vaisman et al., 2001; Basso et 
al., 2003; Wellington et al., 2003), whereas selective deletion of hepatic Abca1 
reduces plasma HDL levels by approximately 80% in chow-fed mice (Timmins et al., 
2005). Numerous studies have also revealed that LXRα and LXRβ upregulate 
expression of rodent as well as human ABCA1 (in macrophages and intestine) (Repa 
et al., 2000b; Costet et al., 2000; Schwartz et al., 2000; Muscat et al., 2002; Sparrow 
et al., 2002; Kotokorpi et al., 2007; Mitro et al., 2007; Zhao et al., 2008).  
 
To investigate whether increased expression of Lxrα in livers of LOE mice leads to 
upregulation of hepatic Abca1 expression, Abca1 mRNA levels were measured in 
liver samples of WT control and LOE mice.  
 
There was no difference in the hepatic levels of Abca1 mRNA between genotypes 
(Figure 3.7), suggesting no change in ABCA1-mediated HDL particle assembly 





























Figure	  3.7:	  Similar	  hepatic	  Abca1	  mRNA	  levels	  in	  WT	  control	  and	  LOE	  mice.	  
Total RNA was extracted from liver of chow-fed, 6-8 week old, male liver 11β-HSD1 
overexpressor (LOE) mice and their wild-type (WT) littermates. Abca1 mRNA levels 
were measured by qPCR and are expressed relative to Tbp mRNA levels, used as an 
internal control. Values are means ± SEM and were analysed by unpaired t-test (two-
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3.3.6.	  The	  initial	  finding	  of	  increased	  levels	  of	  cleaved	  SREBP-­‐2	  protein	  in	  LOE	  liver	  
microsomes	  is	  not	  replicated	  in	  a	  new	  set	  of	  LOE	  liver	  microsomal	  samples	  	  
	  
Preliminary data revealed increased cleaved SREBP-2 protein levels in liver 
microsomal fractions of LOE mice (Figure 3.2). Because cleaved/mature SREBP-2 
protein activates transcription of target genes in nuclei of cells (Brown and Goldstein, 
1997), western blot analysis was carried out to confirm that hepatic 11β-HSD1 
overexpression leads to increased levels of cleaved SREBP-2 in nuclear fractions of 
liver from LOE and control mice. The liver nuclear as well as microsomal fractions 
used in Figure 3.8 were from new LOE and control liver samples (different to the 
samples used in Figure 3.2). 11β-HSD1 antibody was used as a marker for 
microsomes (11β-HSD1 is a microsomal protein (Ozols, 1995; Mziaut et al., 1999)) 
and showed the presence of 11β-HSD1 in nuclear fractions (Figure 3.8), suggesting 
microsomal contamination. Furthermore, cleaved SREBP-2 was clearly present to a 
similar extent in both LOE and wild-type microsomal fractions (Figure 3.8), which is 
inconsistent with the initial finding (Figure 3.2).  
 
To examine if the initial samples still gave the same results as previously, two ‘old’ 
WT and two ‘old’ LOE liver microsomal fractions (used to generate Figure 3.2) were 
selected, at random, for western blot analysis. Despite weaker 124kDa bands 
(uncleaved SREBP-2), the initial findings were replicated here with respect to cleaved 
SREBP-2 protein levels; bands representing cleaved SREBP-2 protein were visible in 
LOE liver microsomes, but undetectable in WT liver microsomes (Figure 3.9).  
 
In order to resolve the discrepancy in cleaved SREBP-2 between original and 
different, ‘newer’ samples, another cohort of WT control and LOE mice were used 
(separate from those in Figures 3.2 and 3.8), to obtain liver microsomal fractions for 
western blot analyses. These samples revealed the presence of cleaved SREBP-2 
protein in liver microsomal fractions from LOE as well as control mice (Figure 3.10) 
with undetectable uncleaved SREBP-2 protein (Figure 3.10). These results are 
consistent with those in Figure 3.8, but still inconsistent with the original pilot study 
finding (Figure 3.2). Repeated experiments on different LOE and control liver 
samples gave results similar to those in Figures 3.8 and 3.10 (data not shown).  
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Figure	   3.8:	   Cleaved	   SREBP-­‐2	   protein	   is	   present	   in	   both,	   WT	   and	   LOE	   liver	  
microsomal	  fractions.	  Liver	  nuclear	  fractions	  reveal	  microsomal	  contamination.	  
Western blotting was used to examine SREBP-2 protein levels in liver microsomal 
fractions and liver nuclear fractions from wild-type control (WT) and liver 11β-HSD1 
overexpressor (LOE) mice. Each lane contains 25µg protein from one mouse. The 
SREBP-2 antibody used detects uncleaved (124kDa) and cleaved (68kDa) SREBP-2 
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Figure	   3.9:	   Initial	   findings	   (increased	   cleaved	   SREBP-­‐2	   protein	   in	   LOE	   liver	  
microsomes)	  are	  replicated	  in	  the	  original	  WT	  and	  LOE	  liver	  microsomal	  fractions.	  
Western blotting was used to examine SREBP-2 protein levels in liver microsomal 
fractions from wild-type control (WT) and liver 11β-HSD1 overexpressor (LOE) 
mice. Each lane contains 25µg protein from one mouse, either WT or LOE as labelled 
appropriately. Here, some of the original liver microsomal fractions have been used. 
The SREBP-2 antibody used detects uncleaved (124kDa) and cleaved (68kDa) 
































Figure	  3.10:	  There	   is	   an	   inconsistency	   in	   cleaved	  SREBP-­‐2	  protein	   levels	  between	  
liver	  microsomal	   fractions	   from	  original	   and	  new	   cohorts	  of	  WT	   control	   and	   LOE	  
mice.	  
Western blotting was used to examine SREBP-2 protein levels in liver microsomal 
fractions from a new cohort of wild-type control (WT) and liver 11β-HSD1 
overexpressor (LOE) mice. Each lane contains 30-35µg protein from one mouse, 
either WT or LOE as labelled appropriately. The SREBP-2 antibody used detects 
uncleaved (124kDa) and cleaved (68kDa) SREBP-2 proteins. The β-tubulin antibody 
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These data show that, in contrast to the hypothesis, overexpression of hepatic 11β-
HSD1 does not lead to increased expression of mRNAs encoding hepatic cholesterol 
biosynthetic enzymes. Increased cholesterol synthesis is accompanied by an increase 
in the activity and mRNA levels of HMG-CoA reductase (Istvan and Deisenhofer, 
2001; Horton et al., 2002) as well as a coordinate increase in the mRNA levels of 
other key enzymes of the mevalonate pathway, such as HMG-CoA synthase, farnesyl 
diphosphate synthase, and squalene synthase (Harris et al., 1997). The mevalonate 
pathway is subject to negative end-product regulation (for example, by mevalonate, 
cholesterol, and other sterols such as oxysterols), and quantitatively, the most 
significant point of suppression is considered to be prior to mevalonate formation 
(Brown and Goldstein, 1980; Goldstein and Brown, 1990; Osborne, 1995). Among 
the enzymes that are essential to convert acetyl-CoA to mevalonate (the committed 
step in the synthesis of cholesterol), two enzymes have been clearly demonstrated to 
be under feedback regulation by cholesterol; microsomal HMG-CoA reductase 
(HMGCR) and cytoplasmic HMG-CoA synthase (HMGCS) (Clinkenbeard et al., 
1975; Goldstein and Brown, 1990), therefore these were included in this study. 
Consistent with its role as the rate-limiting enzyme in cholesterol biosynthesis, 
HMGCR is also the target of statins, an efficacious therapeutic for the treatment of 
hyperlipidaemia and atherosclerotic cardiovascular disease, which act by inhibiting 
HMGCR in hepatocytes, thereby inhibiting cholesterol synthesis (Crouse et al., 1995; 
Jukema et al., 1995; Pitt et al., 1995; Istvan and Deisenhofer, 2000; Istvan and 
Deisenhofer, 2001; Nissen, 2005; Nissen et al., 2006). Glucocorticoids (GC) have 
been reported to inhibit cholesterol biosynthesis (Melnykovych et al., 1976; Russell, 
1992; Russell, 2003) and Ramachandran et al. (1978) showed that GC-mediated 
inhibition of cholesterol biosynthesis in HeLa cells is due to HMGCS repression 
(Ramachandran et al., 1978). However, this remains controversial, for example 
dexamethasone and cortisol stimulated cholesterol synthesis up to 4-fold in human 
fetal hepatocytes (Carr and Simpson, 1983).  
 
Paterson et al. (2004) previously observed a trend for increased hepatic Hmgcr 
mRNA expression in LOE mice, though this did not achieve significance due to high 




inter-animal variability (Paterson et al., 2004). We thought this might be because the 
study was carried out on generation 3 backcross animals, where genetic variability 
could have contributed to phenotypic variability. Here, with mice congenic on the 
C57BL/6 background, there were still no differences in hepatic Hmgcr mRNA levels 
between LOE and control mice. This current study also measured hepatic Hmgcs 
mRNA levels in transgenic LOE and wild-type C57BL/6 mice, and like Hmgcr, 
hepatic Hmgcs mRNA levels did not differ between LOE and control mice. These 
results oppose the hypothesis of this chapter. At the molecular level, SREBP-2 
governs cholesterol biosynthesis by upregulating the transcription of genes that 
encode enzymes of the cholesterol biosynthetic pathway (Horton et al., 1998; Horton 
et al., 2002). Hence, it was surprising that an increase in the mature/cleaved form of 
SREBP-2 protein (preliminary finding) did not lead to increased hepatic expression of 
Hmgcr and Hmgcs mRNAs in LOE mice. However, it remained possible that an 
increase in Hmgcr and Hmgcs expression was not detected because of variation in the 
time that the tissues were collected in this study (between 13:00h and 14:00h), as 
diurnal variation occurs in both cholesterol synthesis and reductase expression with 
maximum activities observed during the dark period and minimum activities around 
noon (12:00h) (Edwards et al., 1972; Shefer et al., 1972; Jones and Schoeller, 1990; 
Cella, 1995; Jurevics, 2000).  
 
Cholesterol is the precursor to oxysterol LXR ligands (Fu et al., 2001; Lund et al., 
2003) and therefore, increased cholesterol synthesis is likely to lead to LXR activation 
(Forman et al., 1997; Janowski et al., 1999). This is consistent with the role of LXRα 
as a sterol “sensor”, activated by the intracellular accumulation of cholesterol 
derivatives to stimulate cholesterol efflux, RCT and cholesterol excretion into bile 
(Joseph et al., 2002; Nomiyama and Bruemmer, 2008; Hong et al., 2012; Zhang et al., 
2012). Therefore, although at first appearing to be contradictory to our hypothesis, it 
was predicted that liver overexpression of 11β-HSD1 leads to activation of hepatic 
Lxrα and its downstream targets involved in cholesterol efflux and excretion, in 
response to excess intracellular cholesterol due to increased cholesterol synthesis. 
There were, indeed, increased hepatic Lxrα mRNA levels in LOE mice compared to 
control mice. This is consistent with a previous study carried out by Paterson et al. 
(2004) which showed that LOE mice have increased hepatic Lxrα expression 




compared to wild-type mice (Paterson et al., 2004). Several studies have 
demonstrated the existence of an autoregulatory loop controlling the expression of 
LXRα but not LXRβ (Laffitte et al., 2001; Whitney et al., 2001; Li et al., 2002). 
However, these studies show that autoregulatory upregulation of LXRα expression 
may be limited to human cells (Laffitte et al., 2001; Whitney et al., 2001). Paterson et 
al. (2004) observed increased hepatic Pparα mRNA levels in LOE mice, and it is 
possible that PPARα induction, which is GC-sensitive (Lemberger et al., 1994), may 
upregulate LXRα expression in these mice (Chinetti et al., 2001; Chawla et al., 
2001); for instance, either directly through a PPAR response element, or indirectly via 
increased levels of acetyl-CoA (produced by lipid oxidation) leading to cholesterol 
biosynthesis, and hence formation of oxysterol LXR ligands.  
 
Cholesterol conversion into bile acids in the liver is a pivotal pathway to reduce 
serum cholesterol levels. Bile acid synthesis and excretion represent the major 
pathway of cholesterol removal from the body (Russell, 2003). Cholesterol 7-alpha-
hydroxylase (CYP7A1) is the rate-limiting enzyme in the classical bile acid 
biosynthetic pathway, accounting for at least 75% of the total bile acid pool (Chiang, 
2004). It has been shown that in mice and rats, but not humans, LXRα activation 
induces the expression of Cyp7a1, thus promoting cholesterol degradation (Janowski 
et al., 1996; Lehmann et al., 1997; Peet et al., 1998; Chiang et al., 2001). 
Furthermore, Cyp7a1 expression is GC-inducible (Princen et al., 1989). However, 
surprisingly, no difference was observed in hepatic Cyp7a1 mRNA levels between 
LOE and control mice, suggesting that there is no change in cholesterol removal via 
bile acid synthesis between genotypes. This is not consistent with the study carried 
out by Paterson et al. (2004), which reported increased hepatic Cyp7a1 expression in 
LOE mice (Paterson et al., 2004). In this previous study, Northern blotting was used 
to investigate hepatic gene expression, and although there was no difference in the 
4.5kb Cyp7a1 transcript, the authors observed an increase in a 7.1kb Cyp7a1 
transcript in LOE mice, and reported an overall increase in hepatic Cyp7a1 mRNA in 
these mice (Paterson et al., 2004). However, database searching using the BLAST 
bioinformatics program and examination of Ensembl genome browser for the mouse 
Cyp7a1 gene only revealed a 4.5kb transcript for Cyp7a1 (not shown here), without 




an alternative 7.1kb transcript. Therefore, the identity of the 7.1kb transcript in the 
previous study remains unclear.  
 
 LOE mice had elevated levels of hepatic Abcg5 (though not reaching statistical 
significance) and Abcg8 mRNA. This is consistent with both Abcg5 and Abcg8 being 
direct targets of LXR activation (Berge et al., 2000; Lee et al., 2001; Repa et al., 
2002). These data suggest increased hepatobiliary cholesterol secretion in LOE mice 
as the induction of hepatic ABCG5 and ABCG8 has been demonstrated to promote 
cholesterol excretion into bile (Graf et al., 2002; Yu et al., 2002; Yamazaki et al., 
2011). This also possibly accounts for normal plasma and liver cholesterol levels 
observed in (control diet-fed) LOE mice (Paterson et al., 2004). However, LOE mice 
also exhibit fatty liver, which was confirmed to be the result of elevated hepatic TG 
levels and this was attributed to LXRα-regulated FAS induction (Joseph et al., 2002b) 
in these mice (Paterson et al., 2004).  
 
The removal of cholesterol through bile acid production occurs exclusively in the 
liver, therefore, excess cholesterol from other tissues must be returned to the liver for 
catabolic elimination. As previously mentioned, RCT is the process by which HDL 
particles mediate the transport of cholesterol from peripheral tissues to the liver. 
Studies in mouse models have shown the crucial role of hepatic ABCA1 in HDL 
biogenesis  (Vaisman et al., 2001; Basso et al., 2003; Wellington et al., 2003; 
Timmins et al., 2005). It has also been shown that LXR activation upregulates 
expression of ABCA1 in macrophages (Repa et al., 2000b; Costet et al., 2000; 
Schwartz et al., 2000; Muscat et al., 2002; Mitro et al., 2007; Zhao et al., 2008). 
However, no differences were observed in hepatic Abca1 mRNA levels between LOE 
and WT mice. This finding does not rule out the possibility of active ABCA1-
mediated cholesterol efflux in LOE macrophages and/or cholesterol efflux mediated 
by ABCG1 and it will be of interest to measure this in the future.  
 
Western blot analyses to examine cleaved SREBP-2 protein levels in liver nuclear 
fractions of LOE mice were not successful due to microsomal contamination. 
Furthermore, despite cleaner blots and extensive attempts, the original finding (of 
increased cleaved SREBP-2 protein in LOE liver microsomes) was not repeated in 




separate cohorts of LOE and control liver microsomal samples. Hence, the 
preliminary data on the effect of liver 11β-HSD1 overexpression upon levels of 
cleaved SREBP-2 protein are not conclusive. The reason behind this remains unclear. 
 
In summary, there is no evidence that liver 11β-HSD1 overexpression promotes 
cholesterol synthesis by increasing levels of mRNAs encoding hepatic cholesterol 
biosynthetic enzymes, at least in chow-fed LOE mice. However, unchanged gene 
expression does not exclude posttranscriptional/posttranslational regulation of enzyme 
activities. As predicted, overexpression of liver 11β-HSD1 leads to increased 
expression and activity of Lxrα, possibly in response to increased intracellular 
cholesterol levels. Despite similarities in some results with those in the initial study 
carried out by Paterson et al. (2004), the current data display some differences. There 
is no evidence in the present study for increased bile acid synthesis in LOE mice. 
However, elevated hepatic Abcg5/8 mRNA expression in LOE mice suggests a role 
for increased hepatic 11β-HSD1 in secretion of cholesterol into the biliary lumen, 

























Chapter	  4.	  	  Effect	  of	  11β-­‐HSD1	  on	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Lipid metabolism and homeostasis are crucially dependent on diet. Although dietary 
fatty acids play an important role in cellular physiology by altering membrane 
fluidity, signal transduction and gene expression (Duplus et al., 2000; Dussault and 
Forman, 2000; Madsen et al., 2005), in excess, they are implicated in the 
development of metabolic syndrome and cardiovascular disease. Trans fatty acids 
(TFA) and saturated fatty acids (SFA) are associated with the development of obesity 
and insulin resistance (Lefebvre et al., 1999; Lovejoy et al., 2001; Dorfman et al., 
2009). Fatty diets lead to high levels of plasma TG, which have also been linked to 
increased risk of atherosclerosis, heart disease and stroke (Labreuche et al., 2009). 
However, this is debatable, as recent reports show no significant association between 
intake of saturated fats and cardiovascular disease (Siri-Tarino et al., 2010; Chowdury 
et al., 2014). Since Western-style diets deliver fat mainly from animal sources, they 
are also cholesterol-rich. In humans, consumption of a Western-style diet has been 
reported to elevate plasma/serum total cholesterol and LDL levels, and increase 
coronary heart disease mortality (Sacks et al., 1984; Ginsberg et al., 1994; 
Riemersma, 2002; Eilat-Adar et al., 2013). Feeding cholesterol-rich diets to wild-type 
C57BL/6 mice shows a switch in lipoprotein profile from HDL to LDL (Morton et 
al., 2004), and in atherosclerosis-prone mouse models (Apoe-/- and LDLR-/- mice), 
high cholesterol diets lead to increased total cholesterol and LDL levels as well as 
extensive atherosclerosis (Ishibashi et al., 1994; van Ree et al., 1994; Zhang et al., 
1994; Meir and Leitersdorf, 2004).  
 
Although no differences were observed in hepatic Hmgcr and Hmgcs mRNA levels 
between chow-fed LOE mice and WT controls (Chapter 3), it is likely that diet is an 
influential factor. 7-Ketocholesterol is formed non-enzymatically by free radical 
oxidation of cholesterol (Hodis et al., 1991), or from dietary intake of cholesterol-rich 
food (Nielsen et al., 1995; Vine et al., 2002). Based on the original hypothesis that 
hepatic 11β-HSD1 converts 7-KC to 7β-HC and, therefore, removes an endogenous 
brake on cholesterol synthesis in liver, feeding LOE mice a cholesterol-rich diet is 
predicted to increase 7-KC availability for liver 11β-HSD1, hence driving synthesis 
of 7β-HC, and thus increasing hepatic cholesterol biosynthesis in cholesterol-fed LOE 




mice. Moreover, chow-fed LOE mice showed evidence for increased biliary 
cholesterol excretion compared to WT controls (Chapter 3) and it would be 
interesting to observe the impact of dietary risk factors.  
 
To investigate the in vivo effects of 11β-HSD1 and dietary risk factors upon hepatic 
cholesterol homeostasis, a dietary experiment was carried out in liver 11β-HSD1 
overexpressor (LOE), wild-type (WT) C57BL/6, and 11β-HSD1 deficient (HSD1 
KO) mice. Liver-specific 11β-HSD1 knockout mice were not used in this experiment 
as their generation was underway at the time. Male WT, LOE and HSD1 KO mice (5-
6 week old, n=6-10/group) were fed standard chow (C; 11% fat), high fat (HF; 58% 
fat) or western diet (WD; 41% fat + 0.21% cholesterol) for 12 weeks. Cholesterol-rich 
WD was used for the above-mentioned reasons, and HF diet was included to 
investigate effects of 11β-HSD1 on cholesterol homeostasis when precursor for 
cholesterol synthesis (acetyl CoA) is increased. Also, these particular diets have been 
used in previous studies within the lab (Paterson et al., 2004; Morton et al., 2004; 
Kipari et al. 2013). Although a matched low-fat diet would be more suitable as a 
control for the HF diet utilised in this study, a standard chow was used, which served 
as a control diet for both WD and HF diet. Apart from the effects on cholesterol 
homeostasis, other metabolic parameters such as weight gain were being investigated 
in this study (see 4.2). Although an increase in body weight can be noticed in 2-3 
weeks of HF-feeding, the increase is gradual (Wang and Liao, 2012) and, therefore, 
the mice in this study were fed these diets for 12 weeks (long enough for significant 
weight gain). Body weight was measured weekly. Liver and fat depots were collected 













4.2.	  Hypothesis	  and	  Aims	  
	  
Hepatic overexpression of 11β-HSD1 will increase 7-KC to 7β-HC conversion in 
liver, removing the brake on cholesterol biosynthesis in this tissue. With a supply of 
7-KC substrate through cholesterol-rich WD, for the above-mentioned reaction, 
higher levels of hepatic cholesterol synthesis are predicted on WD. On the other hand, 
11β-HSD1 deficiency will result in greater levels of 7-KC on WD, providing an 
endogenous brake on cholesterol biosynthesis. Therefore, 11β-HSD1 deficiency is 
predicted to reduce hepatic cholesterol synthesis in mice fed WD. On HF diet, levels 
of acetyl CoA precursor will be greater, and so increased cholesterol biosynthesis is 
predicted in LOE mice. Conversely, HSD1 KO mice will be protected from this 
adverse metabolic phenotype.  
 
Hypothesis: With high fat/cholesterol feeding, increased liver 11β-HSD1 will 
promote hepatic cholesterol biosynthesis via hepatic induction of SREBP-2 target 
genes in the cholesterol biosynthetic pathway. The opposite effect will be observed 





1) To investigate metabolic parameters such as body, liver and adipose tissue weights 
in mice with 11β-HSD1 manipulations fed either standard chow, HF or cholesterol-
rich diet. 
 
2) To determine if mRNAs encoding cholesterol biosynthetic enzymes (SREBP-2 
targets) are altered in livers of mice with 11β-HSD1 manipulations faced with HF or 
cholesterol challenge. 
 
3) To test if mRNAs encoding LXRα and its downstream targets involved in 
cholesterol efflux and cholesterol clearance are altered in livers of mice with 11β-
HSD1 manipulations challenged with HF or cholesterol diets. 
 





4.3.1.	  Significant	  effects	  of	  genotype	  and	  diet	  on	  body	  weight	  gain	  
	  
Previous data revealed reduced body weight gain in HSD1 KO mice fed a HF diet 
compared to wild-type controls on the same diet (Morton et al., 2004). Paterson et al. 
(2004) reported no differences in body weight between HF-fed LOE and control mice 
but the effect of cholesterol-rich diet was not tested in their study. 
 
Effects of HF and cholesterol-rich WD feeding on body weight gain were assessed in 
WT, LOE and HSD1 KO mice in this study.  
	  
After 12 weeks of chow, HF diet or WD, significant effects of diet and genotype were 
observed on body weight gain, with a significant interaction between genotype and 
diet (Figure 4.1). As expected, WT and LOE mice gained more weight with HF- and 
WD-feeding compared to chow diet (Figure 4.1). However, the same was not 
observed in HSD1 KO mice, which showed greater body weight gain on chow diet 


















































Figure	  4.1:	   Significant	  effects	  of	   genotype	  and	  diet	  are	  observed	  on	  body	  weight	  
gain.	  
Male, 5-6 week old wild-type (WT) C57BL/6, liver 11β-HSD1 overexpressor (LOE) 
and 11β-HSD1 deficient (HSD1 KO) mice were fed Chow (C), High Fat (HF) or 
Western (WD) diet for 12 weeks, and had their body weight gain measured. Values 
are means ± SEM and were analysed by two-way ANOVA with Tukey’s multiple 
comparisons post-hoc test; n=8-10/group; * p<0.05, ** p<0.01 for effect of genotype; 
# p<0.05, ## p<0.01, ### p<0.001 for effect of diet; † p<0.05 for interaction between 
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4.3.2.	  Significant	  effects	  of	  genotype	  and	  diet	  on	  liver	  weight	  
	  
The liver plays a major role in regulating metabolic homeostasis and is vital for 
nutrient metabolism. Previous work has shown that increased levels of dietary fat 
intake are associated with increased lipid accumulation in the liver, leading to fatty 
liver disease (Deng et al., 2005; Zou et al., 2006; Sathiaraj et al., 2011). Also, 
Paterson et al. (2004) observed a fatty liver phenotype in LOE mice on both control 
and HF diet (Paterson et al., 2004).  
 
Following chow, HF or WD feeding, liver weights of WT, LOE and HSD1 KO mice 
(which were 17-18 weeks of age at the end of the experiment) were measured. 
 
Although two-way ANOVA analysis showed significant effects of genotype and diet 
on liver weight (Figure 4.2), the Tukey’s post-hoc test did not detect any specific 
genotype or diet differences. This might be due to a combination of the design of the 
experiment (2 factors, but 3 levels each) and the stringency of the post-hoc test. A 
Fisher’s LSD test (which does not correct for multiple comparisons) revealed 
significantly reduced liver weight in WD-fed HSD1 KO mice compared to WD-fed 
WT mice (Figure 4.2). As for diet differences, decreased liver weights were observed 















































Figure	  4.2:	  Significant	  effects	  of	  genotype	  and	  diet	  are	  observed	  on	  liver	  weights.	  
Male, 5-6 week old wild-type (WT) C57BL/6, liver 11β-HSD1 overexpressor (LOE) 
and 11β-HSD1 deficient (HSD1 KO) mice were subject to 12-week Chow (C), High 
Fat (HF) or Western (WD) diet, and had their terminal liver weights measured and 
normalised to body weights. Data are means ± SEM and were analysed by two-way 
ANOVA with Fisher’s LSD post-hoc test; n=8-10/group; * p<0.05, ** p<0.01 for 
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4.3.3.	  Significant	  effect	  of	  diet	  on	  white	  adipose	  tissue	  weight	  
 
Diet-induced obesity (via HF diet and/or high-caloric food) is characterised by an 
increase in adipose tissue, resulting mainly from the excessive storage of TG within 
adipocytes. The literature points out that the adverse metabolic consequences of 
obesity are predicted by the quantity of visceral fat, not just the total adipose mass 
(Vague, 1956; Montague and O’Rahilly, 2000). Dyslipidaemia, fatty liver disease and 
diabetes are closely associated with abdominal obesity (increased visceral fat), which 
is also a feature of metabolic syndrome (Marchesini et al., 2003).  
 
To evaluate the distribution of adiposity in WT, LOE and HSD1 KO mice in this 
study, the weight of three different fat depots was measured: subcutaneous fat, 
epididymal fat and mesenteric fat. 
 
In all genotypes, WT, LOE as well as HSD1 KO mice, WD feeding increased 
subcutaneous (Figure 4.3), epididymal (Figure 4.4) and mesenteric (Figure 4.5) fat 
weights, compared to standard chow diet. Similarly, HF feeding increased weights of 
all white fat depots in WT and HSD1 KO mice (Figures 4.3, 4.4 and 4.5). Two-way 
ANOVA showed no significant effect of genotype on subcutaneous (Figure 4.3) and 
epididymal (Figure 4.4) fat weights, but with respect to mesenteric fat weight, a 
significant effect of genotype was observed and HF-fed LOE mice displayed 










































Figure	  4.3:	  Significant	  effect	  of	  diet	  is	  observed	  on	  subcutaneous	  fat	  weights.	  
Male, 5-6 week old wild-type (WT), liver 11β-HSD1 overexpressor (LOE) and 11β-
HSD1 deficient (HSD1 KO) mice were fed Chow (C), High Fat (HF) or Western 
(WD) diet for 12 weeks, and had their terminal subcutaneous fat weights measured 
and normalised to body weights. Values are means ± SEM and were analysed by two-
way ANOVA with Tukey’s multiple comparisons post-hoc test; n=8-10/group; ## 
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Figure	  4.4:	  Significant	  effect	  of	  diet	  is	  observed	  on	  epididymal	  fat	  weights.	  
Epididymal fat weights of 5-6 week old male wild-type (WT) C57BL/6, liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 deficient (HSD1 KO) mice, which were 
fed Chow (C), High Fat (HF) or Western (WD) diet for 12 weeks, were normalised to 
body weights. Values are means ± SEM and were analysed by two-way ANOVA with 
Tukey’s multiple comparisons post-hoc test; n=8-10/group; # p<0.05, ## p<0.01, ### 
p<0.001 for effect of diet; †† p<0.01 for interaction between genotype and diet; NS, 
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Figure	  4.5:	  Significant	  effects	  of	  genotype	  and	  diet	  are	  observed	  on	  mesenteric	  fat	  
weights.	  	  
Male, 5-6 week old wild-type (WT), liver 11β-HSD1 overexpressor (LOE), and 11β-
HSD1 deficient (HSD1 KO) mice that were fed Chow (C), High Fat (HF) or Western 
(WD) diet for 12 weeks had their terminal subcutaneous fat weights measured and 
normalised to body weights. Values are means ± SEM and were analysed by two-way 
ANOVA with Tukey’s multiple comparisons post-hoc test; n=8-10/group; * p<0.05, 
** p<0.01 for effect of genotype; # p<0.05, ## p<0.01, ### p<0.001 for effect of diet; 
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4.3.4.	  Significant	  effect	  of	  diet	  on	  hepatic	  Srebp2	  mRNA	  levels	  
	  
High-cholesterol diets suppress cholesterol synthesis in the livers of experimental 
animals. As the key regulator of cholesterol biosynthesis, SREBP-2 is expected to be 
significantly reduced with cholesterol feeding. This, indeed, has been observed in 
numerous studies (Hua et al., 1996; Shimomura et al., 1997; Vallim and Salter, 2010; 
Boone et al., 2011). Cholesterol feeding leads to intracellular cholesterol 
accumulation thereby inhibiting the cleavage/maturation of SREBP-2 (Brown and 
Goldstein, 1997; Goldstein et al., 2002; Vallim and Salter, 2010). Moreover, the 
SREBP2 gene contains an active sterol response element (SRE) and has been shown 
to negatively autoregulate its own transcription (Sato et al., 1996), leading to a further 
decrease in mature/nuclear SREBP-2. Fat feeding has either little effect on SREBP-2 
expression (Xu et al., 1999; Kim et al., 1999; Mater et al., 1999; Yahagi et al., 1999; 
Buettner et al., 2006), or, like cholesterol-rich diets, reduces SREBP-2 levels 
(Worgall et al., 1998; Thewke et al., 1998; Vallim and Salter, 2010; Shin et al., 
2013). Paterson et al. (2004) showed no alteration in hepatic Srebp2 expression in 
HF-fed LOE mice compared with control low fat-fed WT littermates. The effect of 
cholesterol feeding on LOE mice has not been investigated. As for Srebp2 expression 
with 11β-HSD1 deficiency, a recent study that used an antisense oligonucleotide to 
knockdown 11β-HSD1 in livers of C57BL/6 mice showed no change in hepatic 
Srebp2 mRNA levels with 11β-HSD1 knockdown (Li et al., 2011).  
 
It was hypothesised that with high fat/cholesterol feeding, increased liver 11β-HSD1 
will promote hepatic cholesterol biosynthesis via induction of SREBP-2 target genes 
involved in the cholesterol biosynthetic pathway (see 4.2). To examine Srebp2 
expression in livers of HF- and WD-fed LOE and HSD1 KO mice, hepatic Srebp2 
mRNA levels were measured via qPCR. WT C57BL/6 mice served as controls. For 
gene expression analysis in this study, six samples were chosen per group 
(n=6/group). 
 
A significant effect of diet was observed on hepatic Srebp2 mRNA levels. As 
expected, WT mice showed reduced hepatic Srebp2 mRNA levels on HF diet and 
WD compared to chow diet (Figure 4.6). LOE and HSD1 KO mice also exhibited 
decreased hepatic Srebp2 mRNA levels with WD feeding (Figure 4.6). The two-way 




ANOVA showed a significant interaction between genotype and diet (Figure 4.6). 
Chow-fed HSD1 KO mice showed decreased hepatic levels of Srebp2 mRNA 
compared to WT mice on the same diet (Figure 4.6). Surprisingly, there were also 
reduced hepatic Srebp2 mRNA levels in chow-fed LOE mice compared to chow-fed 









































































Figure	  4.6:	  Significant	  effect	  of	  diet	  is	  observed	  on	  hepatic	  Srebp2	  mRNA	  levels.	  
Total RNA was extracted from livers of male wild-type control (WT), liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 knockout (HSD1 KO) mice fed one of 
the following diets for 12 weeks from 5-6 weeks of age; chow (C), high fat (HF) or 
western diet (WD). Hepatic Srebp2 mRNA levels were measured by qPCR. Levels of 
Srebp2 mRNA are expressed relative to the average of Hprt and Actb mRNAs, used 
as internal controls. Values are means ± SEM and were analysed by two-way 
ANOVA with Fisher’s LSD post-hoc test; n=6/group; * p<0.05 for effect of 
genotype; # p<0.05, ### p<0.001 for effect of diet; † p<0.05 for interaction between 
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4.3.5.	  Reduced	  hepatic	  Hmgcr	  and	  Hmgcs	  mRNA	   levels	   in	  WT	  and	  LOE	  mice	  with	  
WD	  feeding	  
 
It has been recognised for a long time that feeding cholesterol to animals decreases 
the rate of hepatic cholesterol synthesis to maintain intracellular cholesterol 
homeostasis (Gould and Taylor, 1950; Gould, 1951; Tomkin et al., 1953; Langdon 
and Bloch, 1953), and numerous studies have shown that this is primarily due to 
decreased activity and reduced mRNA levels of enzymes involved in the cholesterol 
biosynthetic pathway particularly HMGCR and HMGCS (Limi, 1967; Kandutsch and 
Packie, 1970; White and Rudney, 1970; Shapiro and Rodwell, 1971; Ness et al., 
1991; Rudling, 1992; Lin et al., 1992; Kushwaha et al., 1995; Maxwell et al., 2003; 
Mutungi et al., 2007; Boone et al., 2011; see 1.4.1.1). Some studies have shown that 
HF feeding in C57BL/6 mice also reduces Hmgcr mRNA levels (Rudling, 1992), and 
HMGCR activity (Sumiyoshi et al., 2006). However, other studies demonstrate that 
HF feeding elevates Hmgcr mRNA (Lin et al., 2005; Wu et al., 2013) as well as 
HMGCR protein and enzyme activity (Wu et al., 2013). Paterson et al. (2004) 
demonstrated a trend for increased hepatic Hmgcr mRNA levels in control diet-fed 
LOE mice, which was abolished with HF feeding. The effect of cholesterol feeding on 
expression of genes encoding cholesterol biosynthetic enzymes in LOE mice has not 
been investigated.  
 
To examine if cholesterol synthesis was altered in HF- and WD-fed LOE and HSD1 
KO mice, via altered expression of SREBP-2 target genes in the cholesterol 
biosynthetic pathway, Hmgcr and Hmgcs mRNA levels were measured in livers from 
male 17-18 week old WT, LOE, and HSD1 KO mice following dietary intervention as 
described above.  
 
A significant effect of diet was observed on hepatic Hmgcr and Hmgcs mRNA levels 
(Figure 4.7A and Figure 4.7B). While WT mice displayed a decrease in hepatic 
Hmgcr mRNA with both HF and WD feeding (Figure 4.7A), hepatic Hmgcs mRNA 
levels were significantly reduced only in WD-fed WT mice compared to chow-fed 
WT mice (Figure 4.7B). WD-fed LOE mice showed reduced hepatic Hmgcr (Figure 
4.7A) mRNA levels compared to chow-fed LOE mice, with a similar trend in Hmgcr 
mRNA expression on HF diet though this did not reach significance (Figure 4.7A). 




LOE mice also showed reduced hepatic Hmgcs mRNA levels with WD feeding 
(Figure 4.7B). HSD1 KO mice displayed no significant differences in hepatic Hmgcr 
mRNA levels with HF and WD feeding (Figure 4.7A), though decreased levels of 
Hmgcs mRNA were observed with WD feeding (Figure 4.7B). A significant 
interaction between genotype and diet was observed on Hmgcr mRNA expression 
(Figure 4.7A) and, consistent with decreased hepatic Srebp2 expression in chow-fed 
HSD1 KO mice, hepatic Hmgcr mRNA levels were reduced in chow-fed HSD1 KO 
mice compared to WT controls on the same diet (Figure 4.7A), though this was not 















































































Figure	   4.7:	   Significant	   effect	   of	   diet	   is	   observed	   on	   hepatic	   Hmgcr	   and	   Hmgcs	  
mRNA	  levels.	  
Total RNA was extracted from livers of male wild-type control (WT), liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 knockout (HSD1 KO) mice fed one of 
the following diets for 12 weeks; chow (C), high fat (HF) or western diet (WD). (A) 
Hmgcr, and (B) Hmgcs mRNA levels were measured by qPCR, and are expressed 
relative to the average of Hprt and Actb mRNAs, used as internal controls. Data are 
means ± SEM and were analysed by two-way ANOVA with Tukey’s multiple 
comparisons post-hoc test; n=6/group; *** p<0.001 for effect of genotype; # p<0.05, 
## p<0.01, ### p<0.001 for effect of diet; †† p<0.01 for interaction between genotype 
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4.3.6.	   Increased	  hepatic	  Lxrα 	  mRNA	  levels	   in	  WD-­‐fed	  LOE	  mice	  compared	  to	  WD-­‐
fed	  WT	  controls	  	  
 
Consistent with its role as a sterol sensor that governs cholesterol absorption, 
transport and catabolism, LXRα is upregulated by cholesterol-rich and high fat diets 
(Janowski et al., 1996; Lehman et al., 1997; Peet et al., 1998; Zhang and 
Mangelsdorf, 2002). Hepatic Lxrα mRNA levels are increased in LOE mice (see 
3.3.2; Paterson et al., 2004). As for 11β-HSD1 deficiency and LXRα expression, a 
recent study that used an antisense oligonucleotide to knockdown hepatic 11β-HSD1 
in C57BL/6 mice showed no alteration in hepatic Lxrα mRNA levels with 11β-HSD1 
knockdown (Li et al., 2011).  
 
To test if LXRα expression was altered in liver of mice with 11β-HSD1 
manipulations challenged with HF or cholesterol diets, Lxrα mRNA levels were 
measured in livers from male 17-18 week old WT, LOE, and HSD1 KO mice fed 
chow, HF diet or WD (for 12 weeks from 5-6 weeks of age).  
 
A significant effect of genotype was observed on the levels of hepatic Lxrα mRNA 
such that WD-fed LOE mice showed increased levels of hepatic Lxrα mRNA 
compared to WD-fed WT mice (Figure 4.8). There was a trend for increased hepatic 
Lxrα mRNA levels in chow-fed LOE mice compared to chow-fed WT mice but this 
did not achieve significance (Figure 4.8), possibly because of low sample number. No 
effect of diet, or interaction between genotype and diet, were observed on hepatic 
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Figure	  4.8:	   Increased	  hepatic	  Lxrα 	  mRNA	  levels	   in	  WD-­‐fed	  LOE	  mice	  compared	  to	  
WT	  mice	  on	  the	  same	  diet.	  
Total RNA was extracted from livers of male wild-type control (WT), liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 knockout (HSD1 KO) mice fed one of 
the following diets for 12 weeks from 5-6 weeks of age; chow (C), high fat (HF) or 
western diet (WD). Hepatic Lxrα mRNA levels were measured by qPCR, and are 
expressed relative to the average of Hprt and Actb mRNAs, used as internal controls. 
Values are means ± SEM and were analysed by two-way ANOVA with Tukey’s 




















4.3.7.	  No	  effect	  of	  genotype	  or	  diet	  on	  hepatic	  Cyp7a1	  mRNA	  levels	  
 
In rodents, CYP7A1 is upregulated in response to lipid and cholesterol feeding, via 
LXRα (Janowski et al., 1996; Lehmann et al., 1997; Peet et al., 1998; Zhang and 
Mangelsdorf, 2002). Hepatic Cyp7a1 mRNA levels are reportedly increased with 
liver 11β-HSD1 overexpression (Paterson et al., 2004), although this was not 
observed in the current study (see 3.3.3). Hepatic Cyp7a1 expression has not been 
examined in 11β-HSD1 deficient mice.  
 
To establish whether hepatic induction of Lxrα in WD-fed LOE mice leads to 
increased clearance of cholesterol via bile acid synthesis, Cyp7a1 mRNA levels were 
measured in the liver samples from male, 17-18 week old LOE mice following dietary 
intervention as described above. Additionally, hepatic Cyp7a1 mRNA levels were 
measured in HSD1 KO mice to determine whether 11β-HSD1 deficiency altered 
cholesterol clearance through the CYP7A1 bile acid pathway. WT C57BL/6 mice 
served as controls. 
 
There were no significant effects of genotype or diet, or interaction between the two, 
on hepatic Cyp7a1 mRNA levels (Figure 4.9). These results suggest no significant 
changes in bile acid synthesis in either LOE or HSD1 KO mice compared with WT 












































Figure	  4.9:	  There	  is	  no	  effect	  of	  diet	  or	  genotype	  on	  hepatic	  Cyp7a1	  mRNA	  levels	  in	  
LOE,	  WT	  and	  HSD1	  KO	  mice	  fed	  Chow	  (C),	  High	  Fat	  (HF)	  or	  Western	  (WD)	  diet.	  
Total RNA was extracted from livers of male wild-type control (WT), liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 knockout (HSD1 KO) mice fed one of 
the following diets for 12 weeks from 5-6 weeks of age; chow (C), high fat (HF) or 
western diet (WD). Hepatic Cyp7a1 mRNA levels were measured by qPCR, and are 
expressed relative to the average of Hprt and Actb mRNAs, used as internal controls. 
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4.3.8.	  Significant	  effect	  of	  diet	  on	  hepatic	  Cyp27a1	  and	  Cyp7b1	  mRNA	  levels	  
	  
Bile acid synthesis can occur through two pathways, the classical pathway or the 
alternative pathway (Ferdinandusse and Houten, 2006). Whilst the classical pathway 
starts with the rate-limiting 7-α hydroxylation of cholesterol by CYP7A1, the 
alternative pathway begins with the hydroxylation of the cholesterol side chain by 
sterol 27 hydroxylase (CYP27A1), followed by 7-α hydroxylation of the oxysterol 
intermediates by oxysterol 7-α hydroxylase (CYP7B1) (Wu et al., 1999; Norlin and 
Wikvall, 2007). Studies using mice in which CYP7A1, CYP27A1, or CYP7B1 was 
rendered non-functional have generated new insights into the quantitative 
contributions of the classic and alternate pathways in this species (Rosen et al., 1998; 
Schwarz et al., 1998; Li-Hawkins et al., 2000; Repa et al., 2000a). These as well as 
other studies carried out in rats suggest that the amount of total bile acid synthesis via 
the alternate pathway is significantly greater in these animal models (up to 25-30%) 
than appears to be the case in humans (6%) (Vlahcevic et al., 1997; Duane and Javitt, 
1999). 
 
To determine whether cholesterol elimination through bile acids is altered in HF- and 
WD-fed LOE and HSD1 KO mice via the alternative bile acid synthesis pathway, 
Cyp27a1 and Cyp7b1 mRNA levels were measured in liver samples from male 17-18 
week old LOE and HSD1 KO mice at the end of this dietary experiment. As above, 
WT C57BL/6 mice served as controls. 
 
A significant effect of diet was observed on hepatic Cyp27a1 mRNA levels with WD-
fed HSD1 KO mice having decreased Cyp27a1 mRNA expression, compared to 
chow-fed HSD1 KO mice (Figure 4.10) Two-way ANOVA also showed a significant 
interaction between genotype and diet (Figure 4.10). HF-fed LOE mice exhibited 
reduced levels of hepatic Cyp27a1 mRNA compared to WT mice on the same diet 
(Figure 4.10), suggesting decreased cholesterol elimination through the alternative 
bile acid synthesis pathway in HF-fed LOE mice relative to HF-fed WT controls. 
	  
Although the two-way ANOVA showed a significant effect of genotype as well as an 
interaction between genotype and diet on hepatic Cyp7b1 mRNA levels (Figure 4.11), 




the Tukey’s post-hoc test did not detect genotype differences on any of the diets. 
Therefore, a Fisher’s LSD post-hoc test was used. There were decreased hepatic 
Cyp7b1 mRNA levels in HF-fed LOE and HSD1 KO mice compared to HF-fed WT 
mice (Figure 4.11). With respect to diet differences, WT mice showed increased 
hepatic Cyp7b1 mRNA levels with HF feeding, and LOE mice exhibited reduced 














































Figure	  4.10:	  There	  is	  an	  effect	  of	  diet	  on	  hepatic	  Cyp27a1	  mRNA	  levels.	  
Total RNA was extracted from livers of male wild-type control (WT), liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 knockout (HSD1 KO) mice fed one of 
the following diets for 12 weeks; chow (C), high fat (HF) or western diet (WD). 
Hepatic Cyp27a1 mRNA levels were measured by qPCR, and are expressed relative 
to the average of Hprt and Actb mRNAs, used as internal controls. Values are means 
± SEM and were analysed by two-way ANOVA with Tukey’s multiple comparisons 
post-hoc test; n=6/group; * p<0.05 for effect of genotype; # p<0.05 for effect of diet; 
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Figure	   4.11:	   Significant	   effects	   of	   diet	   and	   genotype	   are	   observed	   on	   hepatic	  
Cyp7b1	  mRNA	  levels.	  
Total RNA was extracted from livers of male wild-type control (WT), liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 knockout (HSD1 KO) mice fed one of 
the following diets for 12 weeks from 5-6 weeks of age; chow (C), high fat (HF) or 
western diet (WD). Hepatic Cyp7b1 mRNA levels were measured by qPCR, and are 
expressed relative to the average of Hprt and Actb mRNAs, used as internal controls. 
Values are means ± SEM and were analysed by two-way ANOVA with Fisher’s LSD 
post-hoc test; n=6/group; * p<0.05, ** p<0.01 for effect of genotype; # p<0.05, ### 
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4.3.9.	   Increased	   hepatic	   Abcg5	   and	   Abcg8	   mRNA	   levels	   in	   WD-­‐fed	   LOE	   mice	  
compared	  to	  WD-­‐fed	  WT	  mice	  
 
As mentioned previously, in vivo and in vitro experiments have shown that LXR 
promotes cholesterol elimination by upregulating transcription of Abcg5/8 in the liver 
where these ABC transporters promote cholesterol excretion into bile (Berge et al., 
2000; Repa et al., 2002; Graf et al., 2003; Yu et al., 2004; Yu et al., 2014; see 3.3.4), 
as well as activating transcription of intestinal Abcg5/8, where the transporters act to 
limit cholesterol absorption from the gut (Zhang and Mangelsdorf, 2002; Geyeregger 
et al., 2006; Yu et al., 2014). Consistent with a role in preventing excess dietary sterol 
accumulation, levels of Abcg5/8 mRNAs increase in both liver and intestine in 
response to cholesterol-rich diets (Su et al., 2012). Hepatic Abcg5 and Abcg8 mRNA 
levels were increased with liver 11β-HSD1 overexpression (see 3.3.4), and antisense-
mediated inhibition of 11β-HSD1 in C57BL/6 mice reduced hepatic Abcg5/8 
expression compared with controls (Li et al., 2011). Hepatic Abcg5/8 expression has 
not been investigated in HF- and WD-fed LOE or HSD1 KO mice.  
 
To determine whether hepatic induction of Lxrα in WD-fed LOE mice potentially 
leads to increased hepatobiliary cholesterol secretion, and additionally to investigate 
effects of 11β-HSD1 deficiency combined with HF and WD feeding upon 
hepatobiliary cholesterol secretion, Abcg5 and Abcg8 mRNA levels were measured in 
livers of LOE and HSD1 KO mice following dietary intervention. WT C57BL/6 mice 
served as controls. 
 
A significant effect of diet was observed on the levels of hepatic Abcg5/8 mRNAs 
such that LOE mice showed significantly elevated levels of hepatic Abcg5 (Figure 
4.12A) and Abcg8 (Figure 4.12B) mRNA with WD feeding. There were also 
increased hepatic Abcg5 (Figure 4.12A) and Abcg8 (Figure 4.12B) levels in WD-fed 
HSD1 KO and WT mice compared with chow feeding. A significant effect of 
genotype as well as interaction between genotype and diet were observed (Figure 
4.12), and consistent with increased hepatic Lxrα expression in WD-fed LOE mice, 
hepatic Abcg5 (Figure 4.12A) and Abcg8 (Figure 4.12B) mRNA levels were elevated 
in WD-fed LOE mice compared to WT controls on the same diet.  



































Figure	   4.12:	   Hepatic	  Abcg5	  and	  Abcg8	  mRNA	   are	   increased	   in	   LOE	  mice	   fed	  WD	  
compared	  to	  WT	  mice	  on	  same	  diet.	  
Total RNA was extracted from livers of male wild-type control (WT), liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 knockout (HSD1 KO) mice fed one of 
the following diets for 12 weeks; chow (C), high fat (HF) or western diet (WD). (A) 
Abcg5, and (B) Abcg8 mRNA levels were measured by qPCR, and are expressed 
relative to the average of Hprt and Actb mRNAs. Values are means ± SEM and were 
analysed by two-way ANOVA with Tukey’s multiple comparisons post-hoc test; 
n=6/group; * p<0.05, ** p<0.01, *** p<0.001 for effect of genotype; # p<0.05, ### 
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4.3.10.	  Significant	  effect	  of	  diet	  on	  hepatic	  Apoe	  mRNA	  levels	  
 
Apolipoprotein E (ApoE) is a principal component of chylomicron remnants and 
VLDL, and is involved in their hepatic uptake. ApoE is essential for the catabolism of 
these TG-rich lipoprotein constituents (Plump et al., 1992; Zhang et al., 1992). Unlike 
most of the apolipoproteins that are mainly synthesised in the liver and intestine, 
ApoE is also synthesised in macrophages and adipocytes (Curtiss and Boisvert, 2000; 
Mazzone, 1996). In these cells, ApoE facilitates cholesterol efflux in both humans and 
mice (Zhang et al., 1996; Langer et al., 2000; Curtiss and Boisvert, 2000). Apoe gene 
expression is directly regulated by LXR in both macrophages and adipocytes (Laffitte 
et al., 2001). 
 
To investigate whether hepatic induction of Lxrα in WD-fed LOE mice is associated 
with increased hepatic ApoE expression, Apoe mRNA levels were measured in livers 
of mice from the dietary experiment described above. 
 
A significant effect of diet on hepatic Apoe mRNA levels was observed such that 
WD-fed HSD1 KO mice showed decreased hepatic Apoe mRNA levels compared to 

















































Figure	  4.13:	  Significant	  effect	  of	  diet	  is	  observed	  on	  hepatic	  Apoe	  mRNA	  levels.	  
Total RNA was extracted from livers of male wild-type control (WT), liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 knockout (HSD1 KO) mice fed one of 
the following diets for 12 weeks from 5-6 weeks of age; chow (C), high fat (HF) or 
western diet (WD). Hepatic Apoe mRNA levels were measured by qPCR, and are 
expressed relative to the average of Hprt and Actb mRNAs, used as internal controls. 
Values are means ± SEM and were analysed by two-way ANOVA with Tukey’s 
multiple comparisons post-hoc test; n=6/group; # p<0.05, ## p<0.01 for effect of diet; 
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4.3.11.	  Significant	  effect	  of	  diet	  on	  hepatic	  ApoA1	  mRNA	  levels	  
 
Apolipoprotein A1 (ApoA1) is the major protein component of the HDL particle 
(Barter and Rye, 1996) and its concentrations are closely linked with plasma HDL 
(Rubin et al., 1991; Williamson et al., 1992). ApoA1 is secreted mostly by the liver 
and plays an important role in RCT (Plump et al., 1994).  
 
To investigate if ApoA1 expression is altered in livers of mice with 11β-HSD1 
manipulations that were challenged with HF or cholesterol diets, hepatic ApoA1 
mRNA levels were measured in livers of LOE and HSD1 KO mice following dietary 
intervention as described above. WT C57BL/6 mice served as controls. 
 
Two-way ANOVA showed a significant effect of diet, as well as a significant 
interaction between genotype and diet, on hepatic ApoA1 mRNA levels (Figure 4.14). 
However, the Tukey’s post-doc test did not detect diet differences, or any differences 
between genotypes on the diets investigated. Carrying out a Fisher’s LSD test 
revealed significantly decreased hepatic ApoA1 mRNA levels in LOE and HSD1 KO 
mice with WD-feeding (Figure 4.14). Also, there was a reduction in hepatic ApoA1 
mRNA levels in WD-fed LOE and HSD1 KO mice compared to WD-fed WT mice 






























Figure	  4.14:	  Significant	  effect	  of	  diet	  is	  observed	  on	  hepatic	  ApoA1	  mRNA	  levels.	  
Total RNA was extracted from livers of male wild-type control (WT), liver 11β-
HSD1 overexpressor (LOE) and 11β-HSD1 knockout (HSD1 KO) mice fed one of 
the following diets for 12 weeks; chow (C), high fat (HF) or western diet (WD). 
Hepatic ApoA1 mRNA levels were measured by qPCR, and are expressed relative to 
the average of Hprt and Actb mRNAs, used as internal controls. Values are means ± 
SEM and were analysed by two-way ANOVA with Fisher’s LSD post-hoc test; 
n=6/group; * p<0.05, ** p<0.01 for effect of genotype; # p<0.05 for effect of diet; † 
















Genotype   NS
Diet                #
































The work in this chapter was designed to test the hypothesis that liver 11β-HSD1 
overexpression, (through its role in the metabolism of 7-oxysterols), combined with 
cholesterol/fat feeding, promotes hepatic cholesterol synthesis via hepatic induction 
of SREBP-2 target genes involved in the cholesterol biosynthetic pathway, whereas 
11β-HSD1 deficiency leads to the opposite effect.  
 
Contrary to predictions, liver 11β-HSD1 overexpression failed to support a role in 
hepatic cholesterol synthesis, both on WD and HF diet. Unexpectedly, chow-fed LOE 
mice showed reduced hepatic Srebp2 mRNA levels compared to chow-fed WT mice, 
and with WD feeding, both WT and LOE mice reduced hepatic Srebp2 mRNA 
expression compared to chow diet. Furthermore, there were no significant differences 
in the hepatic mRNA levels of Hmgcr and Hmgcs between WT and LOE mice on any 
of the diets, consistent with findings from chow-fed, 6-8 week old LOE mice (Chapter 
3). There are two sources of cholesterol that circulate in plasma; cholesterol derived 
from the diet, and cholesterol that is mainly synthesised by the liver. In animals on a 
cholesterol-free diet, the only source of plasma cholesterol is de novo cholesterol 
biosynthesis, whereas when dietary cholesterol is available/plentiful, feedback 
inhibition of cholesterol biosynthesis occurs so that very little plasma cholesterol is 
derived from de novo synthesis (Gould, 1951; Siperstein, 1970; Brown and Goldstein, 
1997; Edwards et al., 2000; Maxwell et al., 2003). Consequently, numerous studies 
have shown that cholesterol-rich diets lead to downregulation of genes encoding 
hepatic cholesterol biosynthetic enzymes, including HMGCR (Maxwell et al., 2003; 
Mutungi et al., 2007; Boone et al., 2011) and HMGCS (Kushwaha et al., 1995; 
Boone et al., 2011). Effects of HF feeding upon cholesterol synthesis are not as clear; 
whilst some studies demonstrate downregulation of Hmgcr expression and enzyme 
activity with HF feeding (Rudling et al., 1992; Sumiyoshi et al., 2006), others show 
that HF feeding upregulates HMGCR expression (mRNA and protein as well as 
enzyme activity) and increases cholesterol synthesis (Lin et al., 2005; Jensen et al., 
2012; Wu et al., 2013). In the current study, WT mice showed the expected dietary 
effects in that levels of Hmgcr mRNA were reduced in the liver with HF or WD 
feeding, and hepatic Hmgcs mRNA levels were decreased with cholesterol-rich WD. 




However, contrary to the hypothesis, LOE mice behaved like WT mice on the 
cholesterol-rich WD (and also on HF diet to an extent) with respect to hepatic Hmgcr 
and Hmgcs mRNA expression. These results imply that LOE mice show a normal 
physiological response with respect to regulation of cholesterol synthetic enzymes 
when faced with high fat or cholesterol dietary challenges.  
 
Interestingly, chow-fed HSD1 KO mice exhibited decreased hepatic Hmgcr levels 
compared to WT mice on the same diet, suggesting lower levels of basal cholesterol 
synthesis with 11β-HSD1 deficiency. Because GCs inhibit cholesterol biosynthesis 
(Melnykovych et al., 1976; Russell, 1992; Russell, 2003), a possible mechanism to 
explain this may be that 11β-HSD1 deficiency results in elevated levels of 7-KC 
(through lack of conversion to 7β-HC), which provides an endogenous brake on 
cholesterol biosynthesis (Brown et al., 2002). The above-mentioned finding is not 
consistent with a previous study that showed no alteration in hepatic Hmgcr mRNA 
levels with 11β-HSD1 deficiency (Morton et al., 2001). A possible reason for this 
discrepancy is that Morton et al. (2001) used HSD1 KO mice on the original 
MF1/129 background in their study (Morton et al., 2001), whereas the current study 
used HSD1 KO mice that have been rederived onto the C57BL/6 strain.  
 
Cholesterol conversion to bile acids in the liver and their subsequent faecal excretion 
represents a major route for cholesterol elimination from the body (Arias et al., 2009; 
Zhang et al., 2012). LXRα, a nuclear receptor that is upregulated by cholesterol-rich 
diets, is key in governing cholesterol catabolism through activation of transcription of 
hepatic Cyp7a1 (in rodents at least), the gene that encodes the rate-limiting enzyme of 
the classic bile acid synthesis pathway  (Janowski et al., 1996; Lehman et al., 1997; 
Peet et al., 1998; Zhang and Mangelsdorf, 2002; Nomiyama and Bruemmer, 2008; 
Hong et al., 2012). In this study, hepatic Lxrα mRNA expression was unaffected by 
diet in WT and HSD1 KO mice (and did not significantly differ in chow-fed mice 
between genotypes), but was increased in WD-fed LOE mice. Despite this 
upregulation in hepatic Lxrα mRNA levels of WD-LOE mice, there was no evidence 
of increased Cyp7a1 mRNA expression in livers of WD-LOE mice. There were also 
no differences in Cyp7a1 mRNA levels between WD-fed WT and HSD1 KO mice, or 
in HF-fed mice between genotypes. Taken together, these results suggest no change in 




bile acid synthesis in either LOE or HSD1 KO mice with HF and WD feeding. With 
respect to WT mice, these results contradict a previous study by Gnerre et al. (2005) 
who observed elevated hepatic Cyp7a1 mRNA levels in C57BL/6 mice fed a chow 
diet that was supplemented with 2% cholesterol (Gnerre et al., 2005). However, it is 
important to point out that the WD used in this study contained only 0.2% cholesterol 
(a more physiologically relevant level), which was substantially lower than the diet 
used by Gnerre and coworkers. It is possible that the WD used in this study results in 
cholesterol excess that is enough to decrease cholesterol biosynthesis as demonstrated 
by reduced hepatic Hmgcr and Hmgcs mRNA on WD-fed mice, but not high enough 
to increase bile acid synthesis. Also, gender-related effects on bile acid synthesis in 
various species are well-documented. For example, CYP7A1 activity is higher in 
females in both rats and mice (Gielen et al., 1976; Schwarz et al., 2001).  
 
In addition to the regulation of bile acid synthesis, LXR also regulates cholesterol 
excretion from hepatocytes into the bile, and this depends on the ability of LXR to 
activate hepatic Abcg5 and Abcg8 transcription, thereby promoting cholesterol 
excretion into bile (Repa et al., 2002; Yu et al., 2002). Consistent with these studies, 
and with the observed LXRα upregulation in WD-fed LOE mice in the current study, 
hepatic Abcg5 and Abcg8 mRNA levels were elevated in WD-fed LOE mice, 
suggesting increased hepatobiliary cholesterol secretion in these mice on a 
cholesterol-rich diet. These findings corroborate results from chow-fed, 6-8 week old 
LOE mice (Chapter 3).  
 
Apoe is another gene directly regulated by LXR that is involved in RCT, and therefore 
important for cholesterol homeostasis. No genotype effects were observed on hepatic 
Apoe mRNA levels in this study. Nevertheless, this does not exclude that induction of 
LXRα in LOE mice may activate expression of Apoe in macrophages and adipose 
tissue, as previous reports have highlighted tissue-specific regulation of Apoe by LXR 
(Laffitte et al., 2001; Beyea et al., 2006).  
 
Previously, feeding a chow diet supplemented with 2% cholesterol to mice has shown 
to upregulate hepatic Apoe expression (Peet et al., 1998). However, in the current 
study, WD-fed HSD1 KO mice showed reduced hepatic Apoe mRNA levels 




compared to chow-fed HSD1 KO mice. Although in macrophages, ApoE is known to 
facilitate RCT (Zhang et al., 1996; Hara et al., 2003), in hepatocytes, ApoE enhances 
the production of VLDL particles (Tsukamoto et al., 2000). Increased hepatic VLDL 
production leads to accumulation of atherogenic lipoproteins and TG levels in the 
circulation, and is a common characteristic of hyperlipidaemia as well as type 2 
diabetes (Huang et al., 1998; Tsukamoto et al., 2000; Kurano et al., 2011). HSD1 KO 
mice (chow-fed) have previously been shown to display reduced plasma TG levels 
compared to WT mice (Morton et al., 2001). Decreased hepatic Apoe mRNA levels in 
WD-fed HSD1 KO mice in this study may aid in keeping total lipid and lipoprotein 
levels in check.  
 
It is worth noting that there are slight discrepancies between the gene expression data 
from 6-8 week old chow-fed WT/LOE mice in Chapter 3 and 5-6 week old chow-fed 
WT/LOE mice in this experiment. Chow-fed LOE mice in this study revealed reduced 
hepatic Srebp2 mRNA levels compared to chow-fed WT mice although no such 
difference was observed in Chapter 3. Also, in this experiment, chow-fed LOE mice 
revealed a trend (although insignificant) for decreased hepatic Cyp7a1 mRNA levels 
compared to chow-fed WT mice, whereas there were clearly no differences in hepatic 
Cyp7a1 mRNA levels between chow-fed WT and LOE mice in Chapter 3. The 
reasons for these inconsistencies are unclear, but factors such as carrying out these 
studies at different times or on mice of different age might contribute to the above-
mentioned discrepancies. 
 
This study has several limitations and future work should address these issues; for 
instance, total cholesterol levels and cholesterol distribution profiles were not 
investigated, and protein/enzyme activity levels for HMGCR and HMGCS were not 
measured. It is fascinating that chow-fed HSD1 KO mice showed increased body 
weight gain compared to chow-fed WT mice. Food intake per mouse was not 
measured and mice were housed in groups of 5-6 per cage, making it impossible to 
assess the amount of diet consumed by each mouse. Furthermore, this study cannot 
fully distinguish whether the effects observed are dependent on metabolism of GCs or 
of oxysterols by 11β-HSD1 and requires further investigation in adrenalectomised 
mouse models (which have endogenous GCs removed). Also, liver and plasma 




samples of the mouse models in this dietary study were sent to Professor William 
Griffith’s laboratory (Swansea University) for determination of oxysterol levels, but 
the results were not returned in time for inclusion in this thesis.  
 
In summary, the data in this chapter do not support a role for hepatic 11β-HSD1 in de 
novo cholesterol synthesis, and therefore, stand contrary to the hypothesis. LOE mice 
appear to ‘sense’ intracellular cholesterol excess and respond to it by activation of 
hepatobiliary cholesterol excretion demonstrated by increased hepatic Abcg5 and 
Abcg8 expression in WD-LOE mice. This may be mediated through increased hepatic 
Lxrα expression in these mice. Taken together, these results suggest a role for 


















Chapter	  5.	  	  Generation	  and	  Characterisation	  

























As described in Chapters 1, 3 and 4, studies carried out in globally Hsd11b1 deficient 
mice have shown that 11β-HSD1 deficiency improves metabolic outcome in obesity 
and is atheroprotective (Kotelevtsev et al., 1997; Morton et al., 2001; Morton et al., 
2004; Hermanowski-Vosatka et al., 2005; Wamil et al., 2011; Kipari et al., 2013; see 
1.4.1). Given the wide range of 11β-HSD1 expression (Tannin et al., 1991; 
Whorwood et al., 1993; Rajan et al., 1995; Tomlinson et al., 2004), the contribution 
of different tissues to the improved metabolic outcome and atheroprotection observed 
with global deficiency of 11β-HSD1 remains unknown. However, liver is the major 
site of 11β-HSD1 expression (Agarwal et al., 1989; Tannin et al., 1991; Rajan et al., 
1995; Tomlinson et al., 2004). Furthermore, at the start of this PhD study, the 
hypothesis (see 1.9 and 3.1) predicted that elevated hepatic 7-KC and decreased 
mature SREBP-2 levels would result from knockout of hepatocyte 11β-HSD1, 
suggesting decreased hepatic cholesterol synthesis. Findings from the previous 
chapter (Chapter 4, see Figure 4.7A) support this as chow-fed HSD1 KO mice 
showed reduced hepatic Hmgcr mRNA levels compared to WT mice on the same 
diet.  
 
Unlike the model for hepatic overexpression of 11β-HSD1 (LOE mice), there was no 
existing in vivo model for hepatic 11β-HSD1 deficiency when this study commenced. 
To determine the effect(s) of hepatic 11β-HSD1 deficiency on cholesterol 
homeostasis as well as assess the importance of hepatic 11β-HSD1 in metabolic 
syndrome, a Cre-loxP genetic approach was employed to generate a mouse model of 
11β-HSD1 deficiency specifically within the liver by using albumin (Alb) promoter-
driven Cre recombination. 
 
Albumin (encoded by Alb) is a soluble, monomeric protein that comprises about one-
half of the blood serum protein (Gosling, 1995), and its synthesis is restricted to the 
liver (Miller et al., 1951; Lundsgaard-Hansen, 1986). Alb-Cre mice have been useful 
in studies involving Cre-dependent excision of loxP-flanked (“floxed”) sequences in 
adult hepatocytes (Postic et al., 1999). Moreover, Alb-Cre transgenic mice have been 
shown to achieve liver-specific deletions with extremely high efficiency of 




recombination (90% - 100%) (Gu et al., 2003; Fan et al., 2009). Breeding of Alb-Cre 
mice with in-house Hsd11b1flox/flox mice, which have exon 3 of the Hsd11b1 gene 
flanked by loxP sites, should generate liver-specific 11β-HSD1 knockout mice. This 





























5.2.	  Hypothesis	  and	  Aims 
 
Hypothesis: Liver 11β-HSD1 deficiency reduces hepatic cholesterol synthesis via 





1) To generate mice with liver-specific Hsd11b1 deletion (LKO mice). 
 
2) To determine if LKO mice have Hsd11b1 deleted specifically only in their livers. 
 
3) To characterise the effects of liver 11β-HSD1 deficiency on metabolic parameters 
such as body weight, tissue weights, and expression of genes involved in cholesterol 




























5.3.1.	  Reduced	  Hsd11b1	  mRNA	  levels	  as	  well	  as	  decreased	  11β-­‐HSD1	  protein	  and	  
enzyme	  activity	  levels	  in	  livers	  of	  LKO	  mice	  	  
	  
Previously, a conditional Hsd11b1 allele was generated by flanking exon 3 with loxP 
sites, and from this global 11β-HSD1 deficient mice were derived (unpublished). To 
generate liver-specific 11β-HSD1 knockout (LKO) mice, floxed homozygous 
Hsd11b1 mice (Hsd11b1flox/flox) on a C57BL/6 background were crossed with Alb-Cre 
transgenic mice (see 2.2.1 for further details), also on a C57BL/6 background, 
targeting Cre expression to hepatocytes (Postic et al., 1999). This generated mice with 
liver-specific deletion of Hsd11b1. As expected, the line of LKO mice was 
indistinguishable from floxed Hsd11b1 controls with respect to fertility, gestation 
length and sex ratio.  
 
To determine whether Hsd11b1 mRNA levels are reduced/knocked out, as predicted, 
in livers of LKO mice, total RNA was extracted from frozen liver tissue of chow-fed, 
male 10-week-old LKO and their littermate control floxed mice. Hepatic Hsd11b1 
mRNA levels were measured via qPCR. To establish whether the predicted reduction 
in hepatic Hsd11b1 mRNA levels is associated with decreased 11β-HSD1 protein 
levels as well as reduced 11β-HSD1 enzyme activity in liver, western blot analyses 
and enzyme activity assays were conducted, respectively.  
 
Compared to littermate control floxed Hsd11b1 mice, LKO mice showed undetectable 
hepatic Hsd11bl mRNA levels (Figure 5.1) with hepatic 11β-HSD1 protein levels 
being similarly negligible (Figure 5.2). Hepatic 11β-HSD1 enzyme activity was 
measured using TLC as well as HPLC. In the TLC experiment, 11β-HSD1 enzyme 
activity was reduced by ~80% in livers of LKO mice compared with livers of control 
mice (n=5/group; Figure 5.3). In the HPLC experiment, 11β-HSD1 enzyme activity 
was decreased by 88% in livers of LKO mice compared with those of control mice 


















































Figure	   5.1:	   Levels	   of	   hepatic	   Hsd11b1	   mRNA	   are	   undetectable	   in	   LKO	   mice	  
compared	  to	  their	  wild-­‐type	  littermates.	  
Total RNA was extracted from livers of male chow-fed, 10 week old liver 11β-HSD1 
knockout (LKO) mice and their floxed Hsd11b1 littermates (Control). Hsd11b1 
mRNA levels were measured by qPCR and are expressed relative to Hprt mRNA 
levels, used as an internal control. Data are means ± SEM and were analysed by 




























































Figure	  5.2:	  Hepatic	  11β-­‐HSD1	  protein	  levels	  are	  negligible	  in	  LKO	  mice	  compared	  to	  
their	  wild-­‐type	  littermates.	  
Western blotting was used to examine 11β-HSD1 protein levels in liver samples from 
male, chow-fed, 10 week old liver-specific 11β-HSD1 knockout (LKO) mice and 
their floxed Hsd11bl littermates (Control). (A) Image of a representative western blot. 
Each lane contains 25µg protein from one mouse, appropriately labelled. β-tubulin 
was used as a loading control. (B) Density of bands in Figure 5.2A were quantified 
and plotted into a graph. Data are means ± SEM and were analysed by unpaired t-test 
(two-tailed); n=6-8/group; *** p<0.0001. 
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Figure	  5.3:	  11β-­‐HSD1	  enzyme	  activity	  is	  markedly	  reduced	  in	  livers	  of	  LKO	  mice.	  
(A) Image of the phosphorimager tritium image screen showing conversion of 
corticosterone (B) to 11-dehydrocorticosterone (A) in liver samples from male, chow-
fed, 10 week old liver-specific 11β-HSD1 knockout (LKO) mice and their floxed 
Hsd11b1 littermates (Control). Each lane represents one mouse, appropriately labeled. 
Steroids were separated by thin-layer chromatography in this experiment. (B) Density 
of bands in Figure 5.3A were quantified and plotted into a graph. Data are means ± 
SEM and were analysed by unpaired t-test (two-tailed); n=5/group; ** p<0.001. 
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Figure	  5.4:	  11β-­‐HSD1	  enzyme	  activity	  is	  significantly	  reduced	  in	  livers	  of	  LKO	  mice.	  
A second 11β-HSD1 enzyme activity assay was carried out where steroids were 
separated by high-performance liquid chromatography (HPLC). Conversion of 
corticosterone (B) to 11-dehydrocorticosterone (A) was measured in liver samples 
from male, chow-fed, 10 week old liver-specific 11β-HSD1 knockout (LKO) mice 
and their floxed Hsd11b1 littermates (Control). Data are means ± SEM and were 









































5.3.2.	  Similar	  11β-­‐HSD1	  protein	  levels	  in	  epididymal	  fat,	  kidney	  and	  muscle	  of	  LKO	  
and	  control	  mice	  
	  
To confirm that 11β-HSD1 deletion is specific to the liver and had not occurred in 
other tissues (which normally express 11β-HSD1 in mice), western blot analyses were 
carried out to measure 11β-HSD1 protein levels in left sided epididymal fat, kidney 
and (quadriceps) muscle of chow-fed, male 10-week-old LKO and their littermate 
control floxed mice. As expected, there were no differences in 11β-HSD1 protein 
levels between LKO and control mice in any of the extrahepatic tissues examined: 
epididymal fat (Figure 5.5), kidney (Figure 5.6) and muscle (Figure 5.7).  
 
It is interesting that western blot analysis in muscle showed two 11β-HSD1 protein 
bands, at approximately 50kDa and 51kDa (Figure 5.7), unlike the usual 34kDa band 
observed in liver, adipose tissue and kidney (Figures 5.2, 5.5 and 5.6). In previous 
‘test’ western blot analyses, with fewer muscle samples, positive (liver from LOE 
mouse) and negative (liver from HSD1 KO mouse) controls were included to ensure 
that the antibody used recognises the targeted protein (11β-HSD1). Some studies have 
previously reported the presence of two (or more) 11β-HSD1 protein bands in western 
blot analyses (Maser et al., 2002), including a 50kDa band (Kannisto et al., 2004; 
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Figure	  5.5:	  11β-­‐HSD1	  protein	  is	  normally	  expressed	  in	  epididymal	  fat	  of	  LKO	  mice.	  	  
Western blotting was used to measure 11β-HSD1 protein levels in epididymal fat 
tissue from male, chow-fed, 10 week old floxed Hsd11b1 (Control) and liver 11β-
HSD1 knockout (LKO) mice.  (A) Image of a representative western blot. Each lane 
contains 40µg protein from one mouse. β-tubulin was used as a loading control. (B) 
Density of bands in Figure 5.5A were quantified and plotted into a graph. Values are 






































































Figure	  5.6:	   Similar	   levels	  of	   11β-­‐HSD1	  protein	  are	  present	   in	   kidneys	  of	   LKO	  and	  
control	  mice.	  	  
Western blotting was used to measure 11β-HSD1 protein levels (red) in kidneys of 
chow-fed, male, 10 week old Hsd11b1 (Control) and liver 11β-HSD1 knockout 
(LKO) mice. (A) Image of a representative western blot. Each lane contains 40µg 
protein from one mouse. β-tubulin (in green) was used as a loading control. (B) 
Density of bands in Figure 5.6A were quantified and plotted into a graph. Values are 
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Figure	  5.7:	  11β-­‐HSD1	  protein	  is	  normally	  expressed	  in	  muscle	  in	  LKO	  mice.	  	  
Western blotting was used to examine 11β-HSD1 protein levels (red) in muscle of 
chow-fed, male, 10 week old floxed Hsd11b1 (Control) and liver 11β-HSD1 
knockout (LKO) mice. The left lane contains a protein ladder (some of the band sizes 
indicated). Next to the ladder are muscle protein samples from control and LKO mice, 
labelled appropriately. (A) Image of a representative western blot. Each lane contains 
40µg protein from one mouse. β-tubulin (in green) was used as a loading control. (B) 
Density of bands in Figure 5.7A were quantified and plotted into a graph. Values are 
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5.3.3.	  Similar	  body	  weight	  and	  tissue	  weights	  between	  LKO	  and	  control	  mice	  
 
There was no difference in body weight between LKO and control mice (Figure 5.8). 
Tissue weight was recorded and normalised against body weight. As expected, there 
were no differences in tissue to body weight ratios between LKO and control mice in 
any of the tissues examined: liver (Figure 5.9A), epididymal fat (Figure 5.9B), kidney 
(Figure 5.9C), muscle (Figure 5.9D), or brain (Figure 5.9F).  
 
Global 11β-HSD1 deficiency is known to stimulate the HPA axis. Previously, global 
11β-HSD1 knockout mice showed increased adrenal weight compared to control mice 
(Kotelevtsev et al., 1997). Furthermore, hepatic GC regeneration has been implicated 
in the modulation of HPA axis sensitivity (Paterson et al., 2007), and consistent with 
this, Lavery et al. (2012) reported increased adrenal weight in their liver-specific 11β-
HSD1 knockout mice (Lavery et al., 2012). However, in the current study, there were 














































Figure	  5.8:	  Similar	  body	  weight	  between	  LKO	  and	  control	  mice.	  
Chow-fed, 10 week old male, liver-specific 11β-HSD1 knockout (LKO) mice and 
their floxed Hsd11b1 littermates (Control) had their body weights measured. Values 













Figure	  5.9:	  Similar	  tissue	  weights	  between	  LKO	  and	  control	  mice.	  
Tissues from male, chow-fed, 10 week old liver-specific 11β-HSD1 knockout (LKO) 
mice and their floxed Hsd11b1 littermates (Control) were harvested and weighed. 
Weights of (A) liver, (B) epididymal fat, (C) kidney, (D) muscle, and (F) brain are 
expressed as percentage (%) of body weight. Adrenal weight (E) is shown in 





















































































































































5.3.4.	  Similar	  levels	  of	  hepatic	  Srebp2,	  Hmgcr	  and	  Hmgcs	  mRNA	  between	  LKO	  and	  
control	  mice 
	  
Based on the original hypothesis, it was predicted that hepatic 11β-HSD1 deficiency 
would lead to decreased cholesterol synthesis (see 1.9). To test this, mRNAs encoding 
SREBP-2 and its target genes in the cholesterol biosynthetic pathway, such as 
HMGCR and HMGCS, were measured in livers from male, chow-fed 10 week old 
LKO mice and their floxed Hsd11b1 littermate controls. Contradictory to predictions, 
there were no differences in the hepatic levels of Srebp2 (Figure 5.10), Hmgcr (Figure 
5.11A) or Hmgcs (Figure 5.11B) mRNA between genotypes, suggesting no change in 
























































Figure	  5.10:	  Similar	  hepatic	  Srebp2	  mRNA	  levels	  in	  LKO	  and	  control	  mice.	  
Total RNA was extracted from livers of male, chow-fed, 10 week old liver-specific 
11β-HSD1 knockout (LKO) mice and floxed Hsd11b1 littermates (Control). Srebp2 
mRNA levels were measured by qPCR and are expressed relative to Hprt mRNA 
levels, used as an internal control. Values are means ± SEM and were analysed by 




















































































Figure	  5.11:	  Levels	  of	  hepatic	  Hmgcr	  and	  Hmgcs	  mRNA	  do	  not	  differ	  between	  LKO	  
and	  control	  mice.	  
Total RNA was extracted from liver of male chow-fed, 10 week old floxed Hsd11b1 
(Control) and liver-specific 11β-HSD1 knockout (LKO) mice. Messenger RNA levels 
were measured by qPCR. (A) Hmgcr and (B) Hmgcs mRNA levels are expressed 
relative to Hprt mRNA. Values are means ± SEM and were analysed by unpaired t-








5.3.5.	   Similar	   mRNA	   levels	   of	   hepatic	   Lxrα ,	   as	   well	   as	   its	   target	   genes	   Cyp7a1,	  
Abcg5	  and	  Abcg8	  between	  LKO	  and	  control	  mice 
	  
As previously discussed, LXRα plays a vital role in cholesterol homeostasis. Its 
activation is proportional to cellular cholesterol levels and leads to upregulation of 
genes that are involved in cholesterol catabolism (Cyp7a1) and cholesterol excretion 
(Abcg5 and Abcg8) (Lehmann et al., 1997; Repa et al., 2002; Hong et al., 2012; see 
1.5.5 and 3.3.4). LOE mice (both chow-fed and WD-fed) showed increased levels of 
hepatic Lxrα mRNA as well as elevated levels of hepatic Abcg5 and Abcg8 mRNA. 
To examine whether hepatic deficiency of 11β-HSD1 led to the opposite, Lxrα, 
Abcg5 and Abcg8 mRNAs were measured in livers of male, chow-fed, 10 week old 
LKO mice and their control littermates. Hepatic Cyp7a1 mRNA levels were also 
measured in these mice to determine whether cholesterol catabolism via bile acid 
synthesis was altered with liver 11β-HSD1 deficiency.  
 
Unlike LOE mice, LKO mice did not show any differences in the hepatic levels of 
Lxrα (Figure 5.12), Abcg5 (Figure 5.14A) or Abcg8 (Figure 5.14B) mRNAs. Similar 
to findings in LOE mice, there was no difference in hepatic Cyp7a1 mRNA 

















































Figure	  5.12:	  Similar	  hepatic	  Lxrα 	  mRNA	  levels	  in	  LKO	  and	  control	  mice.	  
Total RNA was extracted from livers of male, chow-fed, 10 week old liver-specific 
11β-HSD1 knockout (LKO) mice and their floxed Hsd11b1 littermates (Control). 
Lxrα mRNA levels were measured by qPCR and are expressed relative to Hprt 
mRNA levels, used as an internal control. Data are means ± SEM and were analysed 



















































Figure	  5.13:	  Similar	  hepatic	  Cyp7a1	  mRNA	  levels	  in	  LKO	  and	  control	  mice.	  
Total RNA was extracted from livers of male chow-fed, 10 week old liver-specific 
11β-HSD1 knockout (LKO) mice and their floxed Hsd11b1 littermates (Control). 
Cyp7a1 mRNA levels were measured by qPCR and are expressed relative to Hprt 
mRNA levels, used as an internal control. Values are means ± SEM and were 




















































































Figure	  5.14:	  Levels	  of	  hepatic	  Abcg5	  and	  Abcg8	  mRNA	  do	  not	  differ	  between	  LKO	  
and	  control	  mice.	  
Total RNA was extracted from livers of male, chow-fed, 10 week old floxed Hsd11b1 
(Control) and liver-specific 11β-HSD1 knockout (LKO) mice. Messenger RNA levels 
were measured by qPCR. (A) Abcg5 and (B) Abcg8 mRNA levels are expressed 
relative to Hprt mRNA. Data are means ± SEM and were analysed by unpaired t-test 
(two-tailed); n=10-11/group.  
A 
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5.3.6.	  Similar	  levels	  of	  hepatic	  ApoA1	  mRNA	  between	  LKO	  and	  control	  mice 
	  
Apolipoprotein A1 mRNA, which encodes the major component of the HDL particle 
(Barter and Rye, 1996; see 4.3.11), has been previously shown to be elevated in livers 
of global 11β-HSD1 deficient mice, associated with increased serum ApoA1 levels 
and HDL cholesterol (Morton et al., 2001). To investigate whether hepatic 11β-HSD1 
deficiency leads to increased ApoA1 expression, ApoA1 mRNA levels were measured 
in livers of male, chow-fed, 10 week old LKO mice and their floxed Hsd11b1 
littermate controls. However, unlike global 11β-HSD1 knockout mice, there was no 
difference in the hepatic levels of ApoA1 mRNA between LKO and control mice 























































Figure	  5.15:	  Similar	  hepatic	  ApoA1	  mRNA	  levels	  LKO	  and	  control	  mice.	  
Total RNA was extracted from livers of male, chow-fed, 10 week old liver-specific 
11β-HSD1 knockout (LKO) mice and their floxed Hsd11b1 littermates (Control). 
ApoA1 mRNA levels were measured by qPCR and are expressed relative to Hprt 
mRNA levels, used as an internal control. Values are means ± SEM and were 














The line of liver-specific 11β-HSD1 deficient mice generated here display efficient 
Cre-mediated Hsd11b1 recombination in liver. This is reflected in an almost 100% 
reduction in hepatic Hsd11b1 mRNA and 11β-HSD1 protein levels in LKO mice 
compared with livers of their Cre- littermate controls. Hepatic 11β-HSD1 enzyme 
activity was measured using two methods; TLC and HPLC. Results from the TLC 
experiment (n=5/group) revealed ~80% reduction in 11β-HSD1 enzyme activity in 
livers of LKO mice when compared to livers from control mice. While all LKO mice 
showed no hepatic 11β-HSD1 enzyme activity, there was a small amount of activity 
in the liver homogenate from one LKO mouse (Figure 5.3A). To confirm these 
results, hepatic 11β-HSD1 enzyme activity was also measured using HPLC. This 
experiment was carried out using the samples that were included in the TLC 
experiment together with liver samples from additional LKO mouse and control 
mouse belonging to a separate cohort (n=6/group). Results from this experiment also 
revealed no hepatic 11β-HSD1 enzyme activity in all the LKO samples except for the 
one that displayed a small amount of activity in the TLC experiment. It is possible 
that Cre excision is not 100% in some mice but it would be worth re-genotyping this 
particular sample to confirm its identity. 
 
There were no differences in 11β-HSD1 protein levels in epididymal fat, muscle or 
kidney between LKO and control mice. Along with the above-mentioned data, this 
suggests that LKO mice have a liver-specific knockout of 11β-HSD1.  
 
LKO mice were generated primarily to examine the effect of hepatic 11β-HSD1 
knockdown on metabolic parameters including body weight, tissue weights and 
expression of genes involved in cholesterol homeostasis. There was no effect of 
hepatic 11β-HSD1 deficiency upon body weight, liver weight or adiposity. 
Unexpectedly, no difference was observed in the adrenal weights between LKO and 
control mice. Global knockdown of 11β-HSD1 is known to stimulate the HPA axis. 
In a previous study, global 11β-HSD1 deficient mice displayed increased adrenal 
weight compared to control mice (Kotelevtsev et al., 1997). This HPA axis 




dysfunction was rescued when global 11β-HSD1 deficient mice were crossed with 
liver-specific 11β-HSD1 overexpressor (LOE) mice (Paterson et al., 2007), 
suggesting that hepatic glucocorticoid regeneration regulates HPA axis sensitivity. 
When generation of mice with liver-specific deletion of Hsd11b1 commenced in our 
lab, there were no reports on a liver-specific 11β-HSD1 knockout mouse model. 
However, recently, investigators from other labs have published their work on liver-
specific 11β-HSD1 deficiency. A study by Lavery et al. (2012) that generated liver-
specific 11β-HSD1 deficient mice (on a mixed C57BL/6/129SvJ background) 
reported significantly increased adrenal weight in their liver 11β-HSD1 knockout 
mice (Lavery et al., 2012). Although 11β-HSD1 deficiency on a C57BL/6 
background results in a less dramatic adrenal weight increase compared to 11β-HSD1 
deficiency on a 129 background (Carter et al., 2009), both C57BL/6 and 129SvJ 
strains reveal adrenal hypertrophy with disruption of 11β-HSD1 (Kotelevtsev et al., 
1997; Carter et al., 2009) and, therefore, it is unlikely that background is the reason 
behind the lack of effect on adrenal gland weight in my line of LKO mice. The in-
house Hsd11b1flox/flox mice that were used as controls in the present study may display 
some reduction in 11β-HSD1 activity and could be a possible reason for the unaltered 
adrenal weight in LKO mice.  
 
Although predicted to decrease in LKO mice, no difference was observed in the 
hepatic expression of Srebp2, Hmgcr and Hmgcs mRNA levels between LKO and 
control mice, suggesting that cholesterol synthesis is not altered with the removal of 
hepatic 11β-HSD1. However, with hindsight, this is probably not surprising, as data 
from LOE mice do not reveal increased hepatic Hmgcr and Hmgcs mRNA expression 
as hypothesised.  
 
As LOE mice displayed elevated hepatic Lxrα mRNA levels, removal of hepatic 11β-
HSD1 was predicted to result in decreased Lxrα mRNA expression. However, there 
was no difference in hepatic Lxrα mRNA levels between LKO mice and their Cre- 
littermates. Furthermore, no differences were observed in hepatic Abcg5 and Abcg8 
mRNA levels between genotypes. This is inconsistent with a recent study that 
reported reduced hepatic Abcg5 and Abcg8 mRNA levels following antisense 
oligonucleotide knock down of 11β-HSD1 in livers of C57Bl/6 mice (Li et al., 2011). 




However, the study carried out by Li et al. (2011) used a Western-type diet with a 
high content of fat and cholesterol as opposed to the chow diet used in the present 
study. Moreover, it is also worth noting that the antisense oligonucleotide did not 
simply knock down 11β-HSD1 in liver but also down-regulated 11β-HSD1 in most 
adipose tissue depots (Li et al., 2011), in effect making their model a knockout for 
adipose tissue as well as liver 11β-HSD1.  
 
In conclusion, liver-specific 11β-HSD1 deficiency is achieved in LKO mice. There is, 
however, no evidence that hepatic 11β-HSD1 deficiency alters cholesterol 
homeostasis, at least with chow diet feeding. This is demonstrated by normal levels of 
mRNAs encoding hepatic cholesterol biosynthetic enzymes as well as those encoding 
enzymes/transporters for cholesterol catabolism/excretion in LKO mice. These data 
also indicate that the suggested role for hepatic 11β-HSD1 in hepatobiliary 


















Chapter	  6.	  	  Effect	  of	  Hepatic	  11β-­‐HSD1	  
Deficiency	  combined	  with	  High	  Fat	  Feeding	  


















Although results in Chapters 3-5 do not indicate a role for hepatic 11β-HSD1 in 
cholesterol biosynthesis, levels of hepatic Abcg5 and Abcg8 mRNA (LXRα targets) 
were significantly increased with liver-specific 11β-HSD1 overexpression, both on 
standard chow diet as well as Western-style diet. These data suggest that liver 11β-
HSD1 overexpression promotes hepatobiliary cholesterol efflux, consistent with a 
role for hepatic 11β-HSD1 in cholesterol homeostasis. Although no differences were 
observed in hepatic Lxrα, Abcg5 and Abc8 mRNA levels between chow-fed LKO 
mice and controls (Chapter 5), it is possible that diet is an influential factor, or that 
11β-HSD1 action in another tissue (e.g. adipose, macrophages) compensated for 
hepatocytes in this model.  
 
11β-HSD1 is most abundantly expressed in the liver, and data from the original study 
on global 11β-HSD1 knockout mice highlighted liver as an important site for 11β-
HSD1 effects on glucose homeostasis and type 2 diabetes (Chapter 1, see 1.4.1). 
Several rodent studies have demonstrated the potential of selective 11β-HSD1 
inhibitors to treat the components of metabolic syndrome as well as atherosclerosis 
(see 3.1), and some human clinical data have shown 11β-HSD1 inhibition to reduce 
weight and blood glucose levels in patients with type 2 diabetes poorly controlled by 
metformin therapy (Rosenstock et al., 2010). However, it is important to understand 
the specific sites and mechanisms of action involved, to improve therapy for type 2 
diabetes, dyslipidaemia, obesity and atherosclerosis.  
 
To examine the in vivo effects of hepatic 11β-HSD1 deficiency and dietary risk 
factors upon hepatic cholesterol homeostasis as well as other metabolic parameters, a 
HF diet experiment was carried out with liver-specific 11β-HSD1 deficient (LKO) 
mice. Previous studies from our lab revealed that 11β-HSD1 knockout mice resist 
hyperglycaemia on HF diet, display increased insulin sensitivity in liver and adipose 
tissue, and have decreased visceral fat upon HF feeding (see 1.4.1). To investigate if 
this was due to liver 11β-HSD1, LKO mice were fed HF diet in this experiment (see 
6.2). There are no published data from our lab on WD-fed 11β-HSD1 knockout mice, 




except on Apoe-/- background, and because LKO mice were not on the Apoe-/- 
background, a Western diet experiment was not carried out on them.  
 
Male, 8-10 week old LKO mice, floxed Hsd11b1 mice (Control), complete global 
11β-HSD1 deficient (Del), and ‘old’ hypomorphic 11β-HSD1 knockout (HSD1 KO) 
mice were fed HF diet for 14 weeks. Body weights were measured weekly. A glucose 
tolerance test (GTT) was carried out in week 13 before the mice were culled for tissue 
collection in week 14. This study was part of a larger experiment that also included 
other in-house generated tissue-specific 11β-HSD1 knockout mice (adipose-specific 
and macrophage-specific knockout models) on the HF diet.  
 
The ‘old’ line of 11β-HSD1 knockout mice (referred to as HSD1 KO) is 
hypomorphic, showing partial 11β-HSD1 activity in some tissues, notably lung, 
where most of the 11β-HSD1 is expressed in fibroblasts (Coutinho, 2009; Yang, 
2010). Recently, mice with complete loss of Hsd11b1 were generated in our lab by 
germline deletion of “floxed” Hsd11b1. The complete 11β-HSD1 knockout line 
(referred to as Del here) carry the identical deletion of exon 3 of Hsd11b1 to LKO 

















6.2.	  Hypothesis	  and	  Aims	  
 
At the stage when this PhD project started, the following hypothesis was proposed.  
 
Hypothesis: Liver 11β-HSD1 deficiency, combined with HF feeding, will reduce 
hepatic cholesterol synthesis via reduced hepatic expression of genes encoding 
cholesterol biosynthetic enzymes.  
 
In the light of data from Chapters 3, 4 and 5, with hindsight, it now appears that this 
might not be the case. Nevertheless, in keeping with investigation of the role of 
hepatic 11β-HSD1 in cholesterol homeostasis (evidence for increased hepatobiliary 
cholesterol secretion with hepatic 11β-HSD1 overexpression; Chapters 3 and 4), the 
following work was started at the same time as that carried out in Chapter 5. The 
original aims are listed below. 
 
In addition, this HF diet experiment was carried out with various tissue-specific (liver, 
adipose and macrophage) 11β-HSD1 knockout lines to examine the locus for the 
beneficial metabolic effects of global 11β-HSD1 deficiency. Given that liver seems to 
be the target tissue for anti-diabetic effects of 11β-HSD1 deficiency as well as one of 
the major sites for lipid and cholesterol metabolism, it was hypothesised that liver-
specific 11β-HSD1 deficiency will partly or fully account for the protective metabolic 




1) To investigate the effects of liver 11β-HSD1 deficiency combined with HF feeding 
on metabolic parameters such as body weight gain, liver and adipose tissue weights, 
and glucose homeostasis.  
 
2) To determine if liver-specific 11β-HSD1 deficiency, upon HF feeding, leads to 
altered hepatic expression of mRNAs encoding SREBP-2 and its target cholesterol 
biosynthetic enzymes. 
 




3) To test whether hepatic 11β-HSD1 deficiency combined with HF feeding leads to 
decreased hepatic levels of mRNAs encoding LXRα and its downstream targets 































6.3.1.	   Decreased	   adipose	   tissue	   weight	   in	   HF-­‐fed	   LKO	  mice	   compared	   to	   HF-­‐fed	  
controls	  
	  
LKO mice showed no difference in body weight gain compared with control Hsd11b1 
floxed mice during the entire 14-week duration of the HF diet (Figure 6.1). In 
contrast, Del and HSD1 KO mice showed reduced weight gain compared to control 
mice towards the end of this experimental study; in Del mice this was significant from 
week 11 until the final week (14) of diet, and for HSD1 KO mice, at weeks 13 and 14 
of the study (Figure 6.1).  
 
Tissue weights were recorded and normalised against body weights. There were no 
differences in tissue to body weight ratios between genotypes in either liver (Figure 
6.2A) or adrenal gland (Figure 6.2B). However, intriguingly, HF-fed LKO mice 
showed significantly reduced weights for subcutaneous fat (Figure 6.2D) as well as 
for epididymal fat (Figure 6.2E) when compared with HF-fed control mice, and 
mesenteric fat showed a similar trend though this was not significant (Figure 6.2C).  
 
Previously, HF-fed HSD1 KO mice have shown a general reduction in fat mass gain 
(Morton et al., 2004; Wamil et al., 2011). Furthermore, reduced subcutaneous 
adipocyte hypertrophy was observed in HF-fed HSD1 KO mice compared to HF-fed 
C57BL/6 control mice (Wamil et al., 2011). To investigate if decreased adiposity in 
LKO mice was due to reduced hypertrophy in their adipose tissue, adipocyte sizes 
were measured in picrosirius red stained subcutaneous fat samples. There were no 
differences in the size of subcutaneous adipocytes between LKO and control mice (or 
HSD1 KO mice) (Figure 6.3), suggesting that the decrease in adipose tissue weight 
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Figure	  6.1:	   LKO	  mice	  do	  not	   show	   the	   reduction	   in	  body	  weight	  gain	   seen	   in	  Del	  
and	  HSD1	  KO	  mice	  with	  high	  fat	  diet	  feeding.	  
Body weight was monitored weekly in experimental mice during 14-week high fat 
diet feeding (from 8-10 weeks of age to 22-24 weeks of age). Red squares show liver-
specific 11β-HSD1 knockout (LKO) mice, blue triangles show complete global 11β-
HSD1 deficient (Del) mice, green triangles show ‘old’ hypomorphic 11β-HSD1 
knockout (HSD1 KO) mice, and black circles show floxed Hsd11b1 (Control) mice. 
Data are means ± SEM and were analysed by repeated measures two-way ANOVA 
with Bonferroni post test; n=7-16/group. Del mice had significantly reduced weight 
gain compared to control mice from week 11 to the end of the study (week 14; *** 
p<0.001). HSD1 KO mice had significantly decreased weight gain rate compared to 



































































































































































Figure	  6.2:	  Reduced	  adipose	  tissue	  weight	  in	  LKO	  mice	  compared	  to	  controls.	  
At the end of the 14-week high fat diet experiment, tissues were harvested from the 
mice- liver-specific 11β-HSD1 knockout (LKO), floxed Hsd11b1 (Control), ‘new’ 
complete global 11β-HSD1 deficient (Del), and ‘old’ hypomorphic 11β-HSD1 
knockout (HSD1 KO). Weights of (A) liver, (B) adrenal, (C) mesenteric fat, (D) 
subcutaneous fat and (E) epididymal fat of the mice are shown. All tissue weights 
(except adrenal) are expressed as % of body weight. Data are means ± SEM and were 
analysed by one-way ANOVA with Tukey’s multiple comparisons test; n=7-


















































Figure	   6.3:	   Similar	   adipocyte	   size	   in	   subcutaneous	   fat	   of	   LKO	  mice	   compared	   to	  
subcutaneous	  fat	  of	  control	  mice.	  
Picrosirius red staining was performed on sections of subcutaneous adipose tissue 
samples collected from liver-specific 11β-HSD1 knockout (LKO) mice, complete 
global 11β-HSD1 deficient (Del) mice, ‘old’ hypomorphic 11β-HSD1 knockout 
(HSD1 KO) and floxed Hsd11b1 (Control) mice that were fed high fat diet for 14 
weeks. Adipocyte sizes in the stained tissue sections were measured using ImageJ. 
Data are means ± SEM and were analysed by one-way ANOVA with Tukey’s 
multiple comparisons test; n=4-6/group. Quantification was performed by Oliver 












6.3.2.	   Opposing	   effects	   of	   null	   and	   hypomorphic	   alleles	   of	   Hsd11b1	   on	   adipose	  
tissue	  collagen	  content	  but	  no	  effect	  of	  liver	  11β-­‐HSD1	  deletion	  on	  adipose	  tissue	  
collagen	  
 
Michailidou et al. (2012) previously reported that HF-fed HSD1 KO mice exhibit 
reduced collagen deposition, a key feature of fibrosis (Iredale, 2007), in both 
subcutaneous and mesenteric fat depots compared to control mice (Michailidou et al., 
2012).  
 
Given the impact of liver-specific 11β-HSD1 deficiency on adipose tissue weight and 
to test the involvement of hepatic 11β-HSD1 in adipose tissue remodelling, collagen 
deposition was measured in picrosirius red stained subcutaneous fat sections. 
Quantification of the staining was carried out by Mr. Oliver Brown, an undergraduate 
project student; this was performed blinded to the group, and the work was checked 
by me. 
 
There was a strong trend for reduced collagen deposition in subcunatoeus fat of HF-
fed HSD1 KO mice compared to HF-fed controls though this did not achieve 
significance (Figure 6.4B). This may be because of low number of samples (therefore, 
a type II error). Nevertheless, there was a significant difference in collagen deposition 
between subcunatoeus fat depots of HF-fed Del and HSD1 KO mice; increased 
collagen deposition was observed in subcutaneous fat of HF-fed Del mice compared 
to HSD1 KO subcutaneous adipose tissue (Figure 6.4B), suggesting increased fibrosis 
in subcutaneous fat of HF-fed Del mice (at least) when compared with subcutaneous 
fat of HF-fed HSD1 KO mice. It is also worth noting that although Del mice appear to 
exhibit increased subcutaneous adipose collagen deposition compared to control mice 



































Figure	  6.4:	  Increased	  collagen	  content	  in	  subcutaneous	  fat	  of	  Del	  mice	  compared	  to	  
HSD1	  KO	  subcutaneous	  fat.	  
(A) Representative images of picrosirius red stained sections of subcutaneous adipose 
tissue samples from liver-specific 11β-HSD1 knockout (LKO), floxed Hsd11b1 
(Control), complete global 11β-HSD1 deficient (Del) and ‘old’ hypomorphic 11β-
HSD1 knockout (HSD1 KO) mice, which were high fat-fed for 14 weeks from 8-10 
weeks of age. (B) Collagen staining in the tissue sections was quantified using 
ImageJ. Data are means ± SEM and were analysed by one-way ANOVA with 
Tukey’s multiple comparisons test; n=4-8/group. Quantification of collagen staining 
was performed by Oliver Brown, an undergraduate student. 
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6.3.3.	   Increased	   circulating	   glucose	   levels	   during	   GTT	   in	   LKO	   mice	   compared	   to	  
HSD1	  KO	  mice	  
	  
Previous studies have shown that global HSD1 KO mice display improved glucose 
tolerance when fed HF diet and an attenuated gluconeogenic response to fasting 
compared to wild-type mice (Kotelevtsev et al., 1997; Morton et al., 2004; see 1.4.1). 
Also, pharmacological inhibition of 11β-HSD1 improves glycaemia and increases 
hepatic insulin sensitivity in both humans (Walker et al., 1995; Andrews et al., 2003; 
Rosenstock et al., 2010) and obese, insulin-resistant rodents (Alberts et al., 2002; 
Livingstone and Walker, 2003; see 1.4.1). 
 
Intraperitoneal glucose tolerance tests (GTT) were performed to assess whether liver-
specific 11β-HSD1 deficiency is protective against HF diet-induced hyperglycaemia. 
Blood glucose levels during the GTT were measured immediately using a glucose 
meter as well as in stored plasma samples with a glucose assay. The limited detection 
range of the glucose meter resulted in several “HI” readings without a numerical 
value. Because many data points exceeded the upper limit of the assay and were 
unusable, no statistical test was performed on the GTT glucose levels measured by the 
glucose meter and the data are not shown. Plasma glucose and insulin measurements 
were carried out by Dr. Sophie Turban, and appropriate statistical tests were 
performed to analyse these data.  
 
At 60 min after glucose injection, LKO mice showed a significant increase in glucose 
level compared to HSD1 KO mice at the same time point (Figure 6.5A). By 
comparing area under the curve, there was a trend for reduced glucose levels during 
GTT in HSD1 KO mice compared to control mice (Figure 6.5B) though it did not 
achieve significance. This might be because the sample size of HSD1 KO mice in this 
experiment is smaller than those for other genotypes, especially the controls. 
Nonetheless, in comparison with HSD1 KO mice, LKO mice displayed significantly 
elevated glucose levels during GTT (Figure 6.5B). 
 
There were no differences in fasting glucose levels between LKO and control mice 
(Figure 6.6). In contrast, both HSD1 KO and Del mice showed significant reduction 
in fasting glucose levels compared to control mice (Figure 6.6). It is worth noting that 




the fasting glucose levels observed in this study are quite high (Figure 6.6) (usual 
levels ranging between 4-7mM in mice (and humans)), suggesting these mice are 
highly insulin resistant.  
 
Plasma insulin levels during GTT showed no differences between genotypes, using 
two-way repeated measures ANOVA (Figure 6.7A) or by comparing area under the 



















































Figure	  6.5:	  Increased	  glucose	  levels	  during	  GTT	  in	  LKO	  mice	  compared	  to	  HSD1	  KO	  
mice.	  	  
Male, 8-10 week old liver-specific 11β-HSD1 knockout (LKO; red squares), Hsd11b1 
floxed (Control; black circles), complete global 11β-HSD1 deficient (Del; blue 
triangles), and ‘old’ hypomorphic 11β-HSD1 knockout (HSD1 KO; green triangles) 
mice were subject to 14-week high fat diet, with glucose tolerance testing (GTT) 
carried out in week 13 of the dietary experiment. Circulating glucose levels were 
measured by (A) a glucose assay in the plasma. Data were analysed using two-way 
repeated measures ANOVA with Bonferroni post test; n=6-19/group. (B) Area under 
curve (AUC) of plasma glucose levels during GTT between genotypes. Data were 
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Figure	  6.6:	  Reduced	   fasting	  glucose	   levels	   in	  Del	  and	  HSD1	  KO	  mice	  compared	  to	  
control	  mice.	  
During the experiment described in Figure 6.5 fasting glucose levels were measured 
in liver-specific 11β-HSD1 knockout (LKO), Hsd11b1 floxed (Control), complete 
global 11β-HSD1 deficient (Del), and ‘old’ hypomorphic 11β-HSD1 knockout 
(HSD1 KO) mice that underwent GTT. Data were analysed using one-way ANOVA 





























































Figure	  6.7:	  Similar	  plasma	  insulin	   levels	  during	  GTT	  in	  LKO,	  control,	  Del	  and	  HSD1	  
KO	  mice.	  
During the experiment described in Figure 6.5, (A) plasma insulin levels were 
measured in liver-specific 11β-HSD1 knockout (LKO), Hsd11b1 floxed (Control), 
complete global 11β-HSD1 deficient (Del), and hypomorphic 11β-HSD1 knockout 
(HSD1 KO) mice that underwent GTT. Data were analysed using two-way repeated 
measures ANOVA with Bonferroni posttest; n=7-19/group. (B) Area under curve 
(AUC) of insulin levels during GTT between genotypes. Data were analysed using 
one-way ANOVA with Tukey’s multiple comparisons test; n=7-19/group. 
A 
B AUC of plasma insulin levels
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6.3.4.	   Similar	   hepatic	  Srebp2,	  Hmgcr	   and	  Hmgcs	  mRNA	   levels	   in	  HF-­‐fed	   LKO	   and	  
control	  mice	  
	  
To investigate the effects of liver-specific 11β-HSD1 deficiency and HF feeding on 
cholesterol synthesis, hepatic Srebp2, Hmgcr and Hmgcs mRNA levels were 
measured. 
 
Del mice were omitted from the gene expression analysis in this chapter as they 
showed extremely low levels of hepatic 18S rRNA as well as very low hepatic Actb 
and Hprt mRNA levels (data not shown). Although RNA extractions for this study 
were carried out in batches, at any particular time, there were liver samples from all 
genotypes, chosen at random. Therefore, it is likely that RNA was degraded in Del 
liver samples prior to extraction. Due to time restraint, RNA extractions were not 
repeated from Del liver samples.  
 
HF-fed LKO mice exhibited no differences in hepatic Srebp2 (Figure 6.8), Hmgcr 
(Figure 6.9A) or Hmgcs (Figure 6.9B) mRNA levels compared to HF-fed floxed 
Hsd11b1 controls, suggesting no difference in cholesterol synthesis between 
genotypes. These findings are consistent with those from chow-fed LKO mice 
(Chapter 5). In this HF study, HSD1 KO mice also displayed no significant 
differences in hepatic Srebp2 (Figure 6.8) and Hmgcs (Figure 6.9B) mRNA levels 
compared to control mice. However, significantly increased Hmgcr mRNA levels 
were observed in livers of HF-fed HSD1 KO mice compared to HF-fed control mice 

















































Figure	  6.8:	  Similar	  hepatic	  Srebp2	  mRNA	  levels	  in	  LKO,	  control	  and	  HSD1	  KO	  mice.	  
Total RNA was extracted from livers of male liver-specific 11β-HSD1 knockout 
(LKO), Hsd11b1 floxed (Control) and hypomorphic 11β-HSD1 knockout (HSD1 
KO) mice that were fed high fat diet for 14 weeks, from 8-10 weeks of age. Hepatic 
Srebp2 mRNA levels were measured by qPCR. Levels of Srebp2 are expressed 
relative to the average of Hprt and Actb mRNA levels, used as internal controls. 
Values are means ± SEM and were analysed by one-way ANOVA with Tukey’s 






















































Figure	  6.9:	  Similar	   levels	  of	  hepatic	  Hmgcr	  and	  Hmgcs	  mRNA	   in	  HF-­‐fed	  LKO	  mice	  
and	  control	  mice.	  
Total RNA was extracted from livers of male, 8-10 week old liver-specific 11β-HSD1 
knockout (LKO), Hsd11b1 floxed (Control) and original hypomorphic 11β-HSD1 
knockout (HSD1 KO) mice that were fed high fat diet for 14 weeks. Messenger RNA 
levels were measured by qPCR. (A) Hmgcr and (B) Hmgcs mRNA levels are 
expressed relative to the average of Hprt and Actb mRNAs, used as internal controls. 
Data are means ± SEM and were analysed by one-way ANOVA with Tukey’s 




































6.3.5.	  Similar	  hepatic	  Lxrα,	  Cyp7a1,	  Abcg5	  and	  Abcg8	  mRNA	   levels	   in	  HF-­‐fed	  LKO	  
and	  control	  mice,	  but	  reduced	  Abcg5	  mRNA	  levels	   in	  HSD1	  KO	  mice	  compared	  to	  
controls	  
	    
Hepatic Lxrα mRNA expression is elevated in LOE mice (Chapters 3 and 4), with a 
similar pattern in HF-fed LOE mice (when compared to wild-type mice on the same 
diet) though this observation did not reach significance (see Figure 4.8, Chapter 4). 
To examine whether liver-specific 11β-HSD1 deficiency combined with HF feeding 
reduced hepatic LXRα expression, Lxrα mRNA levels were measured in livers of the 
HF-fed LKO, floxed Hsd11b1 and HSD1 KO mice. Unlike LOE mice, there were no 
significant differences in hepatic Lxrα mRNA expression between LKO, control and 
HSD1 KO mice (Figure 6.10). Interestingly, there was a trend for reduced hepatic 
Lxrα mRNA levels in HSD1 KO mice compared to controls (Figure 6.10).  
 
To investigate the effects of liver-specific 11β-HSD1 deficiency combined with HF 
feeding on cholesterol efflux and excretion, LXRα targets in these processes were 
examined; hepatic Cyp7a1, Abcg5 and Abcg8 mRNA levels were measured. 
 
Consistent with the lack of effect of hepatic 11β-HSD1 on hepatic Lxrα expression, 
target genes involved in cholesterol degradation (Cyp7a1) and hepatobiliary 
cholesterol excretion (Abcg5 and Abcg8) were unaltered in livers of HF-fed LKO 
mice compared to controls on the same diet (Figures 6.11 and 6.12). Surprisingly, 
Abcg5 mRNA expression was significantly reduced in livers of HF-fed HSD1 KO 
mice compared to HF-fed controls (Figure 6.12A), with a similar trend in Abcg8 
















































Figure	  6.10:	  Similar	  hepatic	  Lxrα 	  mRNA	  levels	  in	  LKO	  and	  control	  mice.	  
Total RNA was extracted from livers of male liver-specific 11β-HSD1 knockout 
(LKO), Hsd11b1 floxed (Control) and original hypomorphic 11β-HSD1 knockout 
(HSD1 KO) mice, which were challenged with a high fat diet for 14 weeks from 8-10 
weeks of age. Hepatic Lxrα mRNA levels were measured by qPCR. Levels of Lxrα 
are expressed relative to the average of Hprt and Actb mRNA levels, used as internal 
controls. Values are means ± SEM and were analysed by one-way ANOVA with 



















































Figure	  6.11:	  Similar	   levels	  of	  hepatic	  Cyp7a1	  mRNA	   in	  LKO,	  control	  and	  HSD1	  KO	  
mice.	  
Total RNA was extracted from livers of male, 8-10 week old liver-specific 11β-HSD1 
knockout (LKO), Hsd11b1 floxed (Control) and hypomorphic 11β-HSD1 knockout 
(HSD1 KO) mice that were fed high fat diet for 14 weeks. Levels of hepatic Cyp7a1 
mRNA were measured by qPCR and are expressed relative to the average of Hprt and 
Actb mRNAs, used as internal controls. Data are means ± SEM and were analysed by 
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Figure	  6.12:	  Similar	  hepatic	  Abcg5	  and	  Abcg8	  mRNA	  levels	  in	  LKO	  and	  control	  mice,	  
but	  reduced	  Abcg5	  mRNA	  levels	  in	  HSD1	  KO	  mice	  compared	  to	  controls.	  
Total RNA was extracted from livers of male liver-specific 11β-HSD1 knockout 
(LKO), Hsd11b1 floxed (Control) and hypomorphic 11β-HSD1 knockout (HSD1 
KO) mice, which were fed high fat diet for 14 weeks from 8-10 weeks of age. 
Messenger RNA levels were measured by qPCR. (A) Abcg5 and (B) Abcg8 mRNA 
levels are expressed relative to the average of Hprt and Actb mRNA levels, used as 
internal controls. Values are means ± SEM and were analysed by one-way ANOVA 
with Tukey’s multiple comparisons test; n=7-9/group; * p<0.05. 
A 
B 





	   	  
With 14 weeks of HF diet, liver-specific 11β-HSD1 deficiency did not alter body 
weight gain, liver weight, or adrenal gland weight. Unexpectedly, adipose tissue 
weight was reduced in HF-fed LKO mice, despite no effect on adipose tissue weight 
in HSD1 KO or Del mice. This effect of LKO on adipose tissue weight depends on 
HF diet as there were no differences in adiposity between chow-fed LKO and control 
mice (Chapter 5). These data differ from those of Lavery et al. (2012), who reported 
no difference in epididymal fat weights between their line of liver-specific 11β-HSD1 
knockout mice and control mice after 18 weeks of HF diet (Lavery et al., 2012). 
Other fat depot weights were not reported. The discrepancy between the two studies 
may be a result of background strain differences: Lavery et al. (2012) generated their 
line on a mixed C57BL/6/129SvJ background (Lavery et al., 2012) whereas the LKO 
mice used in the current study are on a pure C57BL/6 strain background. Strain 
background can potently influence the response to HF diet-induced obesity (Black et 
al., 1998; Morton et al., 2004) as well as govern HPA responses to 11β-HSD1 
deletion (Carter et al., 2009). 	  
 
Reduced adiposity with liver-specific knockdown of 11β-HSD1 has clinical 
implications as inhibition of hepatic 11β-HSD1 may be beneficial in diet-induced 
adiposity. This finding suggests a crosstalk between liver and fat and makes it likely 
that hepatic 11β-HSD1 plays a role in adipose tissue lipogenesis/lipolysis or lipid 
storage/transport, at least in diet-induced obesity. Further work is needed to explore 
the mechanisms involved. In this study, there were no differences in subcutaneous 
adipocyte hypertrophy between LKO and control mice. However, a small number of 
samples were examined and it is worth repeating this investigation with a greater 
number of subcutaneous fat samples. Moreover, reduced adiposity could also be a 
result of decreased number of adipocytes and it would be interesting to investigate 
this in the subcutaneous and epididymal fat depots of HF-fed LKO. Additionally, 
gene expression in the adipose tissue of HF-fed LKO mice could be examined. A 
recent study by Beaven et al. (2013) showed that LXRs, at least in the setting of 
obesity, act as physiological suppressors of the SREBP-1c and ChREBP-β lipogenic 




pathways in adipose tissue (Beaven et al., 2013). It would be interesting to investigate 
whether liver-specific 11β-HSD1 deficiency, combined with HF feeding, results in 
increased LXR expression in adipose tissue, thus resulting in a suppression of the 
above-mentioned lipogenic pathways and decreased adipose tissue lipogenesis. To 
study this further, expression of Lxr and its target genes involved in lipogenesis (e.g. 
Srebp1c and Fas) could be measured in adipose tissue (specifically subcutaneous and 
epididymal fat depots) from HF-fed LKO mice.  
 
LKO mice did not show the decreased body weight gain that was observed in Del and 
HSD1 KO mice towards the end of the 14-week HF diet. This suggests that reduced 
body weight gain with 11β-HSD1 deficiency is not due to liver 11β-HSD1. 
Additionally, it is worth noting that despite decreased body weight gain, no 
differences were found in the final body weights (at the time of cull) between Del, or 
HSD1 KO, and control mice (data not shown). These results differ from previous data 
in globally 11β-HSD1 deficient mice, which revealed decreased body weight as well 
as reduced mesenteric fat with HF feeding, compared to control mice (Morton et al., 
2004; Wamil et al., 2011). It is plausible that this discrepancy may reflect the use of 
different controls between the studies- floxed Hsd11b1 mice (correct controls for 
LKO mice in the current study) versus externally-sourced C57BL/6 controls (in the 
published studies). Floxed Hsd11b1 mice may exhibit some reduction in 11β-HSD1 
activity, contributing to different findings between the studies (Zhang, 2010). 
Nevertheless, in another study using HSD1 KO mice, Michailidou et al. (2012) did 
not find any differences in weight gain, final terminal body weights or adiposity 
between HF-fed HSD1 KO mice and C57BL/6 controls (bred in-house) (Michailidou 
et al., 2012).  
 
Fibrosis in subcutaneous fat was previously shown to be attenuated in HF-fed HSD1 
KO mice compared to C57BL/6 controls (Michailidou et al., 2012). In this study, 
HSD1 KO mice showed reduced collagen deposition in subcutaneous fat compared to 
controls though this observation did not reach significance. LKO mice showed similar 
levels of collagen deposition in subcutaneous fat to control mice, suggesting that liver 
11β-HSD1 deficiency (alone) does not contribute to the reduction in adipose tissue 
fibrosis in 11β-HSD1 deficient mice. Del mice exhibited increased collagen 




deposition in their subcutaneous fat compared to HSD1 KO mice. Interestingly, 
evidence shows that HSD1 KO mice exhibit increased lung fibrosis following 
bleomycin injury (Yang, 2010) as well as elevated hepatic collagen deposition and 
increased liver fibrosis following carbon tetrachloride treatment (Zou 2013). It is 
worth noting that the principal difference between HSD1 KO and Del mice is that 
HSD1 KO mice have ~30% residual activity of 11β-HSD1 in tissues that use the P1 
promoter of Hsd11b1. Importantly, this includes fibroblasts. In contrast, Del mice are 
a complete knockout of 11β-HSD1 (unpublished data, Professor Karen Chapman). It 
is possible that the residual 11β-HSD1 activity in fibroblasts (which use the P1 
promoter) in HSD1 KO mice accounts for the differences in subcutaneous collagen 
content between HF-fed Del and HSD1 KO mice. Within the genotypes investigated 
in this study, Del mice are the only ones without fibroblast 11β-HSD1 expression, and 
it would be worth investigating whether Del mice on chow diet show increased 
adipose collagen deposition. Adipose tissue hypoxia gives rise to adipose fibrosis 
(Hosogai et al., 2007; Ye et al., 2007), and it has been shown that transgenic 
overexpression of the hypoxia-inducible factor 1α (HIF-1α) in adipose of ob/ob mice 
exacerbates collagen deposition and fibrosis compared to controls (Halberg et al., 
2009). Therefore, it would also be interesting to study hypoxia in the adipose tissue of 
Del mice; for instance, is the expression of Hif-1α elevated in adipose tissue of Del 
mice?  
 
Previous data revealed improved glucose tolerance and greater insulin sensitivity in 
HSD1 KO mice (Morton et al., 2004). In the current study, there were similar glucose 
levels during GTT in LKO and control mice. Furthermore, LKO mice showed an 
increased AUC for the GTT glucose levels compared to HSD1 KO mice. These data 
suggest that the improved glucose tolerance previously observed in HSD1 KO mice is 
not due to liver 11β-HSD1. Although Lavery et al. (2012) observed a mild 
improvement in glucose tolerance, insulin sensitivity was unaltered in their line of 
liver-specific 11β-HSD1 deficient mice (Lavery et al., 2012). In the current study, 
there were no differences in plasma insulin levels during GTT between LKO and 
other genotypes, and fasting insulin levels appeared to be extremely high in LKO 
mice (as well as in the global knockouts). Nonetheless, for a true measure of insulin 
sensitivity, an insulin tolerance test (ITT) needs to be carried out. Recent work by 




Harno et al. (2013) demonstrated that while administration of 11-
dehydrocorticosterone (11-DHC; substrate for 11β-HSD1) caused marked insulin 
resistance in wild-type controls, liver-specific 11β-HSD1 knockout mice given 11-
DHC were protected from glucose intolerance and hyperinsulinaemia (Harno et al., 
2013). However, a very recent study by Morgan et al. (2014) failed to observe any 
protection from glucose intolerance and hyperinsulinaemia in GC-treated liver-
specific (or even adipose-specific) 11β-HSD1 knockout mice (Morgan et al., 2014). 
The reasons for the discrepancies between these studies is not clear, though the latter 
study, along with the findings from Lavery et al. (2012) and this study, suggest that 
hepatic 11β-HSD1 plays a relatively minor role in glucose homeostasis. Our adipose- 
and macrophage-specific 11β-HSD1 deficient mice in this 14-week HF diet 
experiment did not appear to be protected from glucose intolerance (unpublished data, 
Professor Karen Chapman), suggesting that 11β-HSD1 deficiency in adipose tissue or 
macrophages (alone) do not contribute to the improved glucose tolerance phenotype 
in globally 11β-HSD1 deficient mice. Previous data reveal a role for muscle 11β-
HSD1 in insulin signalling (Morgan et al., 2009) and it may be that 11β-HSD1 action 
in muscle is important in determining whole-body glucose homeostasis. Another 
possibility is that combined knockout of 11β-HSD1 in liver and adipose may be 
needed to recapitulate the glucose tolerance phenotype in HSD1 KO mice as these 
tissues are both highly enriched for 11β-HSD1 and there might be cross talk between 
liver and adipose 11β-HSD1 (see below).  
 
Intriguingly, although both Del and HSD1 KO mice showed reduced fasting glucose 
levels, Del mice did not show improved glucose tolerance; the circulating glucose 
levels during GTT were not decreased in Del mice as they were in HSD1 KO mice. 
The reason for this difference in glucose tolerance between these knockout models is 
unclear. While HSD1 KO mice display 11β-HSD1 deficiency in liver, adipose, brain 
and macrophages, there might be Hsd11b1 expression in lymphocytes (as the P1 
promoter is used in lymphocytes) (unpublished data, Professor Karen Chapman). It is 
worth exploring whether the discrepancies between HSD1 KO and Del mice are due 
to 11β-HSD1 expression and activity in lymphocytes or another cell type that uses the 
P1 promoter, including fibroblasts. In addition, whereas Del mice have exon 3 of 
Hsd11b1 removed and only loxP sites added, the old HSD1 KO mice contain all 




genomic DNA of Hsd11b1 locus (some of it even duplicated) and have a large 
cassette and powerful promoter transcribing in the opposite direction to Hsd11b1. It is 
plausible that the construct, as well as the strong promoter in the cassette, may affect 
neighbouring genes.  
 
Lack of differences in hepatic Srebp2, Hmgcr and Hmgcs mRNA levels between HF-
fed LKO and control mice suggests that hepatic 11β-HSD1 deficiency, combined 
with HF feeding, does not alter cholesterol synthesis. These results are consistent with 
a study that reported unchanged hepatic Srebp2 and Hmgcr mRNA expression 
following antisense oligonucleotide knock down of 11β-HSD1 in livers of C57BL/6 
mice fed a Western-type diet with increased fat and cholesterol (Li et al., 2011). 
Similarly, Lavery et al. (2012) failed to observe any differences in hepatic Hmgcr 
mRNA levels between their liver-specific 11β-HSD1 knockout mice and controls 
(Lavery et al., 2012). These results also corroborate the findings in chow-fed LKO 
mice (Chapter 5). Data from LKO as well as LOE mice (Chapters 3 and 4) in this 
study indicate that hepatic 11β-HSD1 does not play a role in hepatic cholesterol 
synthesis.  
 
In contrast with LOE mice, which showed increased hepatic Lxrα mRNA expression 
on both chow and WD (Chapters 3 and 4), there were no differences in Lxrα mRNA 
levels between livers of LKO and control mice. Consistent with this, Li et al. (2011) 
did not report differences in hepatic Lxrα mRNA levels in C57BL/6 mice with 
antisense-mediated inhibition of 11β-HSD1 (Li et al., 2011). In the current study, 
consistent with the lack of effect of liver 11β-HSD1 on Lxrα mRNA expression, LXR 
target genes involved in biliary cholesterol secretion, Abcg5 and Abcg8, were 
unaltered in livers of HF-fed LKO mice compared to controls. This differs from the 
study by Li et al. (2011) that reported reduced Abcg5 and Abcg8 mRNA expression in 
liver of their experimental mice (Li et al., 2011). However, it was noted that the 
antisense oligonucleotide used in their study knocked down 11β-HSD1 not only in 
liver, but also in adipose tissue and lungs, therefore making the experimental model a 
partial global knockout of 11β-HSD1. In support of this, our data showed 
significantly decreased hepatic Abcg5 mRNA expression in HSD1 KO mice, with a 
similar trend (though not significant) in hepatic Abcg8 mRNA levels. Differences 




between HF-fed HSD1 KO and LKO mice in this study suggest that the cause of 
reduced hepatic Abcg5 and Abcg8 mRNA levels in HSD1 KO mice may lie elsewhere 
than hepatocytes, and this requires further examination.  
 
It is worth noting that mRNA levels in this dietary experiment are different to those in 
a previous dietary experiment; for instance, Srebp2 mRNA levels in HF-fed control 
mice (in this experiment) are not similar to Srebp2 mRNA levels in HF-fed WT mice 
in a previous experiment (Chapter 4). This might be due to the use of different 
controls in the two experiments; floxed Hsd11b1 mice in this study versus C57BL/6 
WT controls in the previous study. Also, factors such as different animal facilities 
(Little France animal facility for this study versus Hugh Robson Building animal unit 
for the dietary experiment in Chapter 4) or stress might also account for the above-
mentioned differences.  
 
Evidence suggests that knockout and pharmacological inhibition of 11β-HSD1 can 
reduce hepatic steatosis (Berthiaume et al., 2007; Berthiaume et al., 2010; Li et al., 
2011). However, it is worth noting that both selective 11β-HSD1 inhibitors and small 
interfering RNA technology are not entirely selective with respect to target tissue and 
decrease 11β-HSD1 activity in both liver and fat. Morgan et al. (2014) showed that 
GC-treated liver-specific 11β-HSD1 knockout mice were not protected against 
metabolic disease including hepatic steatosis but GC-treated adipose-specific 11β-
HSD1 knockout mice were protected from hepatic TG accumulation, increased serum 
free fatty acids (FFA) as well as from increased expression of adipose lipolytic 
enzymes (Morgan et al., 2014). These findings suggest that increased GC availability 
in adipose tissue (not liver) play a key role in hepatic steatosis. Various processes 
contribute to lipid accumulation within the liver, including de novo lipogenesis as 
well as FFA delivery from adipose tissue with subsequent re-esterification into TG. 
GCs are known to directly stimulate adipose tissue lipolysis, resulting in increased 
serum FFA levels (Xu et al., 2009). Therefore, in this model, decreased 11β-HSD1 in 
adipose tissue may limit lipolysis in this tissue, decreasing FFA availability and 
delivery to the Iiver, thereby reducing hepatic TG accumulation (Morgan et al., 
2014). In support, HF-fed adipose-specific 11β-HSD1 knockout mice generated in 
our lab showed decreased liver weights compared to HF-fed control mice despite no 




difference in liver weight of HF-fed HSD1 KO or Del mice (data not shown). It 
would be interesting to measure TG accumulation in livers from adipose-specific 11β-
HSD1 knockout mice on this dietary experiment to investigate whether these adipose-
specific 11β-HSD1 deficient mice are protected from hepatic steatosis.  
 
In summary, there is no evidence that hepatic 11β-HSD1 plays a key role in 
cholesterol synthesis. Therefore, the data refute the original hypothesis. There is also 
no evidence that hepatic 11β-HSD1 deficiency, combined with HF feeding, alters 
cholesterol catabolism/excretion. These findings corroborate results from chow-fed 
LKO mice. Although it appears that the suggested role for hepatic 11β-HSD1 in 
hepatobiliary cholesterol secretion (Chapter 4) may be specific to liver 11β-HSD1 
overexpression, HSD1 KO mice must be further investigated as they exhibit 
decreased hepatic Abcg5 mRNA levels, with a similar trend for Abcg8 mRNA. 
Finally, liver-specific 11β-HSD1 deficiency reduces adiposity upon HF feeding, 
suggesting that inhibition/deficiency of hepatic 11β-HSD1 may be advantageous in 


































This thesis explored the role of hepatic 11β-HSD1 in cholesterol homeostasis. 
Alteration of cholesterol homeostasis is a major risk factor for atherosclerotic 
cardiovascular disease (Stamler et al., 2000; Weingartner et al., 2009; Tyler et al., 
2009) and this work was encouraged by the increasing interest in 11β-HSD1 as a 
therapeutic target for atherosclerosis (Hermanowski-Vosatka et al., 2005; Walker, 
2007). Chronic GC excess is associated with metabolic and cardiovascular disease, 
and 11β-HSD1 amplifies intracellular GC levels (Walker, 2007; Chapman et al., 
2013). In addition, 11β-HSD1 catalyses the reduction of 7-KC to 7-βHC (Schweizer 
et al., 2004; Hult et al., 2004), and 7-KC has the potential to regulate cholesterol 
biosynthesis because it is an inhibitor of SREBP-2 cleavage (Brown et al., 2002). 
Hence, 11β-HSD1 may play an important role in cholesterol homeostasis but this area 
has been largely unexplored. Since liver is the key organ involved in cholesterol 
homeostasis as well as the organ with the highest expression of 11β-HSD1, the liver 
enzyme was chosen for study.  
 
It was hypothesised that hepatic 11β-HSD1 promotes cholesterol biosynthesis. 
However, using models of liver 11β-HSD1 overexpression (LOE mice) and liver-
specific 11β-HSD1 deficiency (LKO mice), data revealed that liver 11β-HSD1 does 
not promote cholesterol biosynthesis, at least through SREBP-2 mediated expression 
of mRNAs encoding hepatic cholesterol biosynthetic enzymes. Nevertheless, this 
study demonstrated increased hepatic Abcg5 and Abcg8 mRNA levels in LOE mice, 
suggesting a role for increased liver 11β-HSD1 in promoting hepatobiliary cholesterol 
secretion, thereby supporting a role for hepatic 11β-HSD1 in cholesterol homeostasis. 
 
There is some evidence that LOE mice empty their gall bladders extremely efficiently 
whereas global deficiency of 11β-HSD1 impairs gall bladder emptying (unpublished 
data, Professor Karen Chapman). These findings might have implications for dietary 
lipid absorption; for instance, 11β-HSD1 deficiency (or inhibition) may reduce lipid 
absorption from the diet as bile release from gall bladder appears to be dependent on 
11β-HSD1. It would be interesting to measure bile fluid and investigate this further in 
global 11β-HSD1 knockout as well as LKO and LOE mice. An interesting question 
that can be raised here is whether the role of 11β-HSD1 in cholesterol metabolism 
impacts on bile acid homeostasis or the other way round. A functional FXR binding 




site has been identified in the Abcg5 gene promoter and hepatic Abcg5/8 expression 
was induced in mouse or human hepatocytes treated with FXR agonist or bile acids 
(Li et al., 2011b). The current study showed no evidence of altered bile acid synthesis 
in the mouse models investigated, and though not measured in this study, previously 
Paterson et al. (2004) reported no difference in hepatic Fxr mRNA levels between 
LOE and wild-type controls (Paterson et al., 2004). Nonetheless, GCs regulate bile 
acid homeostasis (Rose et al., 2011), and bile acids are not just competitive inhibitors 
of 11β-HSD1 (Escher et al., 1998; Ackermann et al., 1999) but also substrates 
(Odermatt et al., 2011), therefore, it is worth studying whether any of the metabolic 
effects of 11β-HSD1 deficiency are meditated through the potential role of 11β-HSD1 
in bile acid metabolism. In this respect, another PhD study in the lab has shown that 
HSD1 KO mice exhibit a 100x decrease in the ratio of 7β:7α hydroxylated bile acids. 
Relevance of this remains unexplored and future studies are required. 
 
It is important to dissect the impact of 11β-HSD1 inhibition/deficiency on 
cardiovascular events, the main cause of mortality in the phenotype of metabolic 
syndrome (Lloyd-Jones et al., 2009; Brown et al., 2010). As the final step in the 
reverse cholesterol transport pathway, hepatobiliary cholesterol secretion aids in the 
reduction of cholesterol accumulation within peripheral cells, including macrophage 
foam cells in atherosclerotic lesions (Ohashi et al., 2005; Wang and Rader, 2007; 
Dikkers and Tietge, 2010). Because hepatic ABCG5 and ABCG8 transporters are 
vital for cholesterol secretion into bile (Yu et al., 2002a; Yu et al., 2002b; Klett et al., 
2004a; Plösch et al., 2004), it can be speculated that increased expression of these 
transporters in LOE mice might reduce atherosclerosis. When mice with 
overexpression of human ABCG5 and ABCG8 were crossed with atherosclerotic 
Ldlr-/- mice, the offspring developed significantly less atherosclerosis compared with 
wild-type control mice (Wilund et al., 2004). LOE mice have elevated levels of 
hepatic Abcg5 and Abcg8 mRNA levels and it is important to measure hepatobiliary 
cholesterol secretion in these mice, compared to wild-type controls. It would also be 
interesting to examine whether LOE mice crossed into the pro-atherogenic Apoe-/- 
background result in decreased atherosclerosis compared with Apoe-/- controls. 
However, preliminary data from breeding LOE mice with Apoe-/- mice showed no 




effect on lesion size (unpublished data, Professor Karen Chapman), though hepatic 
gene expression has not been examined.  
 
In addition to improving metabolic risk factors, recent findings suggest direct 
atheroprotective effects of 11β-HSD1 inhibition/deficiency. A study by Merck on 
11β-HSD1 inhibition in Apoe-/- mice suggested reduced inflammatory gene expression 
in the vasculature as a protective mechanism against atherosclerosis (Luo et al., 
2013). To directly examine the role of 11βHSD1 in atherosclerosis, recent studies 
used 11β-HSD1 knockout mice that were created on the Apoe-/- background 
(Hsd11b1−/−Apoe−/− mice) (Garcia et al., 2013; Kipari et al., 2013). These studies 
showed that transplantation of bone marrow cells from Hsd11b1−/−Apoe−/− mice 
confers atheroprotection to irradiated Apoe-/- mice, suggesting a key role for 
macrophage and/or other leukocyte 11β-HSD1 deficiency in the atheroprotective 
phenotype (Garcia et al., 2013; Kipari et al., 2013). Other important candidates 
include liver and adipose tissue, which are important tissues for cholesterol and lipid 
metabolism as well as abundant in 11β-HSD1. However, mice with liver- or adipose-
specific 11β-HSD1 knockout on an Apoe-/- genetic background are not protected from 
atherosclerosis, whereas myeloid cell 11β-HSD1 deficiency on Apoe-/- background is 
atheroprotective (unpublished data, Professor Karen Chapman). Lipomics analysis of 
atherosclerotic plaques or foam macrophages from Hsd11b1−/−/Apoe−/− versus Apoe-/- 
mice may help establish the involvement of macrophage 11β-HSD1 in 
atherosclerosis. To this end, data from Kipari et al. (2013) revealed increased 
ABCA1-dependent cholesterol efflux in HSD1 KO macrophages compared to 
C57BL/6 control mice (Kipari et al., 2013).  
 
It is intriguing that data from LOE mice suggest a role for liver 11β-HSD1 in 
promoting hepatobiliary cholesterol secretion but data from Kipari et al. (2013) 
suggest that deficiency of 11β-HSD1 promotes cholesterol efflux from macrophages 
(Kipari et al., 2013). Thus, both liver overexpression of 11β-HSD1 and global 11β-
HSD1 deficiency predict increased cholesterol removal, from liver to bile and from 
macrophages back to liver, respectively. It is interesting to speculate that 11β-HSD1 
may have distinct functions in different tissues. LXR activation upregulates 
expression of cholesterol efflux transporters; ABCG5, ABCG8 in hepatocytes, and 




ABCA1 in macrophages (Patel et al., 2008; Zhao and Wright, 2010; Hong et al., 
2014). It has been shown that LXRα is required for reverse cholesterol transport and 
atheroprotection in Apoe-/- mice (Hong et al., 2012), and a very recent study showed 
that cholesterol efflux is dependent on LXRα, rather than LXRβ, in human 
macrophages (Ma et al., 2014). The current study suggests that, in liver, 11β-HSD1 
promotes cholesterol efflux into the biliary lumen, possibly mediated through LXRα 
activation. GCs (down)regulate ABCA1 mRNA and protein levels in macrophages, 
thereby resulting in reduced cholesterol efflux from macrophages (Ayaori et al., 
2006). I speculate that 11β-HSD1 in macrophages may suppress activation of LXRα, 
thereby preventing ABCA1-mediated cholesterol efflux from macrophages (Figure 
7.1). Furthermore, LXR activation in macrophages attenuates inflammation (Joseph et 
al., 2003). Because inflammation and inflammatory signalling play a substantial role 
in atherosclerosis pathology (Tabas, 2010; Im and Osborne, 2011), suppression of 
LXR activation in macrophages would worsen atherosclerosis. 
 
Another disease that is directly linked with biliary cholesterol secretion is gallstone 
disease. Unlike atherosclerotic cardiovascular disease where increased biliary 
cholesterol secretion is desirable, enhanced biliary cholesterol secretion is associated 
with biliary cholesterol super saturation, which increases risk of cholesterol gallstones 
(>90% of all gallstones) (Portincasa et al., 2006; Wang et al., 2009). In humans, 
specific mutations in ABCG5 and ABCG8 increase risk of cholesterol gallstone 
disease (Buch et al., 2007; Grunhage et al., 2007; Katsika et al., 2010). However, this 
has not been investigated in an experimental setting, which allows determination of 
cause-effect relationships. Measurement of cholesterol in the bile of wild-type, 
globally 11β-HSD1 deficient, liver-specific 11β-HSD1 deficient and liver 11β-HSD1 
overexpressing mice would help to explore the involvement of 11β-HSD1 and liver 
11β-HSD1 in biliary cholesterol secretion and cholesterol gallstone pathogenesis.  
 
Although expected to decrease, hepatic Lxrα, Abcg5 and Abcg8 mRNA levels were 
unaltered with liver-specific 11β-HSD1 deficiency. Interestingly, global 11β-HSD1 
deficiency, combined with HF diet, significantly decreased hepatic Abcg5 mRNA 
levels, with a similar trend in Abcg8 mRNA levels (as well as in hepatic Lxrα mRNA 
levels) compared to Cre- Hsd11b1 floxed controls. No side-by-side chow diet study 









Figure	   7.1:	  A	   hypothetical	  model	   of	   the	  distinct	   effects	   of	   11β-­‐HSD1	   in	   liver	   and	  
macrophages	  with	  respect	  to	  LXRα	  expression.	  
With respect to cholesterol metabolism, in liver, 11β-HSD1 results in LXRα 
activation, consequently leading to increased ABCG5/8-mediated hepatobiliary 
cholesterol secretion. However, in macrophages, 11β-HSD1 acts as a suppressor of 






























was carried out as part of this experiment (Chapter 6), and therefore it is not entirely 
clear whether this is an effect of global 11β-HSD1 deficiency alone or is only 
manifest with 11β-HSD1 deficiency upon HF feeding. In a separate dietary 
experiment (Chapter 4), chow-fed HSD1 KO mice showed no differences in hepatic 
Abcg5 and Abcg8 mRNA levels compared to wild-type controls, therefore, it may be 
likely that effect of global 11β-HSD1 deficiency on Abcg5 and Abcg8 expression 
depends on HF feeding. It is important to note the use of different controls here. Cre- 
floxed Hsd11b1 mice were used as controls for studies with LKO mice (Chapters 5 
and 6) and non-transgenic wild-type controls were compared to LOE transgenic mice 
(Chapters 3 and 4). These controls may not necessarily behave in the same way and 
there is now preliminary data showing that Hsd11b1 floxed mice exhibit some 
reduction in 11β-HSD1 activity (unpublished data, Professor Karen Chapman). 
Therefore, it may be worthwhile confirming the above findings in LKO and HSD1 
KO mice with wild-type controls as well as further investigating the consequence of 
the introduced LoxP sites upon expression of the ‘floxed’ Hsd11b1 gene. More 
importantly, differences between HF-fed HSD1 KO and LKO mice in this study 
indicate that the cause of reduced Lxrα, Abcg5 and Abcg8 mRNA expression in HSD1 
KO mice may lie elsewhere than hepatocytes, and this requires further examination.  
 
Another significant (and unexpected) finding from this study is that liver-specific 
deficiency of 11β-HSD1 decreased subcutaneous and epididymal fat weight gain 
upon HF feeding compared to controls. This has implications for diet-induced 
adiposity and liver-specific 11β-HSD1 inhibition/deficiency may be advantageous in 
this respect. Further research is needed to unravel the mechanisms involved. Although 
no differences were observed in subcutaneous adipocyte hypertrophy, only a small 
number of samples (n=4-5/group) were examined and it is worth repeating this 
investigation with a greater number of subcutaneous fat samples as well as extending 
the study to epididymal fat. Additionally, LXRα expression in the adipose tissue of 
HF-fed LKO mice should be measured. Although well known as positive regulators 
of lipogenesis in liver (Repa et al., 2000; Schultz et al., 2000), a recent study by 
Beaven et al. (2013) established that LXRs act as physiological suppressors of the 
SREBP-1c and ChREBP-β lipogenic pathways in adipose tissue, specifically in the 
obese state (Beaven et al., 2013). It would be interesting to investigate whether  




liver-specific 11β-HSD1 deficiency, combined with HF feeding, results in increased 
LXR expression in adipose tissue, thereby resulting in a suppression of the 
aforementioned lipogenic pathways and reduced adipose tissue lipogenesis. To 
investigate this further, adipose tissue from HF-fed LKO mice could be examined 
with respect to expression of Lxr and its target genes involved in lipogenesis 
(Srebp1c, Fas and Scd1). In addition, adipose tissue lipolysis should also be measured 
as LXRs have been implicated in lipolytic regulation as well as decreased fat cell size 
(Ross et al., 2002; Commerford et al., 2007).  
 
This study does not distinguish whether the effects observed in the mouse models 
examined are dependent on metabolism of GCs or of 7-oxysterols by 11β-HSD1. It is 
known that 7-oxysterol substrates competitively inhibit GC metabolism and vice 
versa (Wamil et al., 2008; Balazs et al., 2009). In Chapter 4 of this thesis, liver and 
plasma samples from wild-type, LOE and HSD1 KO mice, which were fed chow, HF 
or WD, were sent to Professor William J. Griffith’s laboratory (Swansea University, 
Wales, UK) for determination of oxysterol levels. However, the data were not 
returned in time for the submission of this thesis. Development of atherosclerotic 
plaques has been studied in adrenalectomised Hsd11b1−/−Apoe−/− mice (with 
endogenous GCs removed) and it was suggested that both reactions of 11β-HSD1 
might be involved in the atherosclerosis phenotype (Mitic et al., 2010).  
  
While studies have highlighted the benefits of 11β-HSD1 inhibition, from a 
translation point of view, one of the important implications from this study is that in 
some cases (e.g. hypercholesterolaemia, atherosclerosis) increased hepatic 11β-HSD1 
might be advantageous as it may promote secretion of cholesterol into bile. However, 
liver-specific 11β-HSD1 inhibition may be beneficial in diet-induced adiposity. 
Therefore, apart from its importance in pathogenesis, it is also important to fully 
resolve and appreciate the physiological functions of liver 11β-HSD1.  
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